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RÉSUMÉ 
Comme à l’approche d’un tsunami, l’incidence grandissante des allergies affecte 
maintenant plus de 30% de la population des pays développés. Étant la cause de 
nombreuses morbidités et un risque significatif de mortalité, les allergies nécessitent des 
dépenses exorbitantes au système de santé et constituent une des plus importantes sources 
d’invalidité. Cette thèse a pour but de contribuer à faciliter la prise de décision éclairée 
dans le développement de politiques en santé en lien avec cette maladie immunitaire 
chronique en utilisant des principes d’éthique comme outils pour guider le développement 
de politiques en santé. Le premier chapitre démontre le présent déficit d’analyses des 
enjeux éthiques en allergologie et démontre de quelle façon les réflexions en éthique 
peuvent guider le développement de politiques et l’élaboration de stratégies appliquées aux 
allergies. Les chapitres qui suivront présentent des applications spécifiques des principes 
d’éthiques ciblant des contextes précis comme des méthodes qui fournissent des outils de 
réflexion et des cadres théoriques qui peuvent être appliqués par les décideurs pour guider 
des interventions en santé concernant les allergies et les conditions de co-morbidité reliées. 
Le second chapitre présente un cadre théorique pour l’évaluation et la priorisation 
d’interventions en santé publique par la diminution des allergènes présents dans 
l’environnement basées sur des théories de justice sociale. Les critères entourant les 
politiques d’évaluation se concentrent sur les enjeux éthiques référant aux populations 
vulnérables, sur une distribution plus égale des bénéfices pour la santé, et sur le devoir 
d’éviter la stigmatisation. Le troisième chapitre offre aux administrateurs et au personnel 
infirmier du réseau scolaire un cadre décisionnel pour guider le développement de 
politiques efficaces et éthiquement justifiables concernant les allergies alimentaires pour les 
écoles. Dans ce contexte, les principes de base d’éthique en santé publique et en bioéthique 
- par exemple, l’empowerment des populations vulnérables dans la prise en charge de leur 
santé et la protection de la confidentialité du dossier médical - servent d’outils pour évaluer 
les politiques. Le dernier chapitre emploie les principes de base de recherche en éthique 
comme méthode pour développer un argumentaire en faveur de la réforme des 
réglementations entourant la production de médicaments immunothérapeutiques. La 
nécessité éthique d’éviter les risques de méfait à l’endroit du sujet humain dans la 
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recherche permettra de servir de guide pour structurer de futures politiques en santé 
publique en égard à la production d’immunothérapeutiques à l’échelle mondiale. 
 
mots clés: Allergies, Bioéthique, Politiques en santé, Santé publique, Analyses de 
politique, Principes d’éthiques, Cadres théoriques 
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ABSTRACT 
Like a slowly rising wave approaching shore, the growing incidence of allergic disease now 
afflicts over 30% of the population in the developed world. Being the cause of severe 
morbidities and a significant risk of mortality, allergy requires huge resource expenditures 
in health care and is a leading cause of disability. This thesis aims to contribute to 
ameliorating decision-making capacities in health policy development for this chronic 
immune disease by employing principles of ethics as tools to help structure policy 
initiatives. The first chapter will demonstrate the current deficiency of ethical analysis in 
allergology and show how ethical assessments could have utility in guiding policy 
developments and treatment strategies for allergy. The subsequent chapters present a 
focused application of ethical principles within specific contexts as a means to provide 
reflective tools and theoretical frameworks that could be used by decision-makers to guide 
health interventions for allergy and co-morbid conditions. The second chapter presents a 
conceptual framework for evaluating and prioritizing public health interventions in 
minimizing environmental allergens based on theories of social justice. Policy assessment 
criteria centre on justice issues pertaining to vulnerable populations, the fair distribution of 
health benefits, and the imperative to avoid stigma. The third chapter provides school 
administrators with a framework to guide the development of efficacious and ethically 
sound food allergy policies for schools. In this context, core principles in public health 
ethics and bioethics – examples being the empowerment of vulnerable populations in 
controlling their health and protecting confidentiality of medical information – serve as 
tools for policy assessments. The final chapter employs core principles from research ethics 
as a method to argue for regulatory reforms in the production of allergen-
immunotherapeutic drugs. The ethical imperative to avoid risks of harm to human subjects 
in research will serve as a guide to structure future health policies in the global production 
of immuno-therapeutics.  
 
Keywords: Allergy, Bioethics, Health policy, Public Health, Policy assessment, 
Principles of ethics, Conceptual frameworks 
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INTRODUCTION 
 
The health of our population: many achievements mirrored with new 
challenges 
 
The deviation of man from the state in which he was originally placed by nature seems to 
have proved to him a prolific source of diseases 
! Edward Jenner 
 
 Many people have experienced a feeling where, despite moving forward at a 
consistent pace, their position seems to remain the same. While this situation may sound 
like a strange dream, the anecdote of remaining in place despite efforts to progress forward 
is an accurate description of the current state of population health in many developed 
nations.  
 The 20th century was a period of marked health improvement: the average life 
expectancy rose and rates of child mortality fell dramatically, in part due to significant 
advances in medicine and nutrition, but also through greater access to clean drinking water 
and widespread population vaccination programmes, to name but a few public health 
interventions [1]. By contrast, observations of growing health stagnation – and in some 
instances, regression [2, 3] – along with mounting concern about a widening of health 
disparities between population subgroups have become the defining attributes of population 
health in many industrialized nations [4-8]. In order to help contextualize this 
epidemiological phenomenon of the 21st century, one can visualize population health as an 
outcome residing on one side of a revolving door that rotates equally well in either 
direction.  
 On the other side of the rotating door reside two forces that are vying to pass 
through and influence population health achievements; entering from the right are novel 
health promotion initiatives, while on the left come novel health challenges. Throughout 
the 20th century, the aforementioned innovations in public health and medicine outpaced 
the influence of infectious diseases and common medical afflictions, thus health 
achievements steadily rose. With the rise in life expectancy and changes in society (e.g., 
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more sedentary lifestyles, economic globalisation), previous health interventions reached 
their full capabilities to improve health, and steadily, chronic diseases emerged as the new 
leading source of pathology. Many chronic diseases entering from the left, such as obesity, 
cancer, and allergy, have continued to outpace medical and public health initiatives that 
could effectively prevent or cure these ailments. Now at the point of population health 
stagnation, researchers and policy makers are seeking new tools in order to improve the 
efficacy of health promotion initiatives, whether they be in the form of conventional 
medicine or from fields previously unrelated to health science. One new tool that has 
recently contributed to the advancement of health initiatives comes from what might appear 
at first to be an unlikely source: ethics and moral philosophy. 
 The interdisciplinary melding of ethical analysis and health research emerged from 
the recognition that the development, enactment, and distribution of health initiatives are 
intricately linked with many value-based judgements [9-11]. What constitutes as an 
effective ‘treatment’ for a given pathology? When bound by resource constraints, which 
pathologies and ailing populations merit priority for targeted intervention? What duties do 
individuals, governments, and private corporations have in protecting individual and 
population health? These questions outline but a few of the many challenging questions 
raised when devising health policy, and they rarely have easy answers. However, what 
determines the values and goals that guide our judgements is a matter of ethics. Cognizant 
of the ethical dimensions of health policy, opportunities arise to enhance the decision-
making capacities of policy makers through the application of principles of ethics as guides 
in the development of health initiatives.  
 This doctoral thesis will present a number of interdisciplinary investigations that 
merge ethics scholarship and health policy research. The aim of this research project is to 
employ principles of ethics as a new tool to enhance decision-making capacities and guide 
the development of health initiatives for a chronic disease that poses a monumental 
challenge to public health: allergy. Before beginning these investigations into ethics and 
health policy, it will be pertinent to first provide an overview of the aetiology and 
consequences of this chronic disease.    
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Caught off-guard: a global pandemic of allergy, and what this entails for 
our future health 
A well-functioning immune system that wages war with the wrong enemy 
When there is no enemy within, the enemies outside cannot hurt you. 
! African Proverb 
 
 Through millions of years of evolution, the immune system has developed into a 
physiological marvel capable of targeting and eliminating an impressive list of pathogens 
from our bodies. Though usually a sentinel against disease, if gone awry, the immune 
system can become a formidable internal enemy. Two general disease categories include 
autoimmune disorders, such as Lupus, where the immune system mistakenly targets 
elements within the body, and hypersensitivity responses to environmental agents, as is the 
case with allergy.  
 There are two primary metabolic pathways that orchestrate immune responses, each 
regulated by distinct classes of antibodies, IgG and IgE. IgG antibodies bind to foreign 
substances and target them for degradation and elimination by immune cells. IgE 
antibodies also bind and recruit other immune cells that locally release histamine, a 
compound that induces inflammation. The inflammation response serves to prevent 
substances from further infiltrating into the body by inducing swelling and restricted blood 
flow. In allergy, the immune system perceives common substances, like pollen, as similar 
to that of a pathogen. However, in allergy the IgE metabolic pathway is favoured. Upon 
exposure to significant levels of an allergen, an allergic individual releases massive 
amounts of histamine and severe inflammation results. 
 Allergic reactions produce a variety of symptoms and morbidities (also defined as 
atopic disorders), with symptoms commonly beginning in early childhood and evolving 
through specific phases of symptoms until early adulthood. Also known as the atopic 
march [12], allergic sensitivities first manifest in infants as atopic dermatitis, eczema, and 
urticaria (skin rash, scaly blisters, and hives), and symptoms can later develop into allergic 
rhinitis (inflamed sinuses) and food allergy. By adolescence, the atopic march culminates in 
some individuals with the development of allergy-induced asthma. This procession through 
atopic disorders does not occur with every allergy sufferer; many individuals develop 
allergy in adulthood and many experience only one disorder. Severe allergic sensitivities 
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carry a high risk for mortality primarily by inducing anaphylaxis (sudden, severe cardiac 
and respiratory arrest). Anaphylactic reactions are systemic (delocalised throughout the 
body) and can arise from exposure to minute quantities of allergens, e.g., when allergic 
individuals suddenly ‘drop dead’ following a bee sting or inhaling peanut particles. Some 
allergy sufferers are fortunate in that their allergic sensitivities can occasionally resolve or 
attenuate with age, a phenomenon that is likely explained by the maturation and 
development of the immune and digestive systems [13]. To summarize, allergy can produce 
a broad variety of morbidities with various degrees of severity. In light of these 
observations, it is particularly interesting to note that the growth in incidence and variations 
in allergic symptoms is mirrored by the number of normally benign substances that induce 
hypersensitivity responses. Moreover, it is common for allergy patients to have sensitivities 
towards more than one allergenic substance, and sometimes more than seven [14].  
 Many allergenic compounds are well known; aeroallergens of pollen, dust mite 
particles, and pet hair are typical examples. However, hypersensitivities exist for hundreds 
of additional compounds ranging from numerous food proteins, food additives, clothing 
fibres, certain metals such as nickel, drugs, colouring agents, insect venom, moulds, 
cockroaches, feathers, and cosmetics. This seemingly endless list of allergenic substances 
continues to grow as rare case studies of previously unknown allergic sensitivities slowly 
become well-characterized in larger patient populations. Two notable examples include 
increasing observations of severe reactions to bed bug bites [15] and from the consumption 
of red meat [16]. Bizarrely, men have become members of this list of allergenic substances, 
as a growing number of case studies are reporting women developing allergies towards 
their male partner’s sweat [17] and semen [17-19]. These latter observations are 
particularly disquieting; not only are we becoming allergic to our environment and 
common consumer goods, we are also gradually becoming allergic to each other. 
 A century ago, allergy was virtually unknown. Since then, evidence suggests that a 
near linear increase in the incidence of allergic sensitivities has accompanied each 
subsequent birth cohort [20]. Today, the incidence of allergy is approaching almost 50% of 
the population in several developed countries [21]; in 2005 [22], the results from a 
population assessment for allergy – accumulated over a period of 18 years – estimated that 
allergic sensitivities were present in the majority of the American population (54%). Due to 
variations and diversity in methodology, geographical region, and study populations, it is 
difficult to define which studies provide the most accurate measure of the incidence of 
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allergic disease. Regardless, the accumulative data indicate that, in the developed world at 
least, allergy afflicts a very large minority of the population and is comparable to the 
incidence of other common chronic ailments, such as obesity [23-25]. An even more 
disturbing observation is that allergies are becoming more common in our domestic pets, 
and born from the recognition of this growing population of allergic dogs and cats is a new 
industry in hypo-allergenic pet food [26]. 
 What could possibly be the cause of this exploding pandemic? 
 
The (ill-)defined determinants of allergy 
 Orchestrated by physiological processes of the body, it should come as no surprise 
that a host of genetic factors correlate with an elevated predisposition to the development 
of immune hypersensitivities and particular atopic disorders (e.g., asthma) [27]. However, 
genetic predispositions cannot account for the sudden explosion in incidence of allergy 
since this rapid increase is too abrupt to stem from genetic shifts in the population [28-30]. 
Such rapid change must originate from socio-environmental and lifestyle transformations. 
 
Too clean, too artificial, or not clean enough? How our living habits prime 
us for allergy 
Disease is not of the body but of the place.  
! Seneca (Seneca the Elder) 
 
 One long-standing theory for the underlying determinant of allergy is the hygiene 
hypothesis [31]. This widely popular hypothesis suggests that modern day life in the 
developed world is abnormally clean; we now rarely encounter filth, pathogens, and 
parasites that were once common in our drinking water, food, and in our urban and home 
environments. Smaller family sizes, now typical in the developed world, also reduce the 
transmission of pathogens (e.g., cold and flu) between siblings [32]. While clean living 
environments provide many benefits to population health, such environments also provide 
few challenges to our immune systems, which might encourage immune development 
primed for hypersensitivity responses. An interesting observation that complements this 
theory is the fact that children who were raised on farms and regularly consumed 
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unpasteurized milk have exceptionally low levels of allergy [33, 34]. Exposure to the ‘less 
sterile’ farm environment and consumption of large amounts of bacteria in milk seem to 
prevent immune sensitivities towards benign substances.   
 As is the case with most complicated diseases like allergy, one straightforward 
unifying theory for its cause is likely an oversimplification. Thus, it is not surprising to see 
that the link between hygiene and allergy is not definitive and has been widely criticised 
due to a lack of supporting evidence [28, 35]. There are specific contradictions to theory as 
well, where prolonged exposure to ‘dirty substances’ or unclean environments can cause 
allergy. For example, exposure to dust is a known risk factor for developing allergies 
towards dust mites [36] and living in substandard housing with poor ventilation and in the 
presence of vermin and insects, is a significant cause of sensitivities towards cockroaches, 
mice, rats, and mould [22, 37]. A complementary observation to these findings is that the 
induction of hypersensitivity responses can occur through exposure to allergenic substances 
in the work environment. Also known as occupational allergy, exposure of workers to 
aerosol sensitizers, which could – depending on the profession – be anything ranging from 
enzymes in detergents, to flour dust, to horsehair. In the situation of occupational allergy, 
the best method to prevent the induction of allergic sensitivities is to enact stringent 
occupational hygiene protocols that prevent contact between workers and allergenic 
substances in the workplace [38]. Thus, depending on the circumstances, it appears that a 
heightened preoccupation with hygiene can either be beneficial or detrimental to preventing 
allergic hypersensitivities. 
 
Are we victims of our own success? Allergy and economic development 
Today’s city is the most vulnerable social structure ever conceived by man.  
! Martin Oppenheimer 
 
 Ask any political leader or economist about their conceptions of an ideal and 
successful economy and they will likely respond that an ideal economy is one positioned 
for long-term growth. While economic growth and development is arguably a marker for 
certain forms of social progress and success, it appears that such development indirectly 
predisposes society to fall victim to epidemics of allergy and atopic disorders. One 
fundamental observation that supports this correlation is that allergy predominates in 
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developed nations; however, as developing nations experience economic growth, so too do 
they witness a growth in allergy [39, 40]. 
 Interestingly, the fall of communism in the late 1980’s enabled researchers to 
scrutinize the process of economic development and allergy within a reasonably short 
timeframe. Consider the formally divided nations of East and West Germany [41-45]. 
Initial hypotheses by allergy specialists reasoned that the impoverished communist East 
would have elevated levels of atopic disorders due to a higher prevalence of polluting 
industries and coal-fired power plants in metropolitan centres. Surprisingly, the less 
polluted and economically advanced West typically had a significantly higher incidence of 
most forms of allergic sensitisations and co-morbid conditions. Following the fall of 
Communism and reunification of the country, inequalities in allergy gradually dissipated as 
the East experienced rapid economic development and a concomitant rise in atopic 
disorders.  
 How might economic development cause populations to become prone to allergy? 
One possible hypothesis is the link between development, increased urbanism, and the 
acquisition of artificial living habitats. Current economic forces favour the establishment of 
industries and businesses in urban centres, which in turn motivates a rural exodus of 
populations into urban areas in order to find more-lucrative employment. However, 
migrations from rural to urban areas correlate with the development of allergic 
hypersensitivities [46]. Urban living environments and lifestyles are radically different, or 
‘artificial’, when compared to the natural environments where humanity first evolved. It is 
theorized [47] that more urban, and thus more artificial, habitats in the form of housing and 
workplaces with central heating, sealed-off from the exterior natural world, may 
dysregulate normal immune development. Furthermore, policies concerning the built 
environment and urban horticulture may also play a role in allergy. Select species of trees 
and plants appear en masse in parks and along streets, often chosen on the basis of 
aesthetics. Unfortunately, many of the most popular and aesthetic species produce 
allergenic pollen, and their monocultivation enables the concentration of allergens in 
densely populated areas [48]. 
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Environmental degradation: opening the gate to alien allergens and 
hypersensitivities   
 The negative influence that environmental degradation inflicts on population health 
is readily apparent; the detrimental ramifications of polluted air and water are well known 
examples. Of additional significance, though less well known, is that specific forms of 
environmental degradation introduce allergenic compounds into novel environments as 
well as enable conditions that amplify immune hypersensitivity responses. In terms of the 
latter, high levels of air pollution originating from diesel exhaust is known to bind 
suspended allergenic particles such as pollen [49, 50]. In addition to compromising the 
breathing capacities of all people (and especially individuals with respiratory illnesses), 
smog from diesel exhaust appears to be one mechanism by which aeroallergens become 
concentrated in the atmosphere and thus raise morbidity levels amongst allergy sufferers, 
and may also induce hypersensitivities in previously non-sensitized populations [51].  
 Climate change and the introduction of foreign invasive species are additional 
factors that induce allergy. Rising global temperatures have lead to new geographical 
regions that can support the growth of highly allergenic plant species [52]. Moreover, 
higher average temperatures during the growing season and elevated atmospheric carbon 
dioxide appear to increase the allergen content of pollen [53]. The accidental introduction 
of foreign species (e.g., by international trade of consumer goods that unknowingly harbour 
plants or insects) has caused a sharp rise in previously unknown, severe allergic reactions. 
A prime example is the surge in anaphylaxis by bites from Red Fire ants, which are 
indigenous to South America, in the South-eastern United States and in Europe  [54, 55].  
 
Common treatment strategies: drugs, immunotherapy, and allergen 
avoidance 
A desperate disease requires a dangerous remedy.  
! Guy Fawkes 
 
 For many individuals with mild to moderate seasonal allergies, symptom relief is 
readily available at their local pharmacy in the form of low-cost, over-the-counter anti-
histamine drugs, the most common being generic varieties of Diphenhydramine 
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(Benadryl™) and Loratadine (Claritin™). More serious atopic disorders, such as asthma, 
necessitate the administration of potent anti-inflammatory drugs in the form of 
corticosteroids and anti-leukotriene inhibitors. In the advent of a severe anaphylactic 
reaction, the immediate injection of epinephrine is the primary means of preventing sudden 
death by allowing time to obtain necessary medical interventions (e.g., mechanical 
ventilation to counter respiratory arrest). Nonetheless, these categories of drug treatment 
only attenuate allergy symptoms; they do not contribute towards preventing future allergic 
reactions or cure hypersensitivity responses (i.e., induce tolerance).  
    One category of therapeutic is distinct in that it is the only intervention that 
attends to the root-physiologic determinants of allergy. Allergen-immunotherapy, also 
known as allergy shots, can induce tolerance, and thus attenuate and sometimes cure 
allergic hypersensitivities. The treatment regime involves small injections of increasing 
doses of a problematic allergen over a period ranging from months to years. While it may 
seem counterintuitive, this controlled exposure of the allergic individual to the allergen can 
physiologically change their immune functioning, so that the IgG-antibody-mediated 
immune pathway becomes encouraged and counteracts the IgE-allergy-inducing pathway. 
Although a tentative cure for certain allergies (i.e., if allergy shots are available for a given 
allergen), immunotherapy is a less-than-ideal therapeutic strategy. A full course of 
immunotherapy requires numerous visits to an allergy specialist over an extended period of 
time. Many patients cannot meet the time commitments required and choose to terminate 
the therapy prematurely [56]. Furthermore, since the therapy requires exposing allergic 
individuals to a substance known to induce a hypersensitivity response, immunotherapy 
carries a small though significant risk of inducing anaphylaxis (recently estimated to occur 
once for every 1000 administered injections [57]). 
 Aside from pharmacological interventions, an additional means to minimize allergic 
reactions is to avoid exposure to allergens. On the basis of “biological rational” [58], 
methods to eliminate or build barriers to contain allergens are effective means to prevent 
allergic reactions. Certain allergen elimination or avoidance efforts are relatively simple, 
such as encasing mattresses and pillows with impermeable covers to provide a barrier 
against dust mites. However, avoidance of allergens such as seasonal pollen can be 
extremely difficult or impractical. Overall, numerous treatment strategies exist for allergy 
and co-morbid conditions. While beneficial, it is worth mentioning that most allergy 
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sufferers are dependant on pharmaceutical interventions in order to obtain a reasonable 
quality of life and health security. 
 A recent legal proceeding concerning refugees epitomizes the absolute necessity of 
access to pharmaceutical treatments for securing the well-being of many allergy suffers1. In 
April 2011, a Filipino family filed a refugee claim in Canada on the basis of their children’s 
allergies to nuts [59]. The family argued that they could not return to Manila because their 
sons’ severe allergic sensitivities required that they have access to epinephrine auto-
injectors (EpiPen), a medication which is not readily available in the Philippines. The 
Federal Court of Canada concluded that refusal to grant a stay to the family would do 
irreparable harm to the children. 
 
Societal burden of allergy: from the exhaustion of medical resources to 
diminished productivity 
 It is no measure of health to be well adjusted to a profoundly sick society.   
! Krishnamurti 
  
 The negative consequences of allergic disease are staggering and alarming 
throughout the world. In Australia, childhood asthma accounts for an estimated 1 million 
days of school absenteeism each year [60, 61]. In the United States, asthma is the leading 
source of disability amongst children and is the leading cause of childhood hospitalisations 
[62]. For adults, allergy is a significant cause of disability amongst the working population 
and is a leading cause of work-place absenteeism; for example, a survey in the United 
States found that employees experiencing allergic rhinitis symptoms were absent 3.6 days 
per year due to the condition, and were unproductive 2.3!hours per workday when 
experiencing symptoms [63]. In terms of costs due to productivity losses, this same survey 
estimated allergic rhinitis to be the most costly disease assayed: $593 for allergic rhinitis 
per employee per year, compared with $518 for high stress and only $40 for coronary heart 
disease. Mounting evidence suggests that the misery caused by allergy symptoms may be a 
significant cause of depression and a risk factor for suicide [64, 65]. (Though still a 
hypothetical association, a possible link between allergies, depression, and suicide provides 
an explanation as to why suicide rates are higher during periods of the year when pollen 
                                                
1 For an interesting case study in public health ethics concerning allergy refugees, see: [66] 
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levels peak in both the northern and southern hemispheres [64]). Additionally, many people 
with severe food allergies abstain from dining in restaurants and taking vacations due to an 
inability to monitor the composition of their meals [67], thus signifying another source of 
lost economic opportunities, not to mention reduced quality of life. 
 The main economic burden posed by allergic disease, however, is due to rising 
resource expenditures for the treatment of allergy and atopic disorders. The following 
summary of findings presented by Weiss, Haus, and Iikura [60] in a section of a report for 
the World Allergy Organization exemplifies the exorbitant health care costs of this one 
chronic immune disease. In 2003, the direct medical expenditures for allergic rhinitis in the 
United States were estimated at $4.4 billion (USD), annually. In Canada, treatment of 
asthma exceeds $433 million (USD), annually. In the United Kingdom, allergic disease 
accounts for 10% of all primary care prescription costs, annually. In Germany, costs 
associated with the treatment of seasonal allergies exceed EUR 1500 per adult, annually. 
From a global perspective, estimates of the disability burden from asthma are pegged at 15 
million disability-adjusted life years (DALYs), annually, thus being a level of disability 
equivalent to that stemming from other common ailments such as diabetes and 
schizophrenia [68].  Cumulatively, these statistics indicate that the effects of allergic 
disease far exceed the harm and disability caused to individual allergy sufferers; indeed, 
this chronic disease is compromising the future sustainability of many social institutions, 
public health care in particular.  
 
Descriptive versus Normative 
 The aim of the above informational overview was to demonstrate that allergy is a 
very complex disease, and one that poses an unprecedented challenge to the health of 
populations of the developed world. Despite over a century of investigation, the exact root 
determinants of allergy and the physiological mechanisms that initiate hypersensitivities 
towards normally benign substances still remain to be defined in detail. What is known is 
that a culmination of multiple genetic, environmental, and social factors is responsible for 
the current epidemic of allergy.  While descriptive, this overview of allergic disease 
contained no normative analysis. In other words, judgments, ethical assessments, and 
proposed moral imperatives concerning the health ramifications of allergy, the population 
distribution of allergy morbidity, and the legitimacy of treatment strategies, have remained 
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absent. Such normative reflections will now be the focal point of discussion and will serve 
to introduce the main problem analysed in this thesis.   
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IDENTIFYING THE PROBLEM: ALLERGY RAISES 
NUMEROUS ETHICAL ISSUES THAT CHALLENGE DECISION-
MAKING IN HEALTH 
 
The distribution of allergy morbidity and treatment strategies: a panoply 
of ethical issues 
Any important disease whose causality is murky, and for which treatment is ineffectual, 
tends to be awash in significance.  
! Susan Sontag 
 
 Upon initiating this doctoral project, my investigations concerning allergy were 
approached from a blind or naïve normative standpoint. Naïve in this context refers to my 
having no defined and preconceived moral judgments concerning this disease or its related 
population distribution of morbidity. Rather, my preliminary analysis centred on 
conducting a broad literature review in order to acquire knowledge of important issues in 
the treatment and population incidence of allergy. Concomitantly, training in applied 
bioethics provided capabilities to analyse observations in allergology and establish 
normative judgements concerning their ethical significance, in order to be able to propose 
strategies to address certain problematic aspects of current health policies. Within this 
analytical strategy, theories and principles of ethics were selected according to their 
relevance to the particular situation concerning allergy, that is, choosing the right tool for 
the appropriate task. For example, in the thesis, the implications of health burdens specific 
to women have been analysed using principles of feminist ethics, while health inequalities 
were analysed from the perspectives of social justice and methods to define health 
inequities (unjust inequalities). Below, I present four examples uncovered in this 
preliminary analysis that pair ethical principles with relevant issues concerning allergy. 
 
Therapeutic developments: ships navigating stormy seas 
 Access to therapeutics is an indispensable requirement for a normal life for many 
allergy sufferers. Ethical concerns thus abound when social, legal, and political factors limit 
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access to life-improving or life-saving drugs. Indeed, numerous challenges exist in terms of 
access to essential drugs for atopic disorders. One main barrier concerns the elevated costs 
for therapeutics; namely, the high costs of drugs is a leading cause of medical non-
compliance amongst impoverished allergy patients [1]. While this observation alone 
highlights the need for greater justice in the provision of essential allergy medications, 
additional questions stem from legal and political factors that encourage elevated drug 
costs. For one, technological innovation in techniques to administer common generic drugs 
have enabled pharmaceutical companies to obtain new patents and monopoly rights on 
previously inexpensive therapeutics [2]. Is this an acceptable business practice given its 
impact on equitable access and population health? Overall, this situation concerning allergy 
therapeutics raises questions concerning how to reach an ethical balance between 
intellectual property rights and innovation, drug costs, and access to essential medicines of 
great importance for public health [3]. 
 At a broader level, the dichotomy in rates of asthma mortality between the 
developed and developing world is disquieting. Though the developing world has the 
lowest population incidence of asthma, asthma mortality predominates in these countries 
[4]. Thus, the basic medical services that can effectively prevent asthma mortality in the 
developed world are obviously not available to many impoverished populations of the 
world. This harsh disparity requires ethical assessment from the perspective of global 
justice in health.  
 
Children 
 Unlike most other forms of chronic disease, which primarily afflict adult and 
elderly populations (e.g., cardiovascular disease, arthritis), allergy predominates in and 
often first manifests symptoms during childhood [5, 6]. Of greater concern are several 
observations that children disproportionately experience severe and life-threatening 
reactions from anaphylaxis and allergen-induced asthma [7, 8]. Since children have little 
control over their health for which they can be held responsible, several questions arise 
concerning what duties health officials, childcare workers, and parents ought to have in 
protecting allergic children from allergic reactions. Furthermore, the onset of allergy in 
childhood suggests that these allergic individuals may experience significant morbidity 
throughout their lives, which is not the case with adult-onset diseases. Therefore, questions 
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arise about whether health interventions and resources for allergy treatment/prevention 
initiatives in children ought to be prioritized over initiatives for adult-onset diseases. 
 
Women 
 One prominent critique advanced by feminist scholars in health is that researchers 
and medical experts tend not to prioritize the specific health needs of women and this in 
turn aggravates unjust gender-inequalities [9, 10]. Is this true for allergy? Perhaps. Relative 
to men, women carry a disproportionate burden of allergy morbidity and mortality [11-13], 
which may suggest that the specific health needs of allergic women are not being met 
appropriately. Moreover, co-morbid conditions such as asthma complicate many biological 
processes that are unique to women, namely pregnancy and childbirth [14]. From a feminist 
ethics perspective, the unique burden experienced by women suggests that the allocation of 
health resources and interventions for allergy ought not to be distributed equally between 
both sexes; rather, women merit a higher priority.  
 
Visible and other minority groups 
 Allergic disease does not discriminate; no individual because of ethnic origin or 
group identity is secure from developing an allergy. However, the severity and incidence of 
allergy morbidity is disproportionate amongst ethnic minority groups in developed 
countries [15]. For example, many new immigrants develop severe allergies five years after 
immigrating from nations that have a low incidence of allergic disease [16]. Moreover, 
within indigenous populations of the United States, the incidence of allergy and asthma 
morbidity is significantly higher amongst minority groups [17], in particular, African 
Americans [18-20]. While annual deaths from asthma attacks in the United States appear to 
have stabilized, death rates amongst racial and ethic minorities have shown little 
improvement [21]. Additional minority groups with elevated incidence of asthma appear to 
be sexual minorities (gays, lesbians), even amongst members of this minority that do not 
have risk factors for the disease (e.g., common risk factors such as smoking, low education 
or socioeconomic status) [22]. These observations raise concerns that factors associated 
with social exclusion, disenfranchisement, and stigma due to group affiliation may 
exacerbate allergy and limit access to effective treatments. Ethical policy interventions thus 
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ought to compensate for the unjust diminished capacities these groups face in terms of their 
illness and ability to access health services. 
 
When a job determines your allergy, the allergy in turn determines your job   
 Recall that exposure to sensitizing agents in the work environment can induce 
debilitating occupational allergic sensitivities. For many workers that develop an 
occupational allergy, their disease often results in termination of employment and long-
term financial insecurity [23-25]. These observations raise several questions concerning 
what should constitute ethical business practices in the manufacturing of known allergenic 
substances, and the duties that employers have in protecting the health and employment 
status of their employees. From a public health perspective, effective health policies to 
manage occupational allergy will need to address how certain business interests can 
compromise efforts related to occupational hygiene and health surveillance. While applying 
stringent occupational hygiene standards and sound health surveillance protocols favour 
securing the health of employees, these efforts might not be what are most favourable for 
private interests and profit acquisition. This area requires vigilance and ethical assessment, 
which could be informed by principles of business ethics in order to provide suitable guides 
in policy development for occupational allergy. 
 
Humble beginnings as a start, not an end: the aims of this doctoral thesis     
 The above overview of ethical issues in allergy does not pretend to represent an 
exhaustive list of topics that would merit further ethical analysis or be the subject of 
targeted health interventions. Indeed, the following chapters of this thesis that focus on 
allergic disease (chapters 1-4) will present four additional issues in allergy for ethical 
inquiry that were not mentioned specifically in the discussion thus far. Due to the vast 
breath and diversity of ethical issues in allergy and related health policies, it is important to 
note that the investigations in this thesis are bound by specific limitations. First, this thesis 
does not aim to outline a comprehensive policy strategy to combat all forms of allergy 
morbidity. Nor does the analysis aim to develop a universal ethical framework to guide 
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health policy2 in dealing with this disease. Instead, this project seeks to reach out to 
clinical, professional, and regulatory communities that do not specialise in ethics, with the 
goal of promoting knowledge transfer between the domains of bioethics, health policy, and 
allergology. This knowledge transfer will take the form of employing principles of ethics to 
structure policy assessment frameworks that aim to empower ‘meso-level’ professionals in 
their daily practice (i.e., the target audience for this thesis are not ‘macro-level’ health 
policy officials, such as top-level ministers of health in government, but rather 
professionals typically employed within institutional settings). These frameworks are 
designed to help strengthen the decision-making capacities of professionals working within 
a rage of institutional settings (e.g., schools, regional health institutions) who are 
responsible for the development of health interventions for allergy and co-morbid diseases. 
The remainder of this chapter will explain these concepts in greater detail. 
 
Unfamiliar territory?: Principles of ethics, decision-frameworks, and 
health policy development 
 Before venturing into an analysis and discussion of policy development for allergic 
disease, certain issues require additional clarification. To begin, it seems reasonable to 
assume that many health professionals may have modest experience with the field of 
bioethics, and moreover, the application of ethics in institutional policy development may 
be for many an unfamiliar methodology [26, 27]. This possibility should come as no 
surprise since bioethics is a relatively young field of scholarship (originating between the 
post-war era of the 1950’s [28, 29] to the ‘technological era in healthcare’ of the 1970’s 
[30]), and the specific sub-field or specialty of health policy ethics is at a very early stage 
of development. In 2005, Nuala Kenny and Mita Giacomini, two leaders in health policy 
studies, described scholarship in health policy ethics to be in its infancy [31]. This expert 
opinion echoes the views of another ethicist and health policy expert, L. R. Churchill [32]. 
A ‘primordial stage of development’ is likewise an apt description of the specialty of public 
health ethics, the origins of which can be traced back to the 1990’s [33]. To attend to the 
likelihood of a reader’s unfamiliarity with the application of bioethics in health policy, the 
                                                
2 For this thesis, the term health policy is in reference to contexts where decisions and analyses centre on 
establishing regulations or general courses of action without reference to defined individuals. This is distinct 
from clinical and research contexts, where analyses are more ‘narrow and defined’ since they typically centre 
on issues involving interactions between clinicians and patients, or researchers and research subjects.    
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following discussion will clarify the process of implementing principles of ethics in policy 
development and the use of ethics frameworks as guides in decision-making processes.  
 
Why is ethics relevant to health policy decisions?  
 At the outset, the most basic question to ask is why health interventions necessitate 
an analysis of their ethical implications. The simplest response is that society now demands 
careful attention to ethics in health contexts [34]. This demand arises from the uncovering 
of well-known abuses of power in what were blatantly unethical biomedical and 
epidemiological studies involving human subjects; the Tuskegee [35] and the recently 
exposed Guatemalan [36] syphilis studies are apt examples, where vulnerable populations 
(numbering in the thousands of people) were denied treatment for this disease in order to 
study its transmission and devastating individual and population health effects. 
Technological innovation in biomedicine is an additional issue of ethical significance 
because along with the benefits of new technology arise novel risks. Assisted reproductive 
technologies are a notable example, where along with curing many forms of infertility, 
science has concomitantly enabled novel means to produce ‘designer babies’ and the 
commodification of human reproduction [37]. Further ethical tensions surface from the 
advent of new challenges to health, as seen with the epidemics of AIDS or allergy; thus, 
questions abound as to what these emerging problems entail for society as a whole and how 
we should best address these threats to individual and population health.         
 In addition to the above societal demands for ethical reflection in health, ethics 
deliberations and analyses also serve a practical function in decision-making and health 
policy contexts. At the very least, an ‘ethics perspective’ offers a different way of assessing 
problems that have long plagued health policy [38, 39, 40 p.4], thus enriching policy 
discourse by expanding policy development beyond solely monetary, political or evidence-
based factors [41]. Health policy development is a complex endeavour that must consider a 
wide variety of issues ranging from economic, social, cultural, and legal factors, as well as 
the opinions of diverse stakeholders [42 p.384]. Equally important are the ethical 
implications3 of health policy, and in order to have all the ‘tools’ necessary to achieve the 
                                                
3 A detailed overview of ethical issues raised in health policy is provided in the subsequent chapter 
concerning practical theory in health (Practical Theory). To minimize redundancy, discussion of this topic 
will be reserved for that chapter. 
  
25 
highest standards in health policy, one tool should arguably be an analysis of the ethical 
implications [43].  
Trevor-Deutsch and colleagues offer an excellent summary of this practical aspect 
of applying principles of ethics as tools to guide health policy:   
Thoughtful bioethical analysis gives rise to well-reasoned, ethically 
justifiable solutions based on widely held ethically justifiable moral beliefs 
that are likely to resonate positively with a society that supports them. It does 
so by offering solutions that optimize as many ethical considerations as 
possible, while recognizing that others may be compromised, and explaining 
why. [44 p.293] 
Simply put, by incorporating ethical reflections in health policy assessments, decision-
makers are better positioned to determine whether the outcomes of policy are indeed 
desirable, and if not, are able to identify possible courses of action that could lead to better 
outcomes [32]. Furthermore, incorporating an ethics analysis into policy development aids 
decision-makers in being meticulous in their reasoning by requiring decisions to uphold 
facts and arguments and not merely personal beliefs or self interest [45]. Using widely held 
principles of ethics as guides helps define goals and core values that should be met by 
health professionals and the policies put in place. In turn, these guides aid decision-makers 
to have greater consistency and transparency with their decisions, and as such, they gain 
additional means to explain how and why they arrived at their decisions [41].  
 Indeed, the outcomes determined by health policy decisions, such as the structuring 
of health care systems, undoubtedly have profound ramifications for society. This fact 
alone highlights the importance that policy decisions be based on important societal values 
and attend to a range of ethical considerations. How exactly is this done and what strategies 
can be employed in order to structure ethically sound health policies that complement core 
social values? 
 
Implementing ethics in health policy development 
 One common method to plan ethically sound policies is to ensure that policy 
development is structured according to a framework composed of defined ethical principles 
and theories. These principles and core theories of ethics represent general values that 
uphold fundamental ‘rules’ (e.g., ensure fairness, avoid harming others, the need to protect 
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the vulnerable) that orient ethical analysis of specific cases or within specific contexts [46 
p.12-18, 47]. Determining which principles should comprise an analytical framework is 
influenced by many factors (e.g., current knowledge of risks and benefits inherent to a 
situation, preconceived goals or common social values, general intuitions on how best to 
handle a dilemma stemming from previous experience). What is most important to note is 
that each ethical principle focuses consideration towards relevant moral issues, which in 
turn “establish and define important concepts and can be used to describe important aspects 
of the positions we hold” [48]. Thus, consider the example of determining whether a health 
care system should subsidize the implementation of a novel technology [49]. In addition to 
issues of financial feasibility and medical efficacy, the merits of this technology can also be 
assessed with regards to its foreseen distribution of benefits and risks across a population. 
Guidance on this front can surface from a framework structured on the ethical principle of 
utility maximisation (maximise benefits while minimising harms) along with the need to 
ensure a fair distribution of utility within society (will certain groups inherently benefit 
from the technology while others will not?) [44]. Following this assessment, if the 
technology is expected to produce greater harms than benefits for society, ethical reasoning 
guided by this framework would suggest that this technology does not merit government 
subsidies. Another problematic situation would be if the technology could provide a net 
benefit but these benefits will be unequally distributed (e.g., the technology can only be 
implemented in urban areas). Once again, ethical reasoning might question whether this 
unequal distribution of benefits is fair and acceptable, and thus provide valuable insights 
when debating the merits of this technology.   
While exercises in normative ethics are typically ‘prescriptive’ in nature [31], such 
that normative conclusions aim to determine (or proclaim) what ought to be done in 
specific circumstances, decision frameworks should not be perceived as prescriptive tools 
for health professionals. To expand, decision-making frameworks do not aim to be 
authoritarian in structure or implementation. That is, these guiding frameworks do not 
‘order’ health professionals to radically change their practice parameters or to conform to 
the values and ethical principles inherent to each framework. Indeed, ethics frameworks are 
not the ‘rule of law’. The function of these frameworks is instead to help indentify and 
articulate the issues and values at stake in decisions-making processes, which in turn can 
empower health professionals so that they may better-evaluate various options and make 
better-informed choices. Ethics-based frameworks “should therefore be understood less as 
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norms that are applied, in the model of “applied ethics”, and more as guidelines that are 
interpreted and made specific for policy and clinical decision making” (original emphasis) 
[50 p.182]. Overall, employing ethics frameworks as guides does not imply dictating the 
content and conclusions drawn from an analysis. Rather, employing frameworks in health 
policy discourses “encourages broader and more robust moral discussion, requiring 
personal sensitivity as well as a trained appreciation of the many issues that can be 
relevant” [48 p.397]. To conclude, frameworks in health policy development serve to 
improve a professional’s decision-making capacities but do not stipulate what these 
decisions must be.  
The development of frameworks to guide decision-making processes in health is 
now a nearly ubiquitous research activity in bioethics scholarship, and ethics frameworks 
constitute a primary instrument for ethical analysis in health contexts [44]. A diverse range 
of frameworks are now available to health professionals as guiding instruments in a breadth 
of decision-making processes. Notable examples include: frameworks for public health 
practice [45, 51] and policy [42], frameworks to guide decision processes for nurses [52] 
and other clinicians [53], and principles that guide professional duties in pandemic flu 
crises [54, 55] and following acts of bioterrorism [56].  
 
Implementing ethics analyses in health policy: Easier said than done 
 Though bioethics scholarship is continually developing ethics frameworks as tools 
to guide policy development, the current implementation of ethics analyses by decision-
makers in health faces notable challenges. For instance, though an analysis of ethical issues 
can provide valuable tools in decision-making processes, Gibson and colleagues [57] 
question whether such tools are actually available to most decision-makers. This does not 
appear to be the case since understanding in how to implement ethics analysis appears to be 
limited amongst most health decision-makers. For example, Gibson et al. note that 
“[a]lthough healthcare decision-makers are increasingly successful in using clinical 
evidence and applying economic analyses to set priorities, they are less confident that their 
priorities are ethically sound” [57 p.51] (emphasis added). This current lack of familiarity 
and confidence in executing ethically sound decisions in healthcare contexts occurs at a 
period where experts observe a significant and growing demand for practical approaches to 
incorporate ethics assessments in health service organizations [57]. 
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 The above observations are indicative of a broader problem amongst decision-
makers in health [41]. Though policy specialists increasingly recognise the utility of ethics 
analysis in policy development, these specialists remain unfamiliar with ethics as a field of 
study and lack experience in employing sometimes abstract theories of ethics in day-to-day 
practice. Therefore, while the targeted end-user for ethics-based frameworks are decision-
makers in health (i.e., the professionals that will determine what policy decisions are put 
forth and implemented in actual, real-world settings), lack of knowledge about the scope 
and use of ethics frameworks means that these professionals may be incapable of 
developing these tools on their own. This division between developers of ethics 
frameworks and actual decision-makers is due to what has been described as a ‘two 
communities’ divide between health professionals [58, 59]; the expertise of health 
professionals has become so specialised that transferring knowledge from one area of 
expertise to another is often difficult [60]. It is here where the interdisciplinary field of 
bioethics demonstrates its ability to ‘bridge’ disparate communities and domains of 
knowledge. 
 
The role of bioethics: Ethics frameworks in health policy necessitate a 
knowledge transfer activity 
 As noted by Jocelyne Saint-Arnaud [61 p.19], the nature of the field of bioethics is 
one that situates itself not exclusively at a theoretical level, nor at a strictly practical level, 
but rather at a dialectic space between the two. This ‘theoretical level’ is in reference to the 
theory-heavy discipline of Philosophy, where abstract principles and theories of ethics are 
typically conceived and serve to advance debates centring on questions of ‘what ought one 
do in a hypothetical situation’. The ‘practical level’ is in reference to real-world health 
contexts where health professionals face immediate dilemmas and ask questions such as 
‘what must we do in this immediate situation’. Occupying the space in between, bioethics 
provides a ‘Rosetta Stone’ function,4 and can serve to implement theoretical tools to aid in 
the resolution of actual dilemmas in health [45]. Being familiar with both philosophical 
theory and practical challenges in health care, the bioethicist can be a key actor in the 
                                                
4 The mere term, Bio-ethics, is representative of a field of study aimed at knowledge transfer between 
theoretical and practical domains of inquiry. As described by Hubert Doucet: “It is clear when looking at the 
origins of the term [bioethics] that it is was coined with a view to bringing two worlds that normally ignore 
one another into dialogue” [62 p.14]. 
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translation of knowledge between these two disparate contexts. In turn, this role of 
‘knowledge translator’ enables the systematic incorporation of ethical principles in 
decision-making processes by uncovering methods to make this process readily tangible to 
decision-makers in health through the development of ethical frameworks as guides in 
policy assessment strategies.   
 
The concluding part of this chapter will provide an overview of the main research 
goals and analytical methods employed in this thesis, i.e., in relation to the knowledge 
translation activity of developing decision frameworks for allergic disease. Only a brief 
explanation will be given here of the research methods, as the broader methodological 
framework of the thesis will be explained in detail in the subsequent chapter 
(Methodology).  
 
“An implicit methodology” for analysing allergy  
 The above title is derived from the work of Hubert Doucet, who offers a description 
of one form of bioethics methodology [62 p.21]. Described as an “implicit methodology”, 
Doucet illustrates a bioethics analysis executed by a multi-professional health care team as 
a four-step process. The first step comprises a ‘fact finding’ activity that consists of 
gathering relevant information on the ethical dilemma faced by the health care team (e.g., 
gather all necessary information concerning an end-of-life decision to determine: is the 
patient competent to provide consent?; what are the treatment options for this patient?; are 
family members are implicated in this process?; etc.). Having gathered the relevant 
information, the analysis moves to the second step, which consists in identifying the ethical 
issues at stake. At this point, evaluations ask ‘what exactly is the problem under 
consideration?’ (e.g., does the dilemma arise from new medical technologies?; are ethical 
tensions due to a clash of values between a patient and a health care professional?). With 
the main ethical issue identified, the analysis moves on to the third step involving the 
application of principles of ethics as guides for thinking through the dilemma. To expand, if 
a dilemma centres on determining what is the best treatment option for a patient, ethical 
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analysis may reflect upon principles5 of beneficence and autonomy in order to assess what 
is ‘good’ for the patient — as medicine defines it — and whether a given treatment option 
will uphold a patient’s wishes. The fourth and final step is the execution, where the 
guidance provided by the principles aids the health professionals in identifying a reasonable 
course of action aimed at resolving the dilemma. Though in reference to ethical 
deliberations in health care teams, this ‘implicit methodology’ is typical of thought 
processes in bioethics (for another example, see: [40 p.204]), and indeed, is a conceptual 
process that is replicated in this thesis (Figure 1).  
 
Figure 1: Situating the research activities and conceptual methods used in this thesis 
 
 
The main research questions and activities of this thesis can thus be summarized as 
a knowledge transfer activity at the nexus of an ethical analysis of allergic disease. 
                                                
5 These two principles serve as examples, and certainly additional ethical considerations are relevant to end-
of-life decisions that have not been mentioned here. A detailed explanation of these principles is presented in 
‘Practical theory’, through an overview of theory and principles of ethics in health. The following two 
principles serve as examples; certainly additional ethical considerations are relevant to end-of-life decisions 
that have not been mentioned here. 
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Investigation begins with a broad and extensive review of the medical, policy, and public 
health literature concerning allergy and co-morbid conditions in order to identify 
challenges faced by health professionals/decision-makers and significant weaknesses in 
current allergy treatment strategies (i.e., identify challenges and problems concerning 
allergy that health professionals within institutional settings encounter on a common basis 
[Figure 1; double headed arrow]). This represents the initial ‘fact finding’ activity. 
Identified challenges and weaknesses then become subjects for focused assessment, where 
a given challenge or weakness is a particular case or context for ethical analysis. This 
analysis segment is analogous to the second step in the implicit methodology that serves to 
identify the main ethical issues that are inherent to the case or context at hand. Moving on, 
the subsequent research activities centre on identifying principles of ethics that are 
pertinent to the context. Principles are chosen based on their ability to provide guidance in 
thinking through the dilemma at hand (step 3). This pairing (or synthesis) of principles to 
the context is based on whether the principles help identify important issues for 
consideration, or help define what a ‘better’ or more ‘ethical’ outcome would be if the case 
at hand were to uphold the principle under consideration. These principles are subsequently 
used to structure decision-making frameworks for the chosen context, with the aim of 
providing a readily implementable tool to guide health policy interventions for allergy. 
Research activities end at this stage; thus, how the frameworks established herein are 
executed (step 4) in actual health policy procedures are not examined in the thesis. 
However, the overarching aspiration is that these frameworks become applied by health 
professionals in common practice with the end-result of helping improve decision-making 
capacities, and thus, health policy development overall within institutions. 
 
Having delineated the research activities and general analytic process employed in 
this thesis, the discussion will now move to a detailed presentation of the thesis’ 
methodological framework.   
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METHODOLOGY: A HYBRID MODEL 
 
 Choose always the way that seems the best, however rough it may be. Custom will soon 
render it easy and agreeable. 
! Pythagoras 
 
 Churchill in 2002 [1] and Kenny and Giacomini in 2005 [2] described health policy 
ethics as a new sub-field of scholarship in bioethics and policy analysis. Being in its 
infancy, investigations in health policy ethics present certain challenges, as well as 
opportunities, when determining the appropriate methodological strategy to employ, and 
for our purposes, when analysing allergic disease. The main challenge is that there are 
currently no widely endorsed methods or ‘tried-and-true’ frameworks for health policy 
ethics [2]. This is unlike the situation with clinical and research ethics, for example, where 
decades of scholarship has produced what are now widely accepted — or at least well-
known — bioethics frameworks and assessment models (e.g., the framework of Principlism 
[3] for clinical ethics, and the Declaration of Helsinki [4] guidelines for research ethics6). 
This challenge, however, also presents an opportunity to be innovative in this thesis with 
regards to the application of bioethics frameworks and core principles of ethics. Innovative 
in this situation is in reference to the opportunity to be ‘flexible’ when determining the 
composition of ethical principles to be employed in the development of decision-
frameworks for allergy that target a broad range of professionals employed within a 
diversity of institutional settings. Flexible in this context does not imply random or 
arbitrary, but instead refers to the fact that a rigid application of one theory or one particular 
framework of principles would be insufficient, thus signifying the need to consider multiple 
principles in bioethics and related sub-fields.  
This insufficiency is due to one primary reason, namely the broad scope and 
diversity of dilemmas observed in allergy. Recall from the previous chapter that allergy 
raises what has been described as a ‘panoply’ of ethical issues whose contexts vary widely. 
To expand, challenges inherent to the allergy epidemic implicate contexts ranging from 
clinical practice, to pharmaceutical innovation, to public health interventions, to the 
                                                
6 Both of these frameworks will be described in the subsequent chapter on practical theory. To avoid 
redundancy, core principles of clinical and research ethics are not described in detail here. 
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distribution of health interventions, and many more. Accordingly, the development of 
policy assessment frameworks for allergy will target the needs of a diversity of decision-
makers in health, ranging from clinicians, to government regulators such as policy analysts, 
to regional public health officials. While implementing one specific analytical framework 
of principles within one context might be sufficient for ethical analysis, this framework 
would likely be ill-equipped for analysis in a different context [3 p.376-377]. For example, 
it is widely accepted that ethical principles developed for clinical contexts are ill-suited for 
analysis of population-level contexts in health [5, 6]. Therefore, in order to address the 
multiple contexts, or ‘layers’ of complexity, inherent to decision-making for allergy, this 
thesis will implement a mixed or ‘hybrid model’ framework of ethical principles. This 
hybrid model thus includes several core principles of ethics developed for ‘individual-level’ 
contexts (namely, core principles of clinical and research ethics) and ‘population-level’ 
contexts (namely, core principles of public health ethics and theories of social and 
distributive justice). Inspiration for implementing a hybrid model in decision-making 
contexts for health is derived from a similar model published in 2006 by Eileen Morrison in 
her book, Ethics in Health Administration: A Practical Approach for Decision Makers [7]. 
The remainder of this chapter will explain this ‘Morrison-inspired’ hybrid model and show 
how it is adapted to meet the research goals of this thesis.  
 
Individual- and population-level principles: a hybrid model  
Written for a target audience of health administrators, Morrison developed a 
comprehensive ethics framework to help improve the decision-making capacities of 
administrators in day-to-day practice (health administrators in this context are upper-level 
management of health care institutions, such as hospitals). It is typical for health 
administrators to encounter a broad diversity of ethical dilemmas in their careers. These 
issues range from resolving conflicts between staff and upper-management, to determining 
what quality of services is appropriate for patients, to establishing what duties should be 
upheld when serving the needs of the broader community, such as defining what services 
should be free of charge in order to assure that underprivileged community members have 
access to necessary health services. Due to this diversity of ethical issues, Morrison does 
not ascribe to one particular theory (e.g., utilitarianism), or one well-recognised framework 
of ethical principles (e.g., Principlism), or centre ethical assessments at only one ‘level’ of 
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analysis (e.g., community-level). Instead, Morrison describes ethical dilemmas as 
occupying various levels that influence ethics decisions, and thus constructs a framework 
that contains principles pertinent to each level of analysis.  
The first level of ethical analysis pertains to the personal character of the 
administrator and ethical nature of their interactions with other staff members. To address 
ethical issues at this level of analysis, Morrison’s framework implements principles of 
virtue and personal ethics  (e.g., Martin Buber’s theory to uphold a minimum I-You 
relationship when interacting with others). Moving one step outwards, the next level of 
ethical issues centre on policy decisions pertaining to individual patients within clinical 
contexts. Here, Morrison implements Beauchamp and Childress’ framework of Principlism 
as the basis for ethical assessments, composed of the four cardinal principles autonomy, 
beneficence, nonmaleficence, and justice. Moving further outwards, the next and broadest 
level pertains to the organisational structure of the hospital and its interaction with the 
community. At this level, Morrison centres ethical analysis on issues related to social 
justice when analysing issues such as the fair access to essential health services. Overall, 
Morrison’s framework constitutes somewhat of a ‘toolbox’ containing a diverse collection 
of theories and core principles of ethics. The context (i.e., level of analysis) will determine 
which ‘tools’ will be used to help resolve the ethical dilemma at hand.  
Morrison’s methodological approach and analytical strategy share many similarities 
with the research question and goals of this thesis. For one, as in health administration, 
decision-making contexts for allergy implicate a broad range of issues that require ethical 
assessments at multiple levels, namely individual- and community-level contexts. Thus, in 
order to have a full set of tools to address ethical issues in allergy, this thesis will take as 
inspiration Morrison’s approach in order to structure a context-specific, hybrid model 
framework for analysis. To attend to individual-level contexts, this thesis will employ 
Principlism as a basis for analysis. However, within broader community- or population-
level contexts, analysis will employ core principles of public health ethics and theories of 
distributive and social justice. Moreover, Morrison’s approach aims to empower health 
administrators within health care institutions, or what is defined herein as ‘meso-level’ 
health professionals implicated in ‘institutional-level’ policy development. Thus, similar to 
Morrison, the frameworks proposed in this thesis target meso-level health professionals 
employed in common institutions, such as childcare facilities, and not ‘macro-level’ health 
officials employed with the upper echelons of government, such as ministers of health 
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tasked with determining broad resource allocation decisions for national health care 
systems.     
While this hybrid framework (i.e., toolbox) will include a diversity of ethical 
principles (i.e., tools), it is necessary to be clear that these principles are not a random 
assemblage. Instead, these principles have been selected on the basis of whether they 
provide valuable insight and the ability to analyse the contexts and cases that will be 
presented in Chapters 2-4. In other words, these principles have been selected based on 
their pertinence to the ethical dilemma at hand and their relevance to the epidemic of 
allergic disease. The following two examples concerning justice theory and virtue ethics 
will help explain further what is meant by pertinence and relevance, and thus will 
demarcate important limitations of scope inherent to this framework and subsequent 
analyses. 
As a first example, unlike the case of Morrison’s framework, the framework in this 
thesis does not use virtue ethics or contain any principles pertaining to the moral character 
of decision-makers in health. Morrison devotes much of her analysis towards the moral 
character of decision-makers (e.g., does one uphold integrity?) as a means for providing 
guidance in situations such as conflicts between staff and management. Assessments of this 
sort are not relevant to the analyses executed in this thesis. As defined in the previous 
chapter, the research activities of this thesis stop at the level of proposing policy assessment 
frameworks for institutional decision-makers in health. Thus, attributes of the decision-
makers targeted for these frameworks are not relevant to this thesis and therefore, ethical 
principles pertaining to the moral character of decision-makers are excluded from analysis.        
Within the field of health policy, justice assessments are commonly divided into 
four main categories that define the context and criteria analysed within equity assessments 
[8, p.30]. One category is intergenerational justice, which centres assessments on issues 
related to the maintenance of resources and health services across generations. An 
additional category is that of deliberative justice, where equity assessments focus on the 
full and effective participation of affected parties and relevant stakeholders in decision-
making processes. A third category is social justice, where strategies to minimise health 
disparities between groups rest at the nexus of equity analysis. The final domain is that of 
distributive justice, which entails analysis of what constitutes a fair distribution of benefits 
and burdens of health policies across individuals and communities.  
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 An analysis that concentrates on all four categories of justice in health policy would 
be too expansive for this doctoral project. This thesis will thus limit analysis to two 
domains, that of distributive and social justice. The reasons for selecting these categories 
are twofold. Of primary importance is the fact that a recent wave of research has raised 
concern about the existence of significant health disparities amongst allergy sufferers, 
disparities that correlate strongly with distinct communities and social determinants [9-13]. 
These concerns indicate that equity issues associated with health disparities and the 
distribution of health interventions across various communities are currently of great 
relevance to decision-making processes for allergy. This does not imply that 
intergenerational or deliberative justice issues are of no relevance to allergy; however, the 
latter category is at arms length to the knowledge transfer activities of this thesis and the 
former is arguably of less significance at this point in the allergy epidemic. To expand, the 
frameworks developed in this thesis focus on providing guidance directly to decision-
makers in allergy. The interactions between decision-makers and relevant stakeholders, or 
stakeholder deliberations in health policy development, are another area of study altogether, 
and thus beyond the scope of this doctoral project. And lastly, the incidence of allergic 
disease has only recently reached epidemic proportions over the course of the past 30 years 
[14, 15]; this suggests that an intergenerational analysis of allergy may be premature, and 
as such, theories of intergenerational justice are not included in the analytical framework.     
 Having explained the methodological approach for this thesis, the following chapter 
will provide a detailed discussion of the ethical principles and core theories that will be 
implemented to analyse allergic disease and subsequently develop individual policy 
assessment frameworks for decision-makers in health. This chapter on practical theory will 
serve two functions, one being to familiarise the reader with these principles prior to their 
implementation in ethical analyses for allergy. Also included in this ‘familiarisation 
process’ are explanations of challenges inherent to the use of specific theories in policy 
development, such as conflicting accounts of social justice theory. The second function is 
that this discussion will provide practical examples of how ethics can be used when 
structuring and assessing health policy so that the link between ethics and meso-level 
policy assessment parameters will become more apparent for readers unfamiliar with 
bioethics. Principles of ethics are grouped into two categories as defined by the 
methodology, namely individual-level and population-level principles.  
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PRACTICAL THEORY: PRIMARY PRINCIPLES OF ETHICS 
IN HEALTH AND THEIR APPLICATIONS IN POLICY 
DEVELOPMENT 
  
A theory must be tempered with reality. 
! Jawaharlal Nehru 
  
 Having delineated the main research question and methodological approach 
employed in this doctoral thesis, this chapter will present a series of ethical principles and 
concepts that are integral analytical tools employed in this thesis. The application of these 
principles within the specific context of allergic disease, however, will not be the primary 
focus at this point in the thesis; a brief summary will be provided by way of conclusion to 
this chapter, and serve to introduce the subsequent chapters (1-4) that focus on ethical 
issues in diverse contexts of allergic disease. Instead, the goals of the present chapter are to 
contextualise principles of ethics relative to general health circumstances (i.e., will not 
focus on one disease, or one treatment strategy), and show the utility of these principles as 
guides in decision-making frameworks for health policy that aim to empower a range of 
professionals working within diverse institutional settings. This chapter thus provides a 
broad description of practical ethical theories used in analysing issues in health 
interventions and policies, and explains how these theories can help identify important 
considerations for structuring policy interventions. With that said, it is important to explain 
further the main goals of this chapter and the methods chosen to present a set of principles 
of ethics and their pertinence to health policy. 
 It is necessary to first state what are not the goals of this chapter. The following 
discussion of ethical principles will not present philosophical debates concerning the 
strengths and weaknesses of principles and theories, or argue that one principle is superior 
to another in a specific context. Rather, the principles will each be presented as separate 
concepts, and a section entitled Theory application will then explain the utility of 
employing the principle or main concepts within decision-making frameworks. The reason 
for this presentation is twofold. First, this layout replicates the strategy employed by 
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Morrison in her framework for analysing ethical issues in health administration, written for 
an audience of health administrators implicated in meso-level policy development for 
health care institutions [1]. Following Morrison’s heuristic approach to applied ethics, the 
descriptions of abstract principles of ethics will be presented with an array of health 
professionals in mind as end-users. Knowing that many health professionals have limited 
knowledge of ethics principles and their application in the context of health policy, these 
abstract principles need to be explicitly formulated for an audience of ‘non-experts’. 
Second, the utility of this approach is that it promotes knowledge transfer between distinct 
domains of scholarship and professions. Recall that this dissertation also aims to contribute 
towards knowledge transfer activities by applying ethical theory in the development and 
analysis of health policy. Thus it is important to note that the development of additional 
ethical theories or further advancing philosophical debate about principles of ethics is not 
the purpose of the current chapter, nor the thesis more generally. 
 Finally, this chapter does not seek to provide an exhaustive depiction or analysis of 
all known or popular ethical principles employed within health contexts, which number 
well over a hundred principles. Rather, the intention is to provide decision-makers in health 
care and public policy with enough background to be able to understand and evaluate the 
ethical arguments and decision-frameworks used in this thesis. Recall from the previous 
chapter that the chosen analytical strategy will include a range of principles and theories 
that are representative of ethical issues occurring at both the micro-level (individual) and 
macro-level (population). Within this chapter, principles of ethics will be presented as two 
groups based on the individual versus population distinction. The discussion will now 
begin with an overview of principles developed to help guide decision-making in health 
where consideration of defined individuals, such as patients, forms the basis for ethical 
reflection. To conclude, the remaining principles of ethics will expand their focus towards 
ethical issues related to the health of populations and specific communities.   
 
The basic tenants of Principlism: a guide for ‘micro-level’ decision-
making in health 
 It would not be an over exaggeration to assert that one of the most important 
contributions to bioethics scholarship in the late 20th Century was the Principles of 
Biomedical Ethics, by Tom Beauchamp and James Childress [2]. First published in 1979 
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and now in its 6th edition, this book has become a cornerstone of medical practice, 
biomedical research, and bioethics7. Also known as Principlism (or the Four Principles 
Model), Beauchamp and Childress developed a comprehensive framework for biomedical 
ethics based on four cardinal principles widely accepted in North America and Europe: 
respect for autonomy, nonmaleficence, beneficence, and justice. [These principles are very 
similar to the three principles first enumerated in the influential US Belmont Report [3], 
Ethical Principles and Guidelines for the protection of human subjects of research 
(autonomy, beneficence, justice; first published in 1979), and reaffirmed in the Canadian 
Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans [4] 
(1998/2010)]. While Beauchamp and Childress do not claim that these four principles 
constitute a general moral theory, taken together they do provide an effective framework 
for identifying and reflecting on moral dilemmas in health [2, p. 15]. The primary function 
of these four principles, in the context of health care service delivery, is to provide 
clinicians with a relatively simple means ('rules of thumb') to evaluate and deal with ethical 
challenges arising in a clinical context, particularly with regards to addressing the needs of 
individual patients and upholding professional duties and responsibilities. 
 
Respect for autonomy 
 A central tenet and strongly held principle in most Western societies is the need to 
protect individual liberty, usually inscribed in human rights documents or charters, because 
every person must have significant freedom to determine their individual life goals and 
ambitions. While this right to ‘self-determination’ is virtually undisputed in the Western 
world, the ability of individuals to exert a significant degree of control over their lives was 
largely absent (upto the 1970s) in the context of medicine, biomedical research, and health 
policy [5]. Until the 1970s, clinicians (as well as researchers and public health 
professionals) typically assumed the role of primary decision-maker with regards to a 
patient’s treatment regimen. This paternalistic approach towards the provision of health 
care operated from viewpoint that patients are often ill informed concerning the complex 
details of their treatment, and so it was up to clinicians to decide what was in the best 
interests of their patients. This presumption, however, came to be recognised as highly 
                                                
7 The 5th edition alone is cited in over 1000 publications. 
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problematic, both in the clinical and research contexts. Clinicians (or researchers) are in 
fact not best placed to determine what is in the ‘best interests’ of a patient (or research 
subject); such assessments necessitate consideration of the personal values and life 
ambitions of the individual, and only they (or their surrogate) can define what those 
personal values are and what they wish to accept as treatment (or in the context of 
research). This recognition that patients should be treated as autonomous individuals 
empowered to consent to treatment options gradually replaced the prevailing paternalistic 
culture of medicine (and biomedical research) and reoriented medical practice, professional 
guidelines, and health law, towards a new focus on the patient as the primary decision-
maker in a shared patient-clinician decision-making relationship. It is now standard practice 
for health professionals to devote time and resources towards educating patients about the 
risks and benefits of treatment options in order to empower their patients to make free and 
informed decisions [1, p. 26-29], including the option to refuse all forms of treatment. The 
mandate to inform and promote voluntary choice – the basis of informed consent – is also 
now mandatory for participation in clinical trials or research projects involving human 
subjects [6]. An additional noteworthy aspect of patient autonomy is the notion that 
provision of truthful and trustworthy information from both the patient and clinician are 
essential to enable truly informed decisions. 
 Following from the tenet of informed consent and individual choice, respect for 
autonomy also requires that these choices be kept private or confidential, and that 
individuals have the power to determine who will know about their medical condition or 
their participation in research. Also described as “autonomy as confidentiality” [1, p. 29-
31], the need to maintain privacy/confidentiality of medical records and health information 
recognises the fact that such information can be sensitive, and compromise an individual’s 
choice or do harm if confidentiality is breached and information accessed by a third party. 
For example, most individuals would likely hesitate to seek treatment for stigmatising 
conditions such as HIV or mental illness if others (e.g., community members, employers) 
could become cognizant of their condition and/or need for treatment. Indeed, breaches of 
confidentiality pose significant risks for both individuals and groups since sensitive 
medical information can be used as a tool to stigmatise and discriminate [2, p. 293-312], 
notably by denying employment opportunities or eligibility for private health or life 
insurance.  
  
49 
 Moving beyond clinical contexts, the principle of respect for an individual’s 
autonomy also sets out an important guiding principle for health policy development and 
decision-making frameworks. 
 
Theory Applications 
 Attention to this first principle, autonomy, can sensitise health professionals and 
decision-makers to the need to consider an individual’s choice as a primary and not a 
secondary concern. At a minimum, it is essential to acknowledge a person’s right to hold 
views, to make choices, and to take actions based on personal values, even if these are 
contradictory with what a decision-maker might think is the best course of action [2, p. 63]. 
Thus, when implementing policies that will influence the health of others, decision-makers 
and professionals need to assess whether such policies are unduly paternalistic or 
compromise the ability for individuals to make decisions concerning their well-being. If 
policies are known to limit choice or restrict the ability to give informed consent, this could 
indicate a need for reform. For example, a standard protocol for an institution might 
mandate that an individual’s consent be given in writing once the individual has been fully 
informed of their treatment options by a health professional. This protocol undoubtedly 
aims to protect patient autonomy; however, this policy can be problematic since the 
individual usually has to give consent in a short timeframe, often when they are in pain or 
less than fully autonomous. An arguably better approach would be to recognise that written 
consent is part of an on-going process of information exchange; from this view, it would be 
completely reasonable to allow individuals to submit their written consent following a few 
days of reflection, instead of ‘on the spot’. 
 Issues related to confidentiality also require reflection. Respect for autonomy 
signifies that decision-makers trusted with access to individual health information must 
ensure that this information remains private. So when, for example, decision-makers 
analyse medical information in order to determine appropriate policy strategies for a 
particular health intervention, security measures must be in place to limit access to that 
information [7] (i.e., accessed only by people that have a legitimate need to know). But 
policies that invariably result in the identification of people based on a health condition 
likely indicate a need for reform. Mandating that children at a day camp with a given health 
condition (e.g., peanut allergies) wear discriminating markers so that they can be easily 
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recognized in a crowd, or having these children form a separate line in a cafeteria when 
retrieving their meals, is problematic, even if the aim is to protect public health. In both 
cases, confidentiality of the children’s medical needs is compromised by them being 
identified as different; better policies would seek alternative, more discrete, means to 
identify individuals in a crowd or distribute specialty meals in the same manner as regular 
meals. 
 
Beneficence 
 At the most basic level of interpretation, beneficence signifies a duty to ‘do good’ 
and thus act in a way that promotes the well-being of others. Since health is an essential 
component of well-being [8, 9 p. 16], the connection between promoting the well-being of 
others through the provision of health services is evident. Beneficence is thus an essential 
principle in medicine, and doing good and ensuring the well-being of others is a duty for 
health professionals. This duty is spelled out in codes of ethics that oblige health 
professionals to: 1) act in the best interests of their patients; 2) care about a patient’s health 
status, and; 3) base treatment decisions on notions of charity and kindness [1, p. 50]. 
Merely following the basic dictums of best practice guidelines or upholding minimum 
standards of care is, thus, insufficient. Consider the example of administering an injection 
to a fearful child. A clinician can simply administer the injection to the child and both can 
subsequently be on their way. While therapeutically acceptable, this act does not fully 
respect the principle of beneficence. Rather, the clinician ought to have taken a moment’s 
time to comfort the child and explain that their fears are understandable, but will likely be 
fleeting after the injection. Caring makes the intervention more than a technical act, but 
instead part of a therapeutic relationship. 
 At a more general level of interpretation, beneficence signifies that health 
professionals have an obligation to be compassionate when making decisions concerning 
the health of others [1, p. 50]. This obligation can help redirect decision-making strategies 
away from an exclusive position of impartiality towards a greater consideration of the 
outcomes a treatment or policy decision will have on others. In other words, the principle 
of beneficence encourages a ‘blurring of the line’ between a purely objective assessment of 
protocols and an empathetic connection to the implications of one’s decisions. Employing 
empathetic approaches towards decision-making in health occur when policy assessments 
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include questions such as: “What if my decisions would have a direct impact on my own 
health; would I make the same decisions?”; “Would this proposed health intervention for 
the elderly be appropriate if it were to implicate my elderly parents?”; “Does this chosen 
course of action cause unnecessary burdens for people that I would find unacceptable if I 
were to experience the burden?”. Overall, by asking such questions, decision-makers cease 
to view those affected by policy interventions as ‘unknown and distant entities’; rather, 
these ‘nameless individuals’ come to be seen as persons that merit a level of compassion 
that would be appropriate when making similar decisions for oneself or for those with 
which we have a close relationship.  
  
Theory applications 
 Beneficence requires that decision-makers in health ‘go the extra mile’ when 
developing health policies or making determinations concerning the health of others. This 
principle of actively doing good or working for the benefit of others helps sensitize 
decision-makers to the possibility that applying the ‘status quo’ may be insufficient. Rather, 
an arguably better vision for policy development would be to base decisions with the best 
interests of others in mind while upholding professional responsibilities to care for those in 
need. Basing reflections on the above criteria can serve as a guide when evaluating the 
adequacies of health policies. During assessments, decision-makers should consider 
whether current policies do indeed meet the best interests of those affected by the policy; if 
this is not the case, a caring response would be to reform policies to better meet the needs 
of individuals that may be ‘left behind’. For example, a recently implemented policy may 
have many observed strengths in that it is effective in improving the health of the majority 
implicated in the policy intervention. However, a minority may accrue less benefit due to 
individual challenges (e.g., some may be more socially excluded due to a language barrier). 
The principle of beneficence would motivate officials to devote extra time and resources to 
meeting the needs of these disadvantaged individuals (e.g., accommodate those that do not 
speak the dominant language by providing health services in more than one language). Not 
only will these efforts likely improve the effectiveness of a policy, such actions are kind 
and compassionate, which in turn encourages a higher ethical standard when evaluating the 
true effectiveness of health interventions. In turn, these higher standards provide impetus to 
question whether the status quo in policy protocols truly employs the best methods 
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available to meet the needs of others. As a last case in point, decision-making frameworks 
that include compassionate reflections gain an additional means to evaluate the 
appropriateness of tentative policies. If a health official would hesitate to implement a 
chosen intervention if it were to affect themselves or others they care about, this sentiment 
likely indicates inherent weaknesses that merit attention. 
 
Nonmaleficence 
 Following the principle of beneficence to ‘do good unto others’ is the closely 
related principle of nonmaleficence, or ‘do no harm’. On initial reflection it may appear 
that the two principles are practically the same or a specification of the other. Beauchamp 
and Childress emphasise, however, that the two principles are distinct due to the fact that 
nonmaleficence requires specific duties towards protecting individual health (and avoiding 
harm), in addition to the obligation to do good [2, p. 165]. To clarify this distinction, doing 
good often involves actively intervening to help others, while doing no harm may simply 
involve refraining from acts that are unnecessary and avoidably harmful [2, p. 113].  
 Here it is important to draw attention to two points. First, the principle of 
beneficence is most pertinent in situations where one evaluates whether a current situation 
is ‘acceptable enough’ or could be ‘better’ (“did I go the extra mile?”); the moral 
imperative to do better is a hypothetical possibility. Nonmaleficence is most relevant in 
situations where a known and unnecessary harm exists or an individual aims to act with 
malicious intent; the cause of concern in these situations is actual rather than a possibility. 
The second point pertains to the notions of unnecessary and avoidable harm [1, p. 46]. 
Nonmaleficence does not imply that any form of harm in a clinical context is indefensible; 
many necessary and ethically acceptable medical procedures do inflict various degrees of 
harm on a patient (e.g., discomfort associated with prostate or pelvic exams, chemotherapy 
or surgery for cancer treatment). Therefore, the central tenet of nonmaleficence is that the 
harms stemming from medical treatment must not outweigh the expected benefits of the 
procedure, meaning that the harm or suffering stemming from the medical intervention are 
a necessary and unavoidable component of the net-beneficial intervention. Nonetheless, the 
principle of nonmaleficence still obligates clinicians to take all necessary steps to use only 
the most appropriate forms of treatment and with the least amount of pain and suffering 
possible [1, p. 46].  
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 The role of nonmaleficence as primary guiding principle in health care has 
additional significance beyond clinical conduct. The obligation to be attentive to harm also 
defines standards of scientific excellence and policies for guiding the ethical conduct of 
biomedical research [6]. It is now standard practice to evaluate the acceptability of research 
with human subjects on the basis of whether the experiment aims to provide a net benefit to 
society or advance the well-being of a patient population (i.e., by gaining greater 
knowledge of disease and possible treatments). Obligations to avoid harm also mandate 
that experimental procedures use the best methods and that the chosen procedure cause the 
least amount of pain and suffering possible to research subjects.  
 
Theory applications 
 When faced with two choices, the most basic level of interpretation of the principle 
of nonmaleficence dictates that the less harmful choice ought to be chosen. However, this 
principle has many additional interpretations that can offer valuable guides in decision-
making and policy development contexts. First, interventions that are known to carry risks 
of harm should not continue to be viewed as favourable if viable and less harmful policy 
alternatives are or become available. This obligation applies regardless of whether the 
previous, more harmful policy, was effective in achieving its desired health goals. This 
obligation is of particular importance in light of technological progress and research 
innovation, for example. With new technology and knowledge come novel means to treat 
pathologies and execute policy interventions, which can include novel methods to avoid 
harm, say, through the development of safer methods in clinical trials. Indeed, the presence 
of known harms often signifies a weakness in a given policy or intervention; following the 
principle of nonmaleficence, the actions of decision-makers may even be judged as 
reprehensible if they do not minimize these harms if reasonable and less harmful methods 
exist.  
 At a broader level, incorporating reflections concerning nonmaleficence in decision-
making processes can also sensitize health officials to the importance of questioning 
whether harms may arise as a result of their decisions, and if so, whether these harms are 
justified. By extension, obligations of nonmaleficence emphasise the importance of 
assessing an intervention or policy in terms of harm prevention versus treatment or 
reparation. In other words, risk or harm assessments should be done before enacting the 
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policy, rather than merely observing whether any harms become evident in the future; 
indeed, attending to harms once they arise is morally inferior to preventing harm to persons 
in the first place [10, p. 140].  
 
Justice 
 The principle of ‘justice’ has many possible definitions that vary depending on the 
context of the normative assessment – i.e., judgement – being made (e.g., legal notions of 
justice, the ‘fair’ distribution of resources, ensuring equal rights for all persons). For the 
current discussion, a ‘narrow’ interpretation of justice that centres on the treatment of 
individual patients in a clinical setting will be the focus of this section. This narrow focus 
does not signify that Principlism is not relevant to (or does not consider) macro-level 
interpretations of justice, such as social or distributive justice; on the contrary, Beauchamp 
and Childress devote much discussion towards distributive justice when presenting 
Principlism [2, p. 226-239]. The broader and various definitions for distributive justice – 
and why these diverse approaches are relevant in health policy – are reserved for a later 
discussion near the end of this chapter. 
 So, what do notions of justice entail for individual patients? Morrison interprets 
patient-centred considerations as an obligation to treat those with fairness, where personal 
characteristics of patients, such as lifestyle or financial circumstances, ought not to 
influence the level of professionalism of a clinician in their interactions with a patient [1 
p.64]. Simply put, equals should be treated equally, and unequals should be treated 
unequally [2 p.227], meaning that patients presenting the same health problems ought to be 
treated according to equivalent standards of care. If clinicians choose not to treat patients 
with equivalent standards, this choice requires detailed justification. 
 Upholding this patient-centred principle of justice is important in a variety of 
circumstances. For instance, justice can serve as an appropriate guide when attempting to 
treat patients that demonstrate unpleasant behaviour, are dirty, or are simply rude [1 p.64]. 
While these patient characteristics may offend a clinician or even compromise their 
professionalism, the principle of justice obligates the clinician to assess whether they are 
treating the patient as well as they would treat more pleasant patients. Another example 
concerns how attention to justice can help identify weaknesses in medical practice by 
questioning the legitimacy of inequalities in care. Ethnic differences are a case in point, 
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where in the United States, the quality of care provided to ethnic minorities has long been 
known to be substandard compared to patients of the ethnic 'White' majority [11]; e.g., 
clinicians are less likely to recommend influenza vaccination to Hispanic and African-
American patients, regardless of whether these people have health insurance [12]. 
Considering justice for patients raises significant concerns about whether these ethnic 
differentials in standards of care can ever be justified; it also points to the need to raise 
clinicians’ awareness about the possibility for ethnic bias in their medical decisions.  
 Though it may at first appear contradictory, the principle of justice can also provide 
guidance when justifying the unequal treatment of patients in specific contexts. Consider 
patient triage in the emergency department, where gravely ill patients are prioritized and 
thus ‘jump the queue’ in front of less ill patients that may have been waiting lengthy 
periods. Moderately ill patients left waiting may conclude that their situation is unfair [1 
p.64]. However, providing immediate service to those with more urgent (severe) medical 
needs supports one aspect of patient justice, namely that urgency is more important than 
waiting time. Furthermore, if the moderately ill patients were in fact seriously ill, they 
would reasonably expect the emergency department to prioritize services to them first as 
well. In other contexts, e.g., where urgency is less an issue, “first come / first served” or 
even lottery approaches may be just means of organising/rationing access to a service. 
 
Theory applications 
 Simply put, within clinical contexts, ‘like-patients’ should be treated ‘alike’. This 
basic interpretation of justice, however, is a germane concept for decision-makers in health. 
First off, this principle provides guidance when assessing what standards ought to be 
upheld when devising policies in light of understandable variations in characteristics of 
individuals. Decision-makers should question whether their standards are equivalent for all 
individuals targeted by the health policy; for instance, by assessing whether a policy will 
treat certain individuals differently than others. Consider the case of an administrator tasked 
with devising a meal programme for an institution (e.g., an old-age residence). The 
administrator is aware that certain individuals attending the institution have food 
intolerances, thus the meal programme must provide alternatives, and so the administrator 
decides to provide gluten-free substitutes since these alternatives are readily available and 
well known by the administrator. However, food intolerances can arise from other foods, 
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such as milk (i.e., lactose-intolerance). The administrator’s choice to provide gluten-free 
alternatives is arguably unfair since consideration is paid to only one form of food 
intolerance and not others. A more just alternative would be to consider the needs of all 
food intolerant individuals and thus provide a wide variety of meal alternatives, including 
milk-free substitutes. Here, the needs of all food intolerant individuals are treated alike. 
This situation clearly also has practical and economic implications, that also lead to 
(distributive) justice concerns if there are insufficient resources (personnel, financial) to 
meet all needs of the population. 
 Individual-centred justice also provides means for decision-makers to assess 
whether their decisions may be biased and encourage undue favouritism. Are policies and 
interventions developed more quickly or made more accessible for people with health 
conditions that are viewed with greater sympathy (e.g., patients with leukaemia versus 
smoking-related lung cancer)? Are policy decisions delayed due to the fact that they will 
mostly implicate a specific and less socially valued group of people (e.g., individuals with 
that health complaint tend to be ‘annoying’, ‘poor’, or less politically active)? If the answer 
to the above questions is ‘yes’, justice signifies an obligation to reconsider the validity of 
this choice. Overall, justice considerations denote that if there is need to treat individuals 
targeted by a policy differently, decision-makers must explain and justify why any 
differences are warranted. By incorporating justice considerations as ‘checks and balances’, 
decision-making frameworks are more likely to provide consistent and fair assessments that 
are more aware of and able to mitigate possible bias. Therefore, individual-centred justice 
reminds decision-makers that individual characteristics that are irrelevant to health or to the 
given health intervention should remain irrelevant to the decision at hand.  
 
At the level of populations: A new ethics for the public’s health 
 The incorporation of Principlism within the professional practice and training of 
health professionals and decision-makers continues to have an important impact on the 
quality and provision of patient services. Though this impact is profound, one must be 
conscious of important limitations inherent with the four cardinal principles of bioethics. 
The limitations of Principlism derive from the fact that these principles were specifically 
developed for application at the level of individuals (‘micro focus’), namely interactions 
between individuals, and specifically clinician-patient interactions. Attempts to 
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subsequently apply the four principles at a collective level (‘macro focus’), where 
assessments focus on populations or communities as in the case of public health, can at 
times prove challenging and even deficient [13, 14 p.26, 15, 16 p.25-27, 17, 18]. In clinical 
medicine, clinicians aim to treat or cure an ailment at the request of the patient, while 
public health generally aims to prevent the spread of communicable disease or the onset of 
chronic disease amongst the population. With this distinction in mind, it should become 
clear that the best interests of a sick individual can be very different from the best interests 
of the community. The former situation centres ethical assessment on issues related to 
individual access to and quality of care, while the latter raises ethical duties to counter 
social and environmental risk factors that may culminate in elevated incidences of illness in 
‘statistical populations’ of typically undefined/unidentified individuals. At the most basic 
level of interpretation, the ethical priorities in medicine and public health may be divergent 
[18]. 
 Consider first the principles of informed consent and autonomy [13, 14 p.27]. 
Questions arise as to whether populations can consent to public health interventions, and 
furthermore, whether the best interests of the population should override an individual’s 
autonomous decisions (which they often do in public health interventions, for example, 
with the imposition of a quarantine on an individual or group to prevent the spread of 
infectious disease amongst community members). In terms of beneficence and 
nonmaleficence, should decisions in public health favour doing good and avoiding harm 
towards individuals, or the community [16 p.26]? For instance, public health regulations 
can deny the employment of a pregnant woman in a job that requires manipulation of 
known teratogens. Though this policy aims for the greater good of the community by 
avoiding risks of harm to women and to future generations (not to mention the foreseen 
health care expenses accrued from foetal malformations), this policy may impose a harmful 
burden of unemployment on pregnant woman. Moreover, notions of justice to treat like 
individuals alike appear distant to the broader needs of populations. As will be described in 
further detail below, population-level justice issues typically focus debate towards: 1) how 
limited health resources will be allocated in society; 2) what interventions ought to be 
targeted towards communities in need, and; 3) what constitutes a fair distribution of 
benefits and burdens stemming from a public health intervention [2 p.226, 19]. As a final 
point, the domain of public health raises a host of new moral considerations that are alien to 
medicine, namely that public health practice often involves the use of governmental, or 
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even ‘police’, powers on populations through the enactment of laws and regulations that 
restrict individual liberties in order to control risk factors for disease [15]. What ethical 
standards should dictate the limits of these powers?  
 Despite the pronounced distinctions and differences, clinical medicine and public 
health share many core moral values (e.g., securing and promoting good health), and 
accordingly, the general values inherent to Principlism are not necessarily antagonistic with 
common values of public health. Indeed, much scholarship into the delineation of core 
ethical principles for public health has used Principlism as a foundation to ‘build upon’, 
where the four cardinal principles become inspirational in the development of core values 
for population, or ‘macro’, assessments. The core values for assessment of public health 
interventions proposed by Massé and Saint-Arnaud are one case in point [17]. Principles 
based on notions of justice, nonmaleficence, beneficence, and autonomy are integral to 
their analytic framework, along with additional values, including utility, precaution, and 
uncertainty; however, these principles are adapted to be representative of populations. For 
example, beneficence remains rooted in the duty to ‘do good’. Yet this duty is in reference 
to the common good of the community, and thus emphasises doing good through communal 
acts that demonstrate solidarity or uphold individual responsibilities towards the 
advancement of health for the population as a whole. As another example, Massé and 
Saint-Arnaud emphasise notions of ‘autonomy as confidentiality’. Even though the ultimate 
aim of a policy may be to protect population health, the authors reiterate that there is a duty 
for policies to respect the private lives of community members. The laudable goals of 
public health ought not provide a carte blanche for health officials to invade individuals’ 
private lives or release personal information. Rather, public health initiatives should find 
means to protect health via the least intrusive means possible, thereby balancing the needs 
of the community with the basic rights of individuals. Similar conclusions are drawn by 
other experts in public health ethics in terms of balancing individual freedoms and liberties 
in order to protect the population’s health [15, 20, 21]. For instance, a primary guiding 
principle for public health policy is that interventions should aim to be the least intrusive in 
people’s private lives as well as aim to be the least restrictive in terms of individual 
liberties. Accordingly, when assessing if policies are sufficiently tempered in terms of their 
use of ‘police powers’, decision-makers ought to determine whether the restrictions 
imposed by the policy are “proportional to the risk of public harm and … necessary and 
relevant to protecting the public good” [22 p.6].  
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Theory applications 
 Generally speaking, scholarship in bioethics has evolved from numerous founding 
theories of moral philosophy into a broad range of principles (values and theories) that can 
help guide decision-making in health. During the course of this evolution, core theories of 
ethics have been applied to specific contexts and have subsequently been ‘adapted’ into 
principles that identify and define issues of moral significance. However, this adaptation 
has lead to the formulation of principles that are best suited for ethical analysis within 
specific contexts. Thus, direct application of principles within novel contexts can prove 
deficient in representing and upholding the priorities and concerns within these novel 
situations. The context-specific adaptation of principles is made apparent when attempting 
to apply micro-level, or individual-focused, ethical principles in health to macro-level, 
population-focused frameworks – i.e., a direct application of Principlism is simply not well 
adapted for the domain of public health ethics. In spite of the initial disjunction between 
population/public health and individual/medicine frameworks, previous ethical principles 
for the latter have served as a foundation for further evolution and adaptation. The result 
has been an expansion of principles and frameworks in order to better represent the health 
of communities.  
 Armed with conceptual ‘tools’ for both micro- and macro-level ethical assessments, 
decision-makers in health have a broad set of principles that can serve as guides in policy 
development, which is significant since decisions in health often require consideration of 
the needs of both individuals and communities. In addition to providing a wider range of 
ethical frameworks for policy analysis, the distinctions between micro- and macro-level 
contexts clarify the need to seek balance between obligations towards communities and 
individuals. Simply overlooking the needs of one or the other may signify an ethical 
analysis that is overly focused on one context, and thus insufficient. Thus, decision-makers 
in public health must question whether their choices are “too extreme, too much in favour 
of the [needs] of the individual, or of the [needs] of the community” [14 p.35]. Through 
such questions, decisions can be more ‘tempered’ and so better suited to meeting the ethical 
obligations that are pertinent within a range of contexts.  
 Having outlined important differences, as well as similarities, between ethical 
principles relevant to both individual- and population-level assessments, the remaining 
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sections of this chapter will now provide an in-depth discussion of prominent principles in 
public health ethics, beginning with a proposed code of ethics for public health. 
 
Deontological guides for health professionals: Codes of ethics in decision-
making frameworks 
 In his book, Everyday Ethics for Career and Personal Development [23, Chapter 7], 
J. R. Jones presents what he describes as “quite simple and straightforward” [p.138] tools 
for ethical decision-making. One such tool is termed ‘The Bell, the Book, the Candle’8, 
which figuratively represents a decision framework that may prove useful when 
encountering ethically problematic situations. The bell represents the metaphorical 
‘warning bells’ that go off in one’s head when faced with an ethical dilemma (i.e., what 
many refer to as an uncomfortable and hesitant sentiment or instinct associated with 
making a decision). When they arise, these sentiments should not be disregarded or 
underestimated. Rather, these sentiments suggest that the dilemma at hand has significant 
implications, and as such, decisions concerning this matter merit greater consideration. 
Now conscious of the need for reflection, decision-makers should then turn to the book for 
guidance, which refers to existing deontological codes for professionals, laws, regulations, 
as well as departmental policies, standards and procedures. After referring to these 
resources, decision-makers should determine which choices concerning the ethical dilemma 
would best meet these guidelines for professional conduct. If a chosen course of action 
violates prominent laws, standards, codes of ethics, etc., one should reconsider the validity 
of this choice. The final step in the framework, the candle, serves to verify the soundness of 
the chosen decision by imaging how the choice would be perceived if ‘exposed to the light 
of day’, that is, exposed to public scrutiny or evaluated by colleagues. Would others view 
this decision as admirable or as contentious? If the latter, one should question whether the 
chosen course of action is still justified relative to other options.  
 On initial assessment, this decision framework is indeed simple and practical; note 
that the bell and the candle are thought processes that virtually every individual is capable 
of making. However, the true strength of this step-wise thought process resides in the 
application of deontological codes of ethics in decision-making. 
                                                
8 Jones identifies Michael Josephson of The Josephson Ethics Institute as the originator of the framework.  
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Embracing a new arrival: A code of ethics for public health 
 Until 2002, public health institutions in the United States were unlike most other 
medical institutions, having not yet published a code of ethics for their professionals [24] 
(abbreviated hereon as the code). Following the formation of a working group of public 
health professionals, numerous experts in public health and bioethics were consulted in 
order to develop a consensus concerning what principles should compose a code of ethics 
for US public health practitioners (table 1; reprinted from: [24]). To date, this code 
comprises 12 principles deemed as essential guiding values that outline duties for public 
health professionals. Since public health professionals come from numerous different 
professions with a diversity of backgrounds and perspectives (e.g., epidemiologists, nurses, 
physicians, and people with social science backgrounds), it is not surprising that the code 
reflects this diversity through a collection of ethical concepts that target a broad range of 
ethical imperatives related to population health. For example, the second principle reflects 
well the previous discussion concerning the need to balance individual rights and concerns 
for the health of the community. Additional familiar concepts in this code are the duties to 
protect the personal information of community members (principle 10) and to promote 
justice through a fair implementation of public health initiatives amongst diverse 
communities (principle 4). Other principles reinforce professional duties to secure the 
public’s trust through transparency (#6), encouraging public engagement in policy 
development (#8 & 12), and ensuring the competency of public health officials (#11).  
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Table 1: Principles of the ethical practice of public health  
 
 
1 
 
Public health should address principally the fundamental causes of disease and requirements for health, 
aiming to prevent adverse health outcomes. 
 
 
2 
 
Public health should achieve community health in a way that respects the rights of individuals in the 
community. 
 
 
3 
 
Public health policies, programs, and priorities should be developed and evaluated through processes 
that ensure an opportunity for input from community members. 
 
 
4 
 
Public health should advocate for, or work for the empowerment of, disenfranchised community 
members, ensuring that the basic resources and conditions necessary for health are accessible to all 
people in the community. 
 
 
5 
 
Public health should seek the information needed to implement effective policies and programs that 
protect and promote health. 
 
 
6 
 
Public health institutions should provide communities with the information they have that is needed for 
decisions on policies or programs and should obtain the community’s consent for their implementation. 
 
 
7 
 
Public health institutions should act in a timely manner on the information they have within the 
resources and the mandate given to them by the public. 
 
 
8 
 
Public health programs and policies should incorporate a variety of approaches that anticipate and 
respect diverse values, beliefs, and cultures in the community. 
 
 
9 
 
Public health programs and policies should be implemented in a manner that most enhances the physical 
and social environment. 
 
 
10 
 
Public health institutions should protect the confidentiality of information that can bring harm to an 
individual or community if made public. Exceptions must be justified on the basis of the high likelihood 
of significant harm to the individual or others. 
 
 
11 
 
Public health institutions should ensure the professional competence of their employees. 
 
 
12 
 
Public health institutions and their employees should engage in collaborations and affiliations in ways 
that build the public’s trust and the institution’s effectiveness. 
 
 
 This début code of ethics for public health practice has many qualities. At the very 
least, the code makes explicit the need to uphold specific standards when devising health 
policies. Moreover, the 12 principles define an exemplary long-term vision for public 
health initiatives, while at the same time providing the diversity of professionals working in 
pubic health with a readily comprehensible ‘moral compass’ [24] to help orient their 
decision-making processes.  
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Theory application  
 Though developed primarily by experts in public health ethics as a deontological 
tool for public health practitioners, the above code of ethics is a noteworthy addition to the 
domains of health policy and decision-making as a whole. Recall that a diverse range of 
health professionals were consulted during the drafting of the code, and as such, the 
accumulative knowledge represented in the 12 principles may provide useful guides in 
decision-making frameworks beyond the borders of public health practice [24]. So in the 
event that a decision-maker experiences the proverbial ‘ringing bell’ when devising health 
policies, this code of ethics can serve as one of many ‘books’ to reference for ethical 
guidance.  
 For example, decision-makers might have reservations when assessing whether or 
not their choices meet professional standards of excellence. Such reservations are expected 
when, for instance, a health professional is tasked with executing interventions that are 
unfamiliar to their daily practice (e.g., a school nurse must collate the medical records of 
students with serious health conditions so that necessary information is available during an 
emergency; but what does this activity entail?). In such circumstances of uncertainty, the 
health professional can verify whether their decisions are up to par with relevant principles 
of the code [e.g., Are these medical records sufficiently detailed so that they can be later 
used as a tool to prevent adverse health outcomes in the school environment? (Principle 1); 
Have I consulted with the group of students implicated by this intervention so that I have 
their consent for its implementation? (Principle 6); These records contain confidential 
information – have I ensured that it will remain confidential? (Principle 10)]. If upon 
referring to the code the health official observes that their choices do not meet professional 
standards of excellence, this likely signifies the need for reforms, or to obtain further 
guidance. If their choices do coincide with ethical standards set by professional orders in 
health, this fact should provide a degree of reassurance. At the very least, the decisions 
made by the health official will meet the final criteria of ‘the bell, the book, and the 
candle’, meaning that when ‘exposed to the light of day’, their decisions are more likely to 
be viewed as ethically legitimate by fellow health professionals. 
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Thanks, but no thanks: policies that stigmatise 
 A popular expression in the English language is, “The road to hell is paved with 
good intentions”. This expression captures one of many ironies of life: while we may base 
our actions on the premise of doing what is good and right, our actions can cause 
unintentional and even significant harm to others. Decisions in health policy are not 
immune to this irony, where even the best intended policies [25] require vigilance towards 
unintended consequences. A well-known unintended harm that may arise from policy 
decisions is the ability to stigmatise recognisable groups of people [14 p.120]. 
Stigmatisation is a social construct that is “characterized by exclusion, rejection, blame or 
devaluation that results from experience, perception or reasonable anticipation of an 
adverse social judgement about a person or group” [26 p.441]. More simply put, stigma 
involves the association of a ‘negative and shameful label’ with a particular community 
that can become a defining, though mistaken, attribute of that group within society.  
 Stigmatisation has long had a significant association with health, where for 
example, specific pathologies and ‘unhealthy behaviours’ have been associated with 
particular communities, or have been used to promote and perpetuate negative stereotypes 
and the denigration of groups of people. For example, a recent study [27] observed a high 
incidence of tuberculosis amongst illegal immigrants in the United States. Given the 
current political climate and hostility towards illegal immigrants, health officials fear that 
these findings may encourage draconian extradition policies and promote amongst the 
public undue alarm and hostility towards this already vulnerable population [28]. Specific 
health policies and public health interventions can also inculcate stigma. North American 
policies that impose a life-long ban on all gay and bisexual men as eligible blood donors – 
due to a higher incidence of HIV within this population – are notable examples. The fact 
that such policies target sexual orientation and not unsafe sexual practices9 has raised fierce 
criticisms that current policies simply perpetuate the misconception that HIV/AIDS is a 
‘gay disease’ [29].  
 Health-related stigma has several negative ramifications for population health, 
contributing as it does to health disparities by discouraging stigmatised and thus ‘shamed’ 
people from seeking health care [30]. But why is stigma an important topic for ethical 
                                                
9 For example, monogamous gay men in long-term relationships remain ineligible for life, while 
heterosexuals with multiple sex partners that do not practice safe sex are eligible blood donors. 
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reflection? It is readily apparent that addressing stigma arising from health policies fits with 
the principle of nonmaleficence, though in this situation the harms are mostly in reference 
to communities and not defined individuals. By extension to a macro-level then, the duty to 
avoid harms as much as feasibly possible signifies an obligation for decision-makers to 
seek less harmful alternatives to pre-existing stigmatising policies [13]. What if non-
stigmatising alternatives are not possible? Duties to minimize harms remain, so health 
officials might enact measures to minimize public misconceptions concerning communities 
targeted for health interventions by, for example, promoting public education campaigns 
that correct misconceptions about disease incidence and offset misattribution of blame to 
particular communities [22].  
 Here it should also be apparent that the principles of avoiding stigmatisation (non-
maleficence) and autonomy as confidentiality are in many aspects complementary. Indeed, 
the need to respect confidentiality in health has been inspirational in the development of 
ethical frameworks aimed at attenuating the risks of stigmatisation in public health [13]. A 
recent example that links the concepts of confidentiality and stigma is contained within the 
decision framework proposed by Thompson and colleagues, developed following the 
SARS epidemic in Toronto [22]. A main source of criticism concerning how public health 
officials and the media handled the influenza epidemic centred on an overemphasis in 
associating the disease with ethnic minorities, namely the Chinese community. SARS 
posed significant risks to all members of the population; therefore, Thompson et al. 
question the utility of health officials informing the public that those infected were 
primarily Asian minorities. Surely identifying the ethnicity of a small collection of those 
infected serves little benefit in controlling the epidemic? From these observations, 
Thompson and colleagues propose the following guiding principle for public health: 
“Disclose only private information that is relevant to achieve legitimate and necessary 
public health goals” [22 p.6]. This principle seeks to balance the need to protect the public 
(by informing them of a known risk factor) with the duty to protect private information of 
individuals, which in turn can avoid unnecessary stigma.  
 As a closing point, failure to avoid stigma is not solely an ethical concern in health 
policy, but also a question of efficacy. Policies perceived as stigmatising become easy 
targets for criticism by members of the public as well as other health professionals [31], 
criticisms that in turn may erode public trust and thus compliance, while also creating 
divisions in professional values amongst health officials. Certainly, the effectiveness of a 
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given health policy hinges on the ability for the policy intervention to be embraced, not 
shunned, by society, which is also contingent on the willingness for health officials to unite 
efforts to ensure its comprehensive implementation.  
 
Theory applications 
 Even with the best of intentions, decisions made with the laudable goal of 
protecting health can have unwanted consequences. In many cases, stigmatisation can 
originate from poor judgements made during the structuring of health policies, such as by 
targeting interventions towards specific communities rather than specific health conditions 
[14 p.13]. In other situations, stigma is an unintended consequence of the public being 
misinformed of a health condition. Regardless of origin, decision-makers have a duty to 
avoid this unwanted and detrimental outcome. By being sensitive to the possibility that 
health decisions can inadvertently stigmatise a defined group of people, decision-makers 
gain a valuable tool to evaluate possible weaknesses and the ethical legitimacy of policy 
interventions.  
 Indeed, attention to stigma provides a guide for a ‘step-wise’ assessment 
framework. First, greater awareness of stigma should motivate decision-makers to be 
critical of the ramifications associated with targeting health interventions towards specific 
communities [13]. If interventions do require targeted health efforts, decision-makers 
should then assess whether this policy may confer a negative label to an identifiable group 
or community. If risks of this harm appear likely, the next step in policy development 
should determine means to minimise or avoid stigma. Reconfiguring policies so that they 
target conditions rather than groups of people, for example, might be a more useful and less 
stigmatising strategy (e.g., policies for sexually transmitted diseases that target high risk 
sexual practices rather than individual sexual orientations). Limiting the provision of 
personal health information of communities is also a valid strategy if such information is 
not essential for the effectiveness of a given health intervention (e.g., when informing 
parents to be vigilant towards head lice, school administrators do not need to inform 
parents which students already have head lice, or the fact that most of these students come 
from a particular neighbourhood). Finally, if stigma cannot be avoided, decision-makers 
have an obligation to implement public education campaigns alongside the chosen health 
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intervention in order to break negative stereotypes (e.g., educate the public that bed bugs 
can infest any residence, not just those of ‘unclean people’).  
  
Beyond feminism: Empathy and the ethics of care for ‘statistical 
populations’ 
 Due to a prolonged history of the near exclusion of women from academia, 
scholarship in most domains of inquiry – including ethics [32, p. 154] – has largely 
overlooked or trivialized the specific life experiences, needs, and intellectual perspectives 
of women. Much has changed following the gradual inclusion of women in academic 
research, and one notable case in point has been the identification of a significant divide, 
and thus distinction, between traditional ethics (i.e., ‘mainstream’, male-dominated moral 
theory) and feminist ethics [33]. Without aiming to be overly simplistic, feminist scholars 
have – amongst many other achievements – demonstrated that there is more than one 
perspective by which to evaluate ethical dilemmas [32, p. 154-169]. Traditional ethical 
theories (e.g., Utilitarianism, Kantian ethics) typically assert only one perspective, centring 
on the need for impartiality during moral deliberations. Impartiality signifies that ethics-
based assessments should be impersonal and free of bias as a necessary means to ensure 
that decisions are truly fair, and thus ethically legitimate. Concluding that a given decision 
is the most ethical choice because that choice suits the best needs of the person making the 
decision is obviously suspect; rather than impartial, this decision is clearly egoist and self-
serving. Favouring decisions so that they prioritise the needs of family or close friends over 
the needs of strangers would also exemplify partial judgements, and thus be interpreted as 
unacceptably biased decisions according to traditional ethics theories.  
 Feminist ethics theory has lead to strong critiques of the previously unquestioned 
assertion for impartiality and impersonality as an ideal in decision-making. It is unlikely 
that absolute impartiality in ethical assessments is feasible, for one, but furthermore, 
feminist scholars question whether it is fundamentally against human nature not to favour 
consideration for those with which we have close relationships, such as family [2, p.371]. 
Surely under certain circumstances it would be reasonable (and even admirable) to give 
greater moral weight to family obligations than obligations to strangers, for instance [32, p. 
155]? It is through our interactions and relationships with others that we develop unique 
attachments that are fundamental to our identities. In times of need, we turn for help to 
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those with whom we have our closest, most caring, relationships. The realisation that at 
some point in our lives we will either provide or need care and support by those close to us 
has lead to the view that ethical deliberations must consider an ‘ethics of care’ [34]. The 
obvious good that arises through these forms of social cooperation between family and 
friends signifies that these caring relationships hold moral significance, so it is argued that 
by incorporating notions of care, compassion, interdependence through support, and 
empathy towards the needs of others can provide moral guidance in decision-making [34]. 
 Notions of care, compassion, and empathy in decision-making are reminiscent of 
the previous exposé of the principle of beneficence; indeed, many aspects of feminist 
theory and Beauchamp and Childress’ explanation of beneficence are complementary [35, 
36]. Recall that obligations of beneficence include the need to feel empathy towards each 
individual. While the notion of having an empathetic interaction with a defined individual 
should be evident in the context of patient-clinician relationships, such interactions are 
impossible (or at least extremely challenging) when orchestrating health interventions for 
populations or communities. No personal connection exists between the health official or 
decision-maker and the population that will be targeted by a given policy; the members of 
that population are in a sense, a faceless, ‘statistical population’. Maintaining this 
impersonal perception of populations targeted by health policies is arguably far from ideal. 
At the very least, conceptions of divisions or ‘one step removed’ from the implications of 
health policy run contrary to the ideals of public health initiatives [24, 37], which instead 
reinforce notions of promoting health through social solidarity, thereby acknowledging the 
importance of interdependence between humans in communities and a collective empathy 
towards those in need of aid [17 p.140-142, 38]. Feminist ethics theories can provide ways 
to bridge this divide between ‘statistical populations’ and the goals of public health by 
informing decision-makers of the need to develop policies built upon premises of care and 
interdependence [38], much like how one would base decisions concerning family 
members. Thus, decision-makers gain guidance through implementing thought experiments 
where they imagine themselves as ‘caring parents’ providing support to fellow ‘family 
members’ of society (e.g., “How would you want to treat everyone in society if you 
imagined yourself as everyone’s parent?” [39, p.1058]). Overall, by orienting policy 
development away from disconnected, impartial, views of ‘statistical populations’ towards 
ideals of interconnectedness and social solidarity, decision-makers are primed to develop 
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more empathetic policies that superimpose well with duties to promote the health of 
communities.  
 
Theory applications 
 The primary utility of feminist ethics theory in policy development is the ability to 
refocus the underlying motives of decisions executed by health professionals. By 
incorporating the most basic interpretations of feminist critiques in decision-making 
processes, health professionals raise their awareness and sensitivity towards the fact that 
health policies will have a direct impact on the lives of others, whether this impact will be 
observed by the health professional or not. In other words, feminist notions of 
connectedness and the need to maintain strong relationships between people can serve as 
guides when implementing policy decisions for ‘statistical populations’. Rather than 
viewing this population as a group of individuals of no personal acquaintance, decision-
makers should instead imagine what their responsibilities would be as a caring parent for 
this population (a justified paternalism). For example, when determining the minimum 
level of health services should be available to community X, such determinations can be 
guided by asking what services, protections, and basic needs are necessary to uphold duties 
of caring for family members that comprise community X. On the whole, by considering 
how a policy may impact actual people, and whether imposition of such policies would be 
acceptable if applied towards those with which we have close relationships, this 
compassionate mind-set will arguably encourage the development of more ethically 
legitimate decisions in health.  
 
Empowerment of vulnerable populations 
 Upon observation of any given population, it should become readily apparent that 
many distinct communities and sub-populations exist within the whole; there are inevitably 
‘haves’ and ‘have-nots’. Common factors that draw distinctions between communities 
include differing levels of power, social exclusion, and disenfranchisement, all of which 
relate to the vulnerability of a community and its members [40, 41]. The concept of 
vulnerability has increasingly become a subject of analysis and concern in public health 
due to its strong correlation with poor health outcomes [42, 43]. Vulnerability of 
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communities denotes social groups that, “because of shared social characteristics, [are] at 
higher risk of risks” [44, p.218]. For example, high rates of violent crime and pollution are 
known risks to health, risks that are more prevalent in impoverished neighbourhoods [45, 
46] with the result that members of impoverished communities are at higher risk of 
encountering these health risks. Well known vulnerable populations in Canada include 
aboriginals, people ‘surviving’ below the poverty threshold, adults without a high school 
degree [47], and sexual minorities [48].  
 The vulnerabilities that define particular communities are due to numerous factors 
[42], but they have in common aspects of social exclusion, disempowerment, and the 
reduced ability of people to protect their own health. The following three examples will 
help make these correlations more explicit.  
1) The current economic crisis and resulting collapse of the housing market in the 
United States has disproportionally lead to homelessness amongst once lower-
middle class citizens; it is now common for these Americans to have to make tough 
choices concerning whether they will devote scarce resources towards health care 
(e.g., pharmaceuticals) or minimally acceptable standards of housing [49]. 
2) People suffering from mental illness frequently encounter significant public stigma 
that motivates many to become introverted, isolated, and thus less inclined to seek 
out appropriate health services [50].  
3) Adolescents that do not accommodate to norms imposed by their peers are often 
ostracised [51], which in turn can make them the target of bullying, a troubling 
phenomena that has recently resulted in a wave of teen suicides in North America 
[52, 53].  
A shared trait in these three examples is that they involve groups with particular 
vulnerabilities that often produce a ‘downward spiral’ in population health. These 
observations have encouraged the development of the ethical principle of empowerment as 
a guiding ideal for policies targeting the health needs of vulnerable people [54, 55].  
 As the word denotes, empowerment in health aims to help individuals and 
communities gain power and control of their lives through interventions that redress social 
problems related to their oppression and exclusion, as well as the attenuation of factors that 
result in the concentration of health risks. The notion of designing health interventions as 
tools for empowerment has marked an important transition in health policy, where analysis 
has advanced beyond principles of beneficence (i.e., the duty to do more for those with 
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special needs), to include consideration of whether policies contribute towards 
emancipating people from inequities and oppression [14, p.xii]. Indeed, this concept is 
integral to the above mentioned Code of Ethics for Public Health, where the fourth clause 
stipulates that “public health should advocate for, or work for the empowerment of, 
disenfranchised community members, ensuring that the basic resources and conditions 
necessary for health are accessible to all people in the community”. With the need for 
empowerment of the vulnerable in mind, health promotion efforts are then primed to reflect 
on, and work to reform, wider social structures associated with vulnerability and not focus 
only on changing individual behaviour [14, p.116]. 
 Notions of empowerment and vulnerability can guide health policy development on 
several fronts. First of all, they raise awareness to the possibility that a universal application 
of a particular health intervention is likely insufficient since a ‘one-size-fits-all’ strategy 
does not take into account differing levels of disenfranchisement within society [41, 56]. 
An arguably better strategy would incorporate methods to redress factors that diminish 
opportunities for vulnerable populations to fully benefit from health promotion activities. 
Thus, policies that support the provision of mental health services are insufficient if policy 
makers do not also include measures that work to help break the social stigma associated 
with mental illness. Similarly, suicide prevention efforts aimed at adolescents require more 
than the provision of counselling services at secondary schools, and should also include 
mechanisms to counter pervasive bullying and harassment. Finally, orienting treatment 
strategies towards the use of pharmaceuticals will do little to help those people who are 
forced to choose between paying for medical treatment or paying their rent; alleviating 
poverty must also be an essential component in such strategy. At the most basic level, the 
above examples demonstrate that policy development must consider the differing needs of 
various communities targeted by a health intervention. Communities will differ in their 
degree of opportunities and abilities to accrue health benefits due to various factors, 
including vulnerability. By incorporating strategies to counter vulnerability through diverse 
empowerment interventions, health policies can be better structured to meet goals of 
promoting health benefits amongst the ‘have-nots’ as well as the ‘haves’. 
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Theory application 
 Helping communities that are consistently subject to social deprivation is no longer 
a question of pity or charity [57] but rather of efficacy and due diligence in public health 
[58]. Diligence in this circumstance signifies that decision-makers must evaluate potential 
health interventions within a broader context that includes consideration of how social 
factors related to vulnerability can impede the success of a chosen policy proposal. By 
overlooking the reality of differentials in power and risk factors for poor health amongst 
different communities, decision-makers miss opportunities to structure interventions that 
can attenuate these differences [40]. Disparities in opportunities, social exclusion, and 
power impose limits on the extent to which a health intervention will benefit some 
communities but not others. However, by attending specifically to such disparities and 
incorporating methods to empower the disadvantaged members of society, decision-makers 
are more inclined to develop interventions that will be of broader benefit across 
communities.  
 For many decision-makers in health, attending to social factors that concentrate 
risks for poor health – such as poverty and violent crime – may appear to be beyond their 
jurisdiction or scope of intervention [56]. Indeed, addressing social determinants of health 
and vulnerabilities will require major political changes that alter the structure of society by, 
for example, reducing unemployment [59]. Regardless, the principle of empowerment is 
still useful as a guide in smaller-scale health interventions since sources of vulnerability are 
many fold and include tangible factors that health professionals encounter in their daily 
practice. For example, work environments that permit harassment compromise the health 
and well-being of employees in general, and not only those that are the target of harassment 
[60]. In addition to reprimanding employees that create such hostile work environments, 
decision-makers should assess what factors allow employees to be harassed in the first 
place [1, p.56]. Thus with empowerment in mind, decision-makers can question what 
aspects of the work environment need reform so that employees can avoid hostility and 
undue influence by others, such as by offering organisational support (e.g., guidelines on 
what behaviour is unacceptable) and job security for individuals that complain about 
substandard working conditions (so-called “whistle-blower” protection) [61]. This shifts 
power towards employees that need it most and offers methods to break free from 
oppressive working relationships. 
  
73 
 On the whole, the concepts of vulnerable populations and the duty to empower 
those who are most vulnerable provide a valuable guide when designing health 
interventions. At the onset, decision-makers should question whether a universal 
application of a policy would be sufficient to address the needs of all members targeted by 
the intervention. Are there particular groups that are less likely to benefit from the 
intervention due to avoidable factors that diminish their opportunities to protect their 
health? If so these groups require due diligence, and decision-makers should then ask, 
“within my professional sphere of influence, what measures can I enact to dispel factors of 
domination and oppression, and in turn enable all people to have a greater degree of self-
determination in relation to their health?”. By addressing these questions, decision-makers 
take the first step towards ensuring health interventions will be effective for the ‘have-nots’ 
as well as the ‘haves’. At the very least, this premise is arguably a more equitable, or just, 
position for policy development. 
 
 The final segment of this chapter on practical theory will now return to the topic of 
justice or equity in health. The initial presentation of justice limited discussion to the fourth 
tenet of Principlism, where micro-level assessments highlight the duty to care for 
individuals fairly by treating ‘like’ circumstances ‘alike’. The concluding sections will now 
focus on macro-level justice assessments that are prominent in debates concerning 
population health, especially in terms of pressing health policy issues related to resource 
allocation in health care, priority setting in policy development, and evaluating the fair 
distribution of benefits and burdens in population health interventions. The theoretical basis 
for these debates in health policy rest on theories of distributive and social justice, debates 
which are made rich and complex by the fact that numerous theories of justice are relevant 
to macro-level policy decisions in health. The following discussion will thus begin by 
describing this complexity and diversity of theories of justice in order to show why each 
theory identifies important concepts to consider when analysing notions of equity in health 
policy. Though this diversity of theoretical frameworks pose certain challenges for policy 
development (i.e., which theories are most relevant?), the following analysis will 
demonstrate the utility of one prominent theory in the development of decision frameworks 
in health, namely Norman Daniels’ adaptation of Rawlsian social justice.  
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Multiple theories of social justice in health: A challenge in policy 
development and decision-making 
 Determining whether a given situation is just or fair can be a surprisingly complex 
task; especially when one aims to define the ‘just nature’ or ‘fairness’ of a given health 
policy decision in terms of macro-level distribution of resources, setting priorities in 
population health, or targeting initiatives towards specific communities. But before 
addressing issues of justice in health policy, it is necessary to first ask what makes notions 
of justice difficult to implement in decision-making, and accordingly, why is it that 
defining justice presents specific challenges. Amartya Sen, a prominent figure in social 
justice theory, highlights the inherent challenges of employing theories of justice in 
decision-making (whether in health or other contexts) by identifying the disagreements that 
arise when trying to define inequality and inequity. Specifically, Sen asserts that difficulties 
become apparent when attempting to answer the following question: justice determinations 
ought to centre on “equality of what?” [62, p. 4, 63].  
 To clarify, justice-centred assessments begin with the observation of an unequal 
distribution of a chosen measure (income, happiness, wealth, life expectancy, etc.) between 
defined groups or individuals. A group having a deficiency or inequality of the chosen 
measure (e.g., income) leads to an inequity when this situation would ameliorate 
(depending on what constitutes as an ‘improvement’) if the inequality of the measure 
between the groups were lessened or eliminated. Sen argues convincingly that the chosen 
measure for justice assessments is itself a value-based judgement (what criteria for equality 
does one value most?) and that striving to achieve greater equality in one measure may not 
coincide with equality in scale of another measure [62, p. 2, 63] (in fact, promoting equality 
in one measure may exacerbate inequality in another) and thus greater equity from another 
perspective. For example, equalizing the wealth between two groups of individuals may not 
equalize their levels of happiness; thus, would equalizing the distribution of wealth produce 
a truly just outcome?   
 At this point, it should become clear that choosing “equality of what” for analysis is 
a matter of profound and longstanding philosophical debate (for an overview the numerous 
theories of social justice developed by philosophers, see: [64]). A review of all prominent 
theories of social justice is beyond the scope of this chapter (and thesis), and so this thesis 
will limit analysis to a select set of theories or principles of justice relevant for decision-
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making in health. It is nonetheless important to clarify how employing various theories of 
social justice can produce conflicting analyses in decision-making. The following 
discussion will present a brief overview of three prominent principles of justice employed 
in health policy, in order to show how each principle focuses justice assessments towards a 
different measure. Following this overview, the discussion of social justice in health will 
conclude with a detailed presentation of a fourth and final theory, that of Rawlsian social 
justice theory applied to health contexts, which will be the focus of health policy proposals 
presented in Chapter 2. 
 
Why not strive to maximize utility and efficiency? 
 What could be better than striving to maximise the greatest amount of health 
improvement with limited resources? Indeed, in these times of severe economic hardship, it 
seems logical that what is most fair for society is to ensure that public resources get the 
greatest ‘bang for the buck’, and accordingly, policies should prioritise efforts to provide 
the greatest accumulative improvement in health for the population. This perspective of 
resource distribution in health originates from theoretical frameworks of Utilitarianism, 
where the basis for ethical analysis resides in determining which action will provide the 
greatest ‘utility’ or ‘welfare’ for the greatest number [64]. However, measuring ‘utility’ or 
‘welfare’ can be somewhat vague concepts in health policy analysis (e.g., what is a unit of 
utility in health?). To address the vague character of these concepts, scholarship in health 
policy has since developed quantifiable measures to calculate the efficacy of health 
interventions, such as Disability-Adjusted Life Years (DALYs).  
 Endorsed by the World Bank [65] and the World Health Organisation [66], DALY 
is a combined measure of morbidity and mortality that quantifies the burden of a given 
pathology. In brief, DALYs combine “time lived with a disability and the time lost due to 
premature mortality” [67] (for a detailed explanation of DALY measurements, see: [67-
69]). Upon establishing DALY units for pathologies, these units can be implemented in 
resource allocation exercises, where a defined goal can be to minimize the disease burden 
in society within budgetary limits (i.e., in terms of cost-effectiveness: with x dollars, what 
is the greatest number of DALYs that can be eliminated?). Minimising DALYs signifies 
maximising utility in health; thus health interventions can be prioritised according to their 
expected utility per unit cost.  
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 Though a well-developed and popular metric employed in health policy around the 
world [70], maximizing the utility of health interventions through DALY measurements is 
hotly contested and viewed by many as an ethically questionable basis to fairly prioritise 
health interventions [69, 71]. One primary source of criticism is that priority frameworks 
based on utilitarian principles often neglect the needs of those in the worst state of health.  
 
Maximising utility will leave the vulnerable ‘out in the cold’ 
 As demonstrated in the previous discussion concerning vulnerable populations, each 
society will inevitably contain a heterogeneous assemblage of communities where some 
fair better, and others worse, in their abilities to secure good health. Recall that a defining 
feature of vulnerable populations is the concentration of health risks within these 
communities, which encourages the compounding of social, economic, environmental, etc. 
factors that challenge the broad efficacy of health interventions (e.g., smoking cessation 
campaigns are less effective for lower socioeconomic classes due to factors ranging from 
lower literacy rates to high unemployment [72, 73]). Understandably, achieving an 
equivalent measure of utility or benefit from a health intervention employed amongst 
deprived and particularly vulnerable populations will likely require greater initiative and 
resources than that needed for more ‘well-off’ populations [68, 74]. In a sense, these 
vulnerable populations are more ‘costly’ and so less ‘cost-effective’. A similar observation 
is made within the context of severely ill or disabled patient populations [68, 74]. For 
instance, an intervention may accrue little health benefit amongst the frail elderly but 
produce great benefit amongst the working adult population (e.g., according to a utilitarian 
perspective, a health programme that aims to extend life expectancy will be of little ‘utility’ 
to those nearing the end of their lives; thus, this programme should be reserved for younger 
populations). Broadly speaking then, adherence to Utilitarian frameworks as an ideal for 
resource allocation can thus give less priority, and thus direct fewer benefits, towards 
communities that are systematically disadvantaged in securing health [9, p.150-158].  
 Many scholars view this situation as discriminatory and unfair [68, 71, 74, 75] 
because strategies based on maximising cost-effectiveness in resource distribution might, 
over the long term, compound and perpetuate a range of disadvantages experienced by 
vulnerable segments of society [9, p.157]. At the very least, compounding disadvantage in 
society is contradictory to many fundamental values of public health (see principles 1-4 & 
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9 of the code of ethics for public health, table 1, above). In response to these concerns, 
alternative theories of justice in health policy have centred assessments on the needs of the 
most disadvantaged members of society, such that their needs should be prioritised over the 
‘healthier majority’ [9, 19, 76, 77]. To exemplify one such theory of justice in health 
policy, Madison Powers and Ruth Faden [9] develop a framework for prioritisation in 
health policy based upon measures of systematic disadvantage across multiple categories of 
well-being; communities observed to have a compounding of disadvantages in well-being 
receive highest priority.  
 Though strategies that focus on promoting the health status of the most 
disadvantaged will likely be less efficient according to strict financial measures [64], 
frameworks for targeted interventions will arguably promote equity by raising the bottom 
segment of health achievers towards the average level of health achievement attained by the 
majority of the population [44]. However, in addition to questions of inefficiency, 
favouring the needs of the ‘worst-off’ have been criticised on numerous grounds ranging 
from libertarian objections10 to a disregard of individual responsibility in health [64].  
 
Will someone take responsibility for his or her actions? 
 While notions of efficiency and acts of solidarity to help the vulnerable have great 
appeal, an additional concept raised in health equity debates is the notion of ‘just desert’ 
[64]. Just desert signifies ‘receiving what one deserves’ based on merit and personal choice, 
and thus justice assessments from this perspective focus on notions of personal 
responsibility in health. Personal responsibility in health has long been a central topic in 
public health policy; the publication of the Lalonde Report [78] in 1974 is an example, 
where a primary determinant of health achievement is attributed to lifestyle choices.  
 At the core of the just desert premise is that the unhealthy choices people make 
(e.g., smoking despite knowing its negative health effects, choosing to practice unsafe sex) 
should be seen as a personal rather than a social responsibility and as such should not have 
priority over unavoidable health needs when establishing resource distribution strategies 
                                                
10  Libertarian philosophy focuses justice assessments on individual freedoms and typically opposes 
government interference in individual control over their resources [64]. Libertarian proponents often contest 
frameworks that favour the needs of the disadvantaged since these usually entail redistributing resources away 
from the privileged (those “who have earned their rewards”) towards those in need. If imposed by 
governments, this redistribution diminishes individual freedom in resource utilisation, which runs counter to 
Libertarian ideals.  
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[79]. However, it is important to define what is meant by choice in unhealthy lifestyles. It is 
well known that certain individuals, due to mere bad luck, live in environments that are 
unfavourable to making healthy choices, and thus these choices are not actually avoidable 
(e.g., individuals living in neighbourhoods that do not provide access to fresh fruits and 
vegetables, AKA ‘food deserts’, should not be held responsible for unhealthy eating habits 
[80, 81]). Allocating health resources towards vulnerable communities is therefore justified 
under many circumstances if such decisions aim to redress the “lack of opportunit[ies] that 
some may have to achieve good health because of inadequate social arrangements, as 
opposed to, say, a personal decision not to worry about health in particular” [63, p.660].  
 While allocating health resources on the basis of giving to those that which they 
deserve has a degree of appeal, many policy experts criticise this framework as being 
socially divisive and impractical in terms of epidemiological evidence [82]. In terms of 
divisiveness, some policy analysts raise concerns that frameworks based on judgements of 
lifestyle choices could lead to undue ‘victim blaming’ in health policy decisions [83]. 
Health priorities might become overly focussed on determining who in society is ‘at fault’ 
for poor health rather than providing care to those in need, and when taken to the extreme, 
such moral judgements may incline health officials to abandon the needs of those judged to 
have been imprudent in their lifestyle choices [84 p.3]. From an epidemiological 
perspective, determining whether or not unhealthy behaviours are a matter of choice is 
often very complex since a wide array of socio-environmental and psychological factors 
influence individual lifestyles. This complexity suggests that justice assessments based on 
just desert are to some extent, or even inevitably, arbitrary [82]. For instance, would it be 
appropriate to blame an individual for heavy drinking following a messy divorce; or how 
about the stressed-out workaholic who is desperately striving to obtain better employment 
opportunities? In both cases it is difficult to determine whether such unhealthy choices are 
readily avoidable, unreasonable, or based on imprudent decisions.  
 
Theory applications 
 Without a doubt, “explicating the demands of justice in allocating public health 
resources and in setting priorities for public health policies, or in determining whom they 
should target, remain among the most daunting challenges in [policy development]” [15 
p.171]. This challenge is obviously not the result of a paucity of philosophical debate or 
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scholarly analysis concerning equity in health contexts. Rather, a wealth of scholarship has 
identified a wide variety of issues that are integral to debates pertaining to health equity and 
what rights and responsibilities should be important considerations in population health 
interventions and policy. Whether it be efficiency, lifestyle choices, favouring the needs of 
the vulnerable, or ensuring equal capabilities for health, these issues – which have each 
been the focus of theories of social justice – are all relevant in health policy discourse. This 
signifies, as stated by Beauchamp and Childress, that “no single principle can address all 
problems of justice” [2 p.227] in health. Employing one theory of justice in policy will 
inevitably result in a difficult trade-off in equity criteria defended by contrasting theories.  
 At this point it may seem that employing any given theory of social justice in 
decision frameworks will inevitably collide and so lead to an impasse. If each theory 
identifies important concepts in health equity, it is difficult – likely impossible – to define 
which perspective of social justice should have precedence over others. Nevertheless, these 
conflicts in theory do not mean that principles of social justice have little utility in health 
policy development or as tools in decision-making by health professionals. On the contrary, 
different theories of social justice provide insight into a range of considerations that are 
important when considering health inequalities and the pursuit of equity. Therefore, 
decision-makers need to first view “health equity as a very broad discipline which has to 
accommodate quite diverse and disparate considerations”, and accordantly, “appreciate that 
health enters the arena of social justice in several distinct ways, and they do not all yield 
exactly the same reading of particular social arrangements” [63, p.660]. No one theory of 
social justice will offer a complete analysis of the equitable nature of a given health policy 
strategy if employed in exclusivity. Instead, assessments made with each theory can 
arguably provide a partial contribution towards a better understanding of equity in 
population health and the associated complex realities that come with these assessments.  
 Overall, when implementing principles of social justice as a guide in policy 
development, decision-makers need to be 1) transparent, and 2) considerate towards 
opposing opinions. Transparency here denotes the need for decision-makers to be explicit 
about their choice of equity criteria that will guide a given policy agenda. Decision-makers 
should be prepared to advance solid arguments as to why these equity criteria are most 
appropriate in addressing health inequalities or in setting priorities. At the very least, these 
arguments should provide insight into questions such as “this intervention aims to promote 
equality of what?” and “why do these principles of social justice identify important issues 
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in this context?”. As such, decision-makers must be humble and open minded, and accept 
that their arguments may be criticised from other perspectives of social justice. Upon 
considering any differences in opinion, decision-makers should then assess means to 
incorporate within the policy development process the additional social justice 
considerations identified through debate. Such actions will encourage the development of 
more accommodating policies that are more attuned to the complex reality of health equity 
assessments. 
 
 To summarise, decision-making frameworks centring assessment on justice require 
openness to debate and consideration of multiple perspectives of equity in health. Abstract 
principles of justice will “provide only rough guidelines for forming specific policies or 
taking concrete actions” and so each theory will “succeed only partially in bringing 
coherence and comprehensiveness to our fragmented visions of social justice” [2, p.230]. 
However, rough as these guidelines may be, all debates require an initiator of discussion, a 
foundation upon which to build. Therefore, many philosophers would argue that “principles 
of justice can offer little help until they have been integrated into a systematic framework” 
[2, p.230]. Indeed, it is logical to assume that much insight into the strengths and 
weaknesses of given principles of justice can be derived from the actual application of 
these principles in health policy development by health professionals. In other words, in 
order to advance debate, it is essential to transfer the knowledge inherent to social justice 
theory into the realm of practical application. The following discussion will aim to 
contribute towards such an initiative by proposing one prominent theory of social justice as 
a guide in policy development. The following presentation of Rawlsian social justice theory 
will serve as an introduction to a later application of this theory as a foundation for 
decision-making frameworks for priority setting in public health. 
 
A theory for targeted application: equality of opportunity in population 
health 
 Consider for the moment the following thought experiment. Imagine that your 
memory has been temporarily and selectively erased so that you no longer have any 
recollection about your age, gender, social class, degree of power in the social order, family 
history... nothing. One area where your memory does not forsake you is your observations 
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of the society to which you belong. You can recall that many people are fortunate in that 
they have access to all the necessities to live well and be content. However, many people 
fare far worse, where for some, life is a constant struggle. Those less fortunate are burdened 
by many factors, such as extreme poverty, substandard housing, discrimination, a collective 
disregard for the needs of the disadvantaged, and so forth. Worst of all, you can recall that 
those experiencing severe burdens have few opportunities to escape this disadvantaged 
state; their condition is often hopeless. Your temporary amnesia prevents you from 
knowing whether you are a member of the fortunate or unfortunate segments of society. At 
this point, a simple question is posed to you: if you had the power to change society, how 
would you amend it so that it will suit your best interests? Would you want the current 
social arrangements to remain, or would you be better off if social institutions ensured that 
all people have equal opportunities for achievement? Knowing that the possibility exists 
that you are a member of the less fortunate in society, it appears that your safest bet would 
be to reform society so that it would enable all people to escape such forms of destitution.  
 The above scenario is a variation of John Rawls’ [85] famous thought experiment, 
known as the veil of ignorance. Rawls argues that any self-interested individual who cannot 
foresee their future well-being would want society to ensure fair opportunities to achieve 
one’s goals in life for all citizens, rather than allow social inequalities to form based on 
biological and social lotteries to which individuals have no control over (e.g., being born 
with or without ‘healthy’ genetics; being born into a rich or poor family; possessing – or 
not – talents that are in high demand within society [e.g., virtuoso musical abilities]). 
Rawls’ conception of justice, entitled justice as fairness, derives from two core concepts: 
equality in opportunity and the allocation of primary resources based on the difference 
principle.  
 Rawls proposed that social institutions have the duty to redress social inequalities in 
abilities and disabilities, and a guiding rule for such redress is to instate a social system that 
will ensure equality of opportunity for all. An essential duty for social institutions is 
therefore to ensure equal rights, protect liberties, and provide conditions for self-respect to 
all citizens, independent of factors such as wealth, gender or ethnicity [85, p.477]. 
Discrimination in any form is understandably counterproductive and so social institutions 
must safeguard human rights and foster citizen participation in political discourse so that 
everyone is guaranteed equivalent protections, and thus abilities to achieve. In addition to 
the non-material goods of rights, freedoms and feelings of self-worth, Rawls proposed that 
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social institutions should also ensure a fair distribution of primary resources amongst all 
citizens. Primary resources can assume many forms, such as minimum standards for 
housing, nutrition, and equal access to education. Consider the latter example of education. 
The ideals advanced by Rawls would uphold the duty for society to provide equal access to 
education so that all citizens may educate themselves to the fullest of their abilities and 
desires, and not be limited by factors such as the ability to pay for these services. 
Furthermore, those people unfortunate in the biological lottery, such as those born with 
learning disabilities, should have access to specialised training in order to overcome these 
disabilities as much as possible, regardless of whether such services would cost more [2, 
p.236].  
 However, to ensure a true equal distribution of opportunities amongst all citizens, 
Rawls advanced the argument that the distribution of primary resources cannot be equal. 
Rather, distribution of resources must follow the difference principle, where resources are 
directed first towards those in greatest need. More specifically, Rawls proposed that the 
best method to eliminate unacceptable inequalities in opportunities was for resources to be 
directed towards the most vulnerable and disadvantaged members of society (i.e., those 
who are the ‘worst-off’). By targeting resources towards those in greatest need, Rawls 
argued that this strategy would be the best method to eliminate inequalities in opportunity 
that serve no benefit to society as a whole. 
 
Uniting Rawls with health policy 
 The initial conception of justice as fairness advanced by Rawls pertained to the 
structuring of society and was not designed specifically in terms of population health 
inequalities [85]. Only later did scholarship begin to apply Rawls’ theory within the 
specific context of health, a notable example being the work of Norman Daniels [10, 76, 
77, 86]. Daniels argues that health services are an essential component of social justice 
since disease will diminish an individual’s capacity to function normally. This signifies that 
individuals in a poor state of health have reduced opportunities in life compared to others in 
healthier states. Accordingly, if society aims to promote equality of opportunity amongst its 
population, health institutions must aim to restore individuals to the level of functioning 
they would have enjoyed if they were healthy [10, 76]. Here we see that by applying 
Rawlsian conceptions of social justice, health care should not be viewed like any other 
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service available through the free-market. Instead, health care is best viewed as a special 
kind of good that enables greater equality of opportunity if a reasonable level of care is 
made available to all members of society. 
  Following the thesis that securing health is an essential component of equality of 
opportunity, Daniels, in collaboration with the epidemiologists Ichiro Kawachi and Bruce 
Kennedy, advanced the thesis that upholding Rawlsian principles of justice can be a 
strategy for improving population health [77]. Their argument rests in part on an observed 
trend in population health. While relatively wealthy, developed nations achieve the highest 
levels of life expectancy, health measures plateau when per capita GDP reaches $9000 
(US$). Therefore, population health does not necessarily follow a linear relationship with 
respect to the net wealth of a nation. From this observation, Daniels and colleagues propose 
the hypothesis that net wealth is not the sole determinant of health achievement; rather, 
how evenly wealth is distributed in society can play an equally important role. Daniels and 
colleagues correlate this hypothesis by examining nations such as Japan and Sweden, 
which have more equal income distributions and higher life expectancies than the US, 
despite having less net wealth [87]. Daniels and coauthors also refer to longitudinal studies 
demonstrating that in the US, states with the highest income inequalities between social 
classes have slower rates of improvement in average life expectancy when compared to 
states with more equitable income distributions [88]. Recent nation-wide assessments of 
other developed countries, such as Canada [89], continue to substantiate the existence of 
socio-economic gradients in population health that do not correlate with differentials in 
access to health care [90, 91]. Overall, empirical findings suggest that the degree of income 
and resource equity may have dramatic effects on population health. For Daniels and 
colleagues, a solution to observed health differentials between social classes is to an extent, 
straightforward: one must reduce gradients in income and available resource between 
socio-economic strata within currently inequitable societies. Rawlsian social justice theory 
is thus proposed as one framework to guide government institutions in the development of 
social safety nets and income redistribution strategies as a broad public health intervention 
that address the needs of worse-off members in society [77, 91].  
 In addition to the work of Daniels and collaborators, Andrew Courtwright [30] 
recently questioned whether Rawlsian social justice theory could help identify important 
considerations in health policy outside the context of resource distribution. Courtwright has 
focused on the distribution of non-material goods, specifically liberties and ability for self-
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respect, and examined the significance that these non-material goods have in terms of 
health disparities. He notes that stigmatisation of vulnerable community groups can 
exacerbate health inequalities, because feelings of shame and diminished self-respect 
discourage stigmatised individuals from seeking appropriate health services and following 
healthy lifestyle choices [30]. From these observations, Courtwright argues that efforts 
aimed at reducing health inequalities entail more than addressing questions of resource 
distribution; they must also include specifying the duties for government institutions to 
ensure a social environment that fosters self-respect and feelings of self-worth. On the 
whole, Courtwright recommends that upholding Rawlsian principles of equality of 
opportunity in relation to non-material goods could serve as a useful guide towards 
reducing health inequalities related to stigmatised health conditions.  
 
Theory applications 
 Are the central tenets proposed by Rawls the ultimate and best theory of social 
justice to guide health policy development? No. Just like all other theories of social justice, 
the principles upheld by Rawls address a select set of a broad range of considerations that 
are pertinent to health equity assessments. However, many health officials will likely share 
the general intuition that the central tenets proposed by Rawls will do more to advance, 
rather than impede, efforts to achieve greater justice in population health [92]. Regardless, 
one does not need to adhere strictly to this theory if one agrees that the promotion of 
equality of opportunity and improvement of the situation of the worst-off members of 
society are two concepts that require consideration when designing policy agendas. Thus, 
rather than a philosophical conviction, Rawlsian principles should be viewed as one of 
many knowledge foundations that can help structure decision-making frameworks in 
health.  
 Even in the absence of debate, it is reasonable to conclude that decision-making 
frameworks gain an advantage if they include, rather than overlook, an assessment of equal 
opportunities in health. Indeed, merely being aware of the potential for certain communities 
to have reduced opportunities in securing health is a valuable asset for decision-makers. In 
addition to this awareness, assessments that incorporate analysis of opportunities in health 
can help identify inadequacies in proposed health services and programmes. Consider a 
situation where a diverse group of people all suffer from a given pathology, which, for the 
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most part, is treatable via a pharmaceutical regimen. However, a minority of individuals do 
not respond well to the therapeutic regimen or experience adverse drug reactions. A 
decision-maker may conclude in this situation that the health benefits accrued by the 
majority would justify the provision of the pharmaceutical treatment to all those that could 
benefit. Though the aims of this decision are laudable, attending to the principle of equality 
of opportunity would show that this policy is inadequate. By focusing the health 
intervention on the provision of pharmaceuticals, the majority of people suffering from the 
pathology gain opportunities to improve their health while a minority does not. This 
situation will predictably exacerbate inequalities in opportunities amongst this population, 
which runs counter to ideals of promoting health equity. An arguably better strategy would 
be one that incorporates additional treatment options so that all individuals gain means to 
treat their affliction.  
 It is understandable that policy development will often focus on issues pertaining to 
the equitable provision of material goods, such as pharmaceuticals. However, the principle 
of equality of opportunity shows that non-material goods should also be included in health 
equity assessments. Decision-makers must be aware that non-material goods, such as basic 
human rights, dignity, and feelings of self-worth play an equally important role in securing 
population health [93, 94] and should therefore be important factors for consideration in 
health policy. Yet many decision-makers in health might regard issues pertaining to rights 
as being beyond their remit, or consider issues of dignity and self-worth are solely personal 
matters. Yet, recall that Courtwright delineated how stigma impinges on feelings of dignity 
and self-worth, which in turn can undermine efforts to achieve equity in population health. 
Also recall that decision-makers do have a degree of control over structuring policies so 
that they avoid stigmatising vulnerable populations. Thus by merging these two concepts, 
we observe how decision-makers can promote equal opportunities in health in relation to 
non-material goods by avoiding the development of stigmatising health interventions. 
Overall, the choices made by health officials within their professional jurisdiction are 
actions that can contribute towards ensuring a social environment that fosters self-respect 
and feelings of self-worth.  
 Another tangible example concerns non-material goods in the form of power or 
influence, key factors that form the crux of lobbying or political pragmatism in health 
policy development [95]. Communities and organisational bodies (e.g., patient advocacy 
groups, industry representatives) differ in their opportunities to attract attention and direct 
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political action towards addressing their health needs. Differences in abilities to 
successfully lobby for a cause (e.g., funding for a given treatment) may be due to many 
factors [96] (e.g., of particular importance being financial support and political influence 
from the pharmaceutical industry [95, 97, 98]). Regardless of the source, these differentials 
in lobbying power and political influence should raise concern since, at the very least, they 
likely undermine equal opportunity in addressing population health concerns. Thus, with 
the principle of equality of opportunity in mind, decision-makers should question whether 
lobbying efforts might unduly bias their decisions in policy development. If this appears to 
be the case, this situation should encourage decision-makers to amend their decisions so 
that they are more inclusive of the needs of other groups that are unable to deploy 
equivalent levels of influence on decision-making processes. Overall, a more ethical and 
democratic approach to decision-making is one that bases choices on the premise of 
providing equal consideration to the interests of all members of the community. 
 An additional challenging situation faced in health policy relates to priority setting. 
Since it is often impossible to meet the health requirements of all communities all at once, 
decision-makers will need to justify their choice in executing certain interventions before 
others and explain why these interventions should favour the needs of defined groups in 
society. A growing consensus amongst scholars is that the poor health measures amongst 
systematically disenfranchised communities are of primary concern in health equity 
discourses [19, 24, 76, 99, 100]. Arising from these concerns are arguments that prioritising 
the needs of the worst-off is ethically justified since, at the very least, such efforts will 
avoid exacerbating the already disadvantaged state of these communities relative to those 
that are better-off [101, p.214]. If decision-makers share these convictions, upholding 
Rawlsian principles to favour the needs of the worst-off within priority-setting frameworks 
can provide guidance and means to ethically justify the targeting of health interventions to 
particular groups. 
 
General conceptions of distributive justice in health policy 
 Analysis of health equity is not exclusive to situations concerning health 
inequalities between population groups. In addition to social justice issues, health policy 
interventions inevitably also raise many distributive justice issues. Unlike the multiple and 
sometimes conflicting perspectives of social justice, a primary tenet of distributive justice 
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has emerged and appears to have attained widespread consensus amongst health scholars, 
namely the principle of the fair distribution of benefits and burdens [2, p.326-394, 13, 19, 
102, 103, p.30, 104].  
 At the heart of distributive justice assessments is an analysis of the positive and 
negative outcomes or features of health policy interventions. Positive attributes are broadly 
termed as ‘benefits’, which signify the advantages gained by policy initiatives, such as a 
health intervention’s success in reducing or preventing morbidity and mortality (within the 
context of health research, benefits are typically in reference to the knowledge gained from 
biomedical investigations). Negative attributes fall under the heading of ‘burdens’, which 
refer to any disadvantages that arise from health initiatives, such as risks of harm, hardship 
or restrictions in civil liberties. Recall that population health interventions may require the 
imposition of hardships or restrictions on individuals and communities [19, 20], for 
instance, by restricting freedom of movement and association due to quarantine, or 
requiring citizens to pay taxes on ‘unhealthy’ products (e.g., tobacco tax) in order to 
dissuade consumption, or by introducing risks of harm from breaches in personal privacy.  
 Previous sections of this chapter have identified why benefits and burdens in health 
policy are main concerns in ethical assessments: the duty to minimise harms through acts of 
nonmaleficence and the duty to implement the least restrictive or invasive health policies 
being apt examples. In addition to consideration of the relative amounts of advantages 
versus disadvantages in health policy outcomes, justice assessments move one-step further 
by focusing assessments on whether the allocation of benefits and burdens across 
individuals and communities are fair [103, p.30]. But what is meant by fair?  
 Fairness in distributive contexts does not imply that benefits and burdens must 
always be distributed equally [102]; rather, justice assessments raise concerns when the 
benefits and burdens of health interventions appear concentrated towards some 
communities (or individuals) and not others. Reliance on mere intuition would likely lead 
one to question whether such a concentration of benefits and burdens is suggestive of 
undue favouritism, or indicative of double standards in policy development (i.e., upholding 
professional standards in some contexts but not others). Duties to promote health equity 
appear particularly compromised if benefits or burdens are exclusive to certain communities 
while comparable communities remain excluded. The following examples will help place 
these concepts into context.  
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 Consider a situation where a health intervention, say a vaccine, is made available to 
a paediatric population; however, health officials conclude that the most efficient means to 
distribute the vaccine would be to limit its distribution to urban areas. This situation seems 
fundamentally unfair since this policy decision will inevitably exclude people in rural areas 
from benefiting directly from this intervention. From the perspective of burdens, many 
would likely agree that justice is compromised if health regulations impose 
disproportionate burdens on particular segments of society [13]. Such criticisms arise, for 
instance, concerning taxes on sweetened beverages as a means to curb rising rates of 
obesity [105]. Concerns centre on whether such taxes would be regressive in that they 
would impose a disproportionate burden on the poor, since this population segment 
allocates a higher percentage of annual income to food (thus, relative to more wealthy 
groups, the poor will loose a greater percentage of their income due to this tax).  
 Gostin and Powers [19] offer another example in relation to crisis situations, as 
would be the case with a natural disaster. Government officials may direct a population to 
evacuate or seek shelter in safe areas. Though rational, this evacuation order is deficient 
from a justice perspective: health officials did not consider that disabled and impoverished 
citizens will not have equivalent mobility and access to private transport as would the 
majority of citizens. A more fair evacuation strategy would devise plans to ensure these 
vulnerable members are not left behind. This example identifies how notions of justice 
encourage health officials to question whether a policy can be of benefit to all, including 
those disadvantaged members of society.  
 A third example pertains to issues of exploitation, a concern when specific 
communities are exposed to risks of harm, but taking these risks will provide no net 
benefit. Conducting clinical trials for experimental medications in the developing world is a 
notable example [106]. Clinical trials for experimental drugs carry risks of harm to research 
participants (e.g., unforeseen adverse drug reactions), risks that most would find acceptable 
if outweighed by the expected benefits from the research endeavour (e.g., the development 
of a novel treatment). This arguably just balance of risks and benefits would not be 
obtained if clinical trials conducted in the developing world would serve to produce 
medications that will only be made available to developed world populations. Overall, it is 
becoming widely accepted [6] that it is fundamentally unfair to inflict significant risks on 
populations that are unlikely to enjoy the benefits from health research. By extension, 
equivalent conclusions can be made for public health interventions.  
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Theory applications 
 Decision-making in health policy will undoubtedly raise issues pertaining to 
distributive justice. Assessing whether or not a given health intervention is effective at 
reducing morbidity and mortality is only one component of a larger analysis. Equally 
important to questions of efficacy are issues pertaining to the fair distribution of benefits 
accrued from health policy agendas. A complimentary issue in policy analysis concerns 
burdens; merely designing health interventions to avoid burdens as much as feasible is 
insufficient. Decision-makers must also assess whether their chosen strategies in policy 
development will disproportionally impose burdens on specific population segments. 
Overall, if benefits or burdens must be targeted towards particular groups, this requires 
strong justification. At the very least, those who must bear the burdens from a policy 
intervention should also accrue a net benefit. Thus, standard equity assessments should ask 
who stands to benefit or be harmed when implementing strategic decisions? If the 
distribution of these factors appears unduly exclusive to some and not others, this likely 
indicates the need for reforms. 
 
Applying practical theory in decision-making frameworks for allergy: A 
synopsis 
 Having provided a general overview of principles of ethics and their utility in health 
policy contexts, the following chapters of this thesis will apply these principles within a 
novel context: allergy. These principles will serve two functions: first as analytical tools to 
assess the ethical implications of allergic disease, and second, to structure decision-making 
frameworks to help guide health professionals in the development of health policies for 
allergy. Rather than focus on policy officials employed within the upper echelons of 
government, these frameworks specifically target ‘meso-level’ health professionals 
employed within common institutions (such as schools or regional public health 
departments).  
 Chapter 1 provides an overview of existing research concerning ethical issues in 
allergy. Written for a target audience of allergologists, this chapter is in preparation for 
submission to the journal, Clinical and Experimental Allergy. This investigation involved a 
preliminary literature review of academic articles that discuss ethical issues in allergology 
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or employ principles of ethics to guide decision-making in allergy health policy. Thus far, 
this literature search retrieved fewer than 35 academic articles that contain a significant 
ethical analysis concerning allergic disease, which suggests that ethical analysis in 
allergology is a largely overlooked area of investigation. In raising attention to this 
apparent paucity of ethical analysis concerning allergy, the article argues that the 
allergology community should engage in further ethical analysis within their specialization, 
in order to improve health policy and promote research innovation. This chapter also serves 
a more indirect purpose, that is, it demonstrates the novelty of this doctoral research and 
how this project contributes to advancing research in the largely overlooked and 
underdeveloped domain of ethics in allergology. 
 Defining the unequal distribution of allergy morbidity amongst socioeconomic 
classes and minority groups as a social injustice frames the debate in Chapter 2. Published 
in a special edition on public health ethics in the journal, Les ateliers de l’éthique/The 
Ethics Forum [107], this chapter was inspired by the work of Daniels, Kennedy, and 
Kawachi [73] and the use of Rawlsian theories of social justice to analyse population health 
inequalities. However, for this chapter, Rawlsian principles of social justice are not 
employed within resource allocation discourses. Rather, such principles serve to structure a 
step-wise assessment framework to prioritize and assess the ethical legitimacy of public 
health policies that reduce environmental allergens. This assessment framework calls 
attention to the diversity that exists within the allergic population and the unequal 
morbidity levels experienced amongst sub-populations of allergy sufferers. In terms of 
justice, policies should reflect this diversity and aim to provide equal opportunities in 
health to all members of the allergic population. In situations where targeted policies are 
merited, the allergic sub-population selected for a particular public health intervention 
should constitute a particularly disadvantaged group in their abilities to control their allergy 
morbidity. Additionally, such interventions must have built-in safeguards that ensure 
policies do not inadvertently stigmatize the population targeted by the public health 
intervention.  
 School nurses and administrators of childcare institutions are the target audience in 
Chapter 3. Published in the Journal of School Nursing [108], this chapter aims to address 
known weaknesses in food allergy policies for schools and childcare settings. To this end, 
core principles in bioethics and public health ethics are used to develop a framework to 
assess the adequacy and ethical legitimacy of food allergy prevention efforts. Principles 
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such as the protection of confidentiality, fair provision of health benefits and burdens, 
avoiding stigmatization, and empowerment all serve as points for assessment. This policy 
assessment protocol, in turn, provides a reflexive tool to aid administrators and school 
nurses in their decision-making capacities when structuring food allergy policies for 
childcare and educational institutions. 
 The final chapter investigates ethical issues inherent in current drug regulations 
concerning the production of allergen vaccines used in allergen-immunotherapy. Published 
in the Journal of Asthma and Allergy Educators [109], this chapter raises questions about 
the need to assess the potency of these drugs in highly allergic human test subjects. Human 
subject testing is a necessary procedure in prominent drug regulations that aim to 
standardize the batch-to-batch consistency of allergen vaccines. Though beneficial, in that 
this testing enables the production of higher quality therapeutics, such testing is not free of 
risks, risks that ought to be avoided as much as possible. Following an overview of 
innovation in in-vitro testing methods, this chapter argues that capabilities in reducing or 
eliminating human subject testing are rapidly approaching fruition. Thus allergy educators 
and drug regulators should prepare to reform current standardization guidelines to phase-
out human subject testing. To guide this regulatory transition, the article concludes with a 
reflexive framework to structure drug regulatory policies based on principles of 
nonmaleficence, beneficence and the fair distribution of benefits and burdens stemming 
from research. 
 
 The following chapter (1), will now aim to answer two basic questions: What is 
known in terms of ethics in allergology, and why is this domain of inquiry important? 
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CHAPTER 1: ISLANDS SEPARATED BY VAST OCEANS: THE 
PAUCITY OF ETHICAL ANALYSIS IN ALLERGOLOGY 
 
The following chapter is in preparation for submission to the journal Clinical and 
Experimental Allergy. The analysis herein is thus preliminary, oriented specifically to this 
thesis, and subject to further modifications prior to submission for peer-review. 
 
Abstract 
While a growing body of research is uncovering the aetiology and effective treatments for 
allergy, research that assess the broader ethical implications of this disease is virtually non-
existent. This article will demonstrate both the paucity of academic research concerning 
ethical implications in allergy – especially in terms of policy and public health issues – and 
explain why ethical analysis is integral to formulating effective health strategies for allergic 
disease. An exhaustive literature search identified less than 35 academic articles focussed 
on the topic of ethics and allergy; this is a miniscule number when compared to the amount 
of articles published on ethical issues related to other chronic illnesses, such as obesity. It is 
important to demonstrate to allergy specialists the need for, and utility of, further 
incorporating ethical analyses in allergology, and in the development of health policies for 
allergy. Indeed, health policy and public health interventions will undoubtedly encounter 
ethical dilemmas and the allergology community should play a significant role in helping to 
address these issues. However, incorporating ethical analyses in allergology does not imply 
that the allergology community must acquire extensive knowledge in bioethics; instead, 
interdisciplinary research that incorporates expertise from allergology, public health, and 
bioethics would enable allergy specialists to advance critical knowledge development in 
this largely overlooked domain of study.    
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Introduction 
Without a doubt, the sudden development of an epidemic of a chronic disease 
would garner significant concern amongst the public, clinicians and health officials. It is 
reasonable to assume that such concern would then motivate the conduct of empirical 
studies to identify the underlying mechanisms of the disease in order to then evaluate 
possible health interventions. With such knowledge, value-based judgements and 
thorough debate centring on how best to prioritize and disseminate treatment options 
and preventive efforts would likely follow. While logical, this sequence of events 
appears to be less-than-ideal with regards to the treatment of allergy and atopic 
conditions.  
 A seeming weakness in allergology is how the field has addressed debates 
concerning the implementation of treatment strategies, and the justification of value-
based judgements about particular health policies. Or in other words, there is a 
considerable lack of analysis concerning the ethics and legitimacy of allergy research 
initiatives, treatments, and health policies. A recent editorial written by prominent 
researchers in allergology and published in the journal Allergy is a prime example [1]. 
This editorial provides an overview of several global allergy research networks and 
future research areas that are of foremost interest. Rather surprisingly, only 
investigations centring on physiological aspects of allergy were deemed of importance; 
no mention is made of the need for future analyses that serve to identify the broader 
social, political, and ethical factors that significantly influence allergy treatment 
strategies and the population distribution of morbidity. The omission of the latter should 
not be misconstrued to imply that the broader and “less technocratic” socio-
environmental and ethical issues of allergy have been investigated in depth and thus 
merit little, if any, priority. In fact, this article will demonstrate that concerted ethical 
analysis in allergology has barely begun.  
 Should the global community of allergy specialists care about this arguably 
underdeveloped sub-domain of allergology? This article will contend that indeed, they 
should. However, these arguments will not claim that allergologists should tear-off their 
lab coats and then focus on philosophical debates concerning “how many allergens can 
one fit on the head of a pin?”. Rather, the aim here is to further sensitize allergy 
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specialists to the range of social and political factors that influence clinical practice and 
the implementation of research findings, and the contexts in which such research raises 
important ethical issues. With greater awareness of such issues, allergy specialists will 
be better positioned to engage in interdisciplinary research with members of the 
bioethics community in order to advance ethical analysis and debate in allergology. 
More generally, interdisciplinary research between these communities will help define 
the values that ought to guide decisions in health policy and public health interventions 
for allergy.  
Scientific research and clinical experience serve to inform us of the underlying 
causes of disease, what the risks and benefits are concerning known treatment strategies, 
and whether emerging treatment modalities show promise in further reducing morbidity. 
It is wrong, however, to assume that scientific investigation and clinical practice in 
allergology – and the influence of both on health policy – exist within a purely 
objective, value-free space. Rather, all of these domains in health are interlinked and 
raise ethical questions in need of consideration [2-4]. What are the goals of allergy 
research, and how ought these goals define how resulting medical innovation is 
implemented and distributed amongst the population? Which forms of allergy morbidity 
are most significant and, under inevitable conditions of limited resources, which 
populations of allergy sufferers merit priority in targeted health interventions? What 
constitutes an effective treatment of atopic disorders, and what proportion of treatment 
strategies ought to comprise disease prevention efforts? The above are but a brief list of 
important ethical questions – with no simple answers – that must be subject to ethical 
reflection and analysis in order to achieve a measure of consensus and recognition of 
legitimacy, as well as to enable political action (i.e., public policy). It is evident that the 
voice of the allergology community is essential to these discussions, and in turn, will 
determine society’s success in attenuating the devastating health consequences of the 
expanding epidemic of allergy. 
But first, this chapter will now demonstrate the current (limited) extent of ethical 
analysis in allergology. 
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Methodology 
 An exhaustive literature search was conducted during the months of January to 
March 2012, via the Internet using the following academic search engines and online 
databases: GoogleScholar (www.googlescholar.com), PubMed 
(www.ncbi.nlm.nih.gov/pubmed), Web of Knowledge (Thompson Reuters; 
www.webofknowledge.com), CAIRN.info (www.cairn.info), Érudit (www.erudit.org), 
and Refdoc.fr (www.refdoc.fr). Manuscripts in the form of publications in academic 
journals written in English or French were included in the analysis; publications other 
than manuscripts appearing in academic journals or books (e.g., theses, institutional 
newsletters, conference proceedings, news articles) were excluded from the analysis.  
 An exhaustive search for ethics analyses concerning allergic disease and 
common atopic disorders was conducted using the keywords: ‘allergy’, ‘atopy’, ‘atopic’, 
‘urticaria’, ‘rhinitis’, ‘dermatitis’, ‘anaphylaxis’, and ‘asthma’, which were paired with 
‘bioethics’, ‘ethics’, ‘ethical’, ‘moral’, and ‘unethical’ to enable independent searches 
for each possible pairing of terms (e.g., ‘asthma ethics’, ‘atopy moral’, etc.). An 
equivalent search was repeated using the same key words in French (uticaire, rhinite, 
dermatite, atopie, atopique, allergie, anaphylaxie; éthique, bioéthique, morale, moraux). 
Manuscripts retrieved for each pair of search terms were assessed for content and 
inclusion in this study. Manuscripts were further excluded from analysis if they met the 
following criteria: 1) ethics terminology was mentioned only in passing (e.g., appear in 
two or fewer sentences) and the analytical content of the manuscript did not focus 
discussion on ethical issues; 2) the manuscript only mentioned ethics in relation to the 
research project having passed ethical review by an Insitutional Review Board (e.g., 
IRB, ethics advisory board, protocols for the ethical conduct of human subjects in 
research, etc.); 3) provided titles and abstracts in English or French but the text of the 
manuscript is of another language. The remaining manuscripts were read and 
categorized by content in relation to sub-specialisations in Bioethics, that is, relating to 
clinical, research, health policy, and public health ethics. (To expand: clinical ethics 
pertains to ethical issues arising in clinical contexts, often involving interactions 
between health professionals and individual patients/families; research ethics concerns 
the ethical conduct of human subjects research; health policy ethics concerns the 
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structuring, implementation, organisation, and provision of health services; and public 
health ethics pertains to health interventions targeting populations rather than individual 
patients). These manuscript were further divided into two categories which determined 
their inclusion in the primary analysis or whether they were delegated to annex of this 
chapter: 1) manuscripts comprising academic articles of several pages are included in 
the primary analysis; 2) manuscripts comprising short works, such as correspondences, 
letters to the editor, commentaries of fewer than 3 printed pages, and editorials are listed 
in the annex only and are not included in the main analysis herein. Manuscripts were 
deemed to be of particular interest (marked with an ‘X’) if they devote a significant 
discussion of ethics in relation to allergy (rather than limit discussion of ethical issues to 
a paragraph or only a short section heading within the manuscript, or if ethical issues are 
delegated as a distinct topic for analysis such that ethical issues are not framed 
particularly within the context of allergy).  
 In order to provide a simple comparison in the amount of ethics research 
available for chronic diseases other than allergy, the parameters of the literature search 
were repeated for obesity. However, this literature review was limited to the term 
‘obesity’ (e.g., using search terms ‘obesity ethics’, ‘obesity moral’, etc.), and did not 
include searches employing terms for common co-morbid conditions (e.g., metabolic 
disorder, diabetes).   
  
Results and Analysis: The paucity of academic articles concerning 
ethics and allergy 
 If time is represented anecdotally as ‘water’ and academic investigations as 
‘land’, the accumulated knowledge concerning ethics and allergy is accurately described 
as “islands separated by vast oceans” (Table 2). The results from the exhaustive 
literature search identified fewer than 50 academic articles on the subject of ethics and 
allergy, which spans 31 years of academic research (1980-2012). The majority of 
articles retrieved from this search (approximately 90%) have been published within the 
last ten years alone (2002-2012).  Of these 50 articles, fewer than 35 contain a 
significant analysis of ethical issues in allergology (i.e., articles in which the authors 
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provide a detailed description of ethical issues concerning allergy, rather than merely 
mention ethical issues within a paragraph or brief section within the manuscript; in 
Table 2, these articles are indentified with an ‘X’). This publication history indicates 
that most investigations centring on ethical issues in allergy are exceptionally recent and 
not representative a significant effort to advance knowledge in this interdisciplinary 
domain of study; that is to say, ethical concerns do not appear to “be on the radar” of the 
international allergology community. 
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Table 2: Summary of results from the literature search for ethical analysis in 
allergy 
 Year of 
publication 
 
Author(s) 
Bioethics 
sub-domain 
Notable ethics analysis--of 
particular interest 
 
Reference 
Kreger et al Health policy, Public health X [5] 
Behrmann Health policy, Research X [6] 2011 
Master et al. Research X [7] 
Landrigan et al. Public health  [8] 
Behrmann Health Policy, Public Health X [9] 
Behrmann Health Policy X [10] 
2010 
Ellwood et al.  Research X [11] 
Engler et al Clinical X [12] 2009 
Brody et al. Research X [13] 
Park, Grayson Research X [14] 2008 
Craner Research, Health policy X [15] 
Scherer et al. Research X [16] 
Canonica Research  [17] 2007 
Wise Research X [18] 
Liss Research  X [19] 
O’Lonergan, Milgrom Research X [20] 
Brody et al. Research X [21] 
2006 
Clark et al. Research  [22] 
O’Lonergan, Milgrom Research X [23] 
Brody et al. Research X [24] 
Roberts Clinical  [25] 
Scherer et al. Research X [26] 
Resnik et al. Research X [27] 
2005 
Onder Research X [28] 
Rous, Hunt Health Policy X [29] 
Sutherland Research  [30] 
Dolen Research  [31] 
Coffey et al. Research X [32] 
Annett et al. Research X [33] 
2004 
Brown et al. Health policy, Public health X [34] 
Brown et al. Health policy, Public Health X [35] 
Midulla Clinical, Research  [36] 2003 
Brody et al. Research X [37] 
Miller, Shorr Research X [38] 2002 
Miller, Shorr Research X [39] 
Payne et al. Clinical  [40] 2001 
 Holley et al. Research  [41] 
2000 Holt, Sly Research  [42] 
1996 Storrs Clinical  [43] 
Harth, Thong Research X [44] 
Feingold Clinical  [45] 1995 
Gibson et al. Clinical  [46] 
1994 Holt Clinical  [47] 
A
rti
cl
es
 in
 E
ng
lis
h 
1990 Olivier Clinical X [48] 
2009 Piette, Demoly Clinical X [49] 
2001 Duguet et al. Clinical  [50] 
1999 Del Volgo Clinical  [51] Fr
en
ch
 
1996 Lacronique Clinical  [52] 
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 While the ‘water’ is vast, the ‘land’ is minimal at best and largely represents one 
form of ‘landscape’. Of the less than 35 articles which do devote significant ethical 
analysis to issues in allergology, approximately 70% of these articles target ethical 
issues within research contexts. Of these articles concerning research ethics, the vast 
majority (nearly 75%) concern research on asthma. Only 8 articles identified in this 
literature search conduct a significant ethical analysis on issues pertaining to public 
health and health policy in allergology, 3 of which are articles presented in subsequent 
chapters of this thesis. No books devoting chapters to ethical issues in allergy treatment 
or the distribution of atopic morbidities were found. The small collection of articles 
identified are also representative of ‘islands’ of knowledge, where most articles remain 
separate from the others in terms of subject for ethical scrutiny. In other words, there are 
few links between these research publications, such that the information provided in 
earlier publications rarely cites or ‘builds upon’ in subsequent works concerning ethics 
and allergy. However, there are notable exceptions to this observation, being the 
publications by Brown and colleagues [34, 35] concerning environmental justice and 
asthma, as well as the publications concerning research subjects in asthma studies 
conducted by Brody and colleagues [13, 21, 24, 37]. 
 Though the results from this literature review indicate ethical analysis in 
allergology appears quite limited, these results are not necessarily indicative of a true 
deficiency of knowledge or a lack of initiative in this area of study. It could be argued 
that ethical analysis in health science and policy (i.e., different from clinical or research 
ethics) is a relatively new domain of scholarship; thus, it is unsurprising that 
investigations concerning ethical issues pertaining to the particular disease of allergy are 
still in their infancy. Indeed, research in biomedical ethics only began to develop 
prominence in the 1960’s, and the sub-specialization of public health ethics gained 
notoriety at the beginning of the 1990’s [53, p. vi-viii]. To address this possibility, the 
parameters of the literature search were replicated for the chronic disease of obesity in 
order to enable a simple comparison between the amount of ethics scholarship in 
relation to both diseases.  
Obesity is a useful disease for comparison due to its similarities with allergy. 
Namely, both are chronic diseases that predominate in the developed world, both have a 
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high population incidence (>25% of populations in developed countries), and both have 
recently exploded into epidemic proportions that pose a significant challenge to public 
health [54-56]. From this less expansive literature search, over 60 manuscripts 
pertaining to obesity and ethics were identified, and accumulatively represent several 
hundreds of pages of published material on the subject (data not shown). Between 2007 
and 2010, alone, 23 research articles were published on ethics and obesity [57-79]. 
Moreover, unlike allergy where retrieved manuscripts were exclusive to academic 
articles, analysis of ethical issues related to obesity has been the focus of a book [80] 
and the subject of several book sections [81-88]. Comparing obesity to allergy, a 
reasonable conclusion derived from both literature searches is that ethical analysis 
concerning allergy is very limited and at an embryonic stage of academic development. 
Arguments that ethics in health policy and public health is too new a field of study for 
there to be extensive application when analysing recent epidemics of disease are not 
supported by these findings. Instead, the wealth of scholarship available for ethics and 
obesity should serve as inspiration concerning the future potential for ethics in 
allergology. Overall, the paucity of ethical scrutiny for allergy likely stems from other 
factors, such as lack of awareness, interest, or capacities to engage in interdisciplinary 
research that integrates ethical reflection with allergy research and clinical practice [89]. 
The following section will attempt to address these potential inhibitors to an applied 
bioethics in allergology.  
 
Discussion: Adding ethics to the arsenal starts with greater awareness 
 The provision of a broad argument supporting the need for, and utility in, 
applying ethical principles to aid decision-making capacities in the domain of health is 
not necessary for this article. For one, the vast majority of clinicians and researchers – 
including those specialising in allergology – are probably already well familiar with 
basic principles of clinical and research ethics that are now a mandatory component of 
most medical training curricula and that regulate practice in scientific research. The 
groundbreaking work by Beauchamp and Childress [90], Principles of Biomedical 
Ethics is likely familiar since it has been incorporated into numerous best practice 
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medical guidelines. Without question, attending to principles of patient autonomy, 
beneficence, non-malevolence, and justice support good clinical practice and patient 
care. In terms of research, most health scientists will be familiar with the need to submit 
research proposals for institutional ethics review, and core principles for the protection 
of human subjects in research are essential elements of international laws governing 
human experimentation [91]. 
 
Ethical issues unique to allergology 
 While the above safeguards are well established in legislation, in professional 
codes of ethics and in medical practice guidelines, these documents are not all-
encompassing. There are circumstances unique to allergology that require greater 
awareness, scrutiny, and debate in order to ‘fine-tune’ the decision-making capacities of 
clinicians and researchers. Consider the observation that visible minority patients in the 
United States, such as African Americans, are less likely to receive asthma treatment 
according to best practice guidelines and are less likely to receive adequate education 
concerning how to properly administer their asthma medication [92]. These inequalities 
in treatment provision do not necessarily arise because of endemic racism in medicine; 
instead, these inequalities might stem from patient characteristics such as socioeconomic 
status [93], where patients possessing a higher education level are more inclined to ask 
their physician necessary questions concerning their treatment [94]. Regardless, clinical 
allergists must be aware of the potential for inadvertent bias and thus strive to uphold 
principles of justice in the provision of appropriate information and asthma treatments to 
all patients.  
 Another example pertains to research, where emerging clinical trials show 
promise in the development of immunotherapy for food sensitivities [95]. The expected 
success of these trials will encourage further development of additional food allergen 
vaccines and novel treatment modalities. Yet, how ought future clinical trials be 
constructed to investigate these novel drugs and treatments, and what population(s) 
ought to compose the primary study group? Since food allergy and associated risks of 
anaphylaxis disproportionately afflicts children [96, 97], ought trials focus on 
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establishing appropriate dosing schemes for this population? While children will stand 
to benefit most from clinical developments from these trials, including this vulnerable 
population in research is typically discouraged and often encounters significant ethical 
challenges (e.g., informed consent with young children is often impossible) [23, 98]. 
The allergy research community will need to debate these ethical issues. At the very 
least, such ethical reflection will help avoid possible challenges concerning innovation 
in immunotherapy and assist in securing public, academic, and political support for 
these research endeavours. Overall, these two examples of ethical issues in allergology 
demonstrate the need for specific ethical analysis in this field of health science. Greater 
ethical scrutiny in allergology will undoubtedly uncover numerous additional issues of 
interest. 
 
The importance of health policy and public health 
 Whereas clinical and research matters are readily tangible to allergologists, a 
focal point for greater scrutiny and ethical analysis must include the broader social, 
political, and legal factors that impact treatment provision and the translation of 
scientific knowledge into health interventions. Greater sensitivity towards these broader 
issues is arguably in the best interests of allergy specialists. Allergologists should, 
without a doubt, play a significant role in contributing to policy debates concerning how 
best to address the public health consequences of allergy; but the potential of health 
policy and public health developments in controlling allergy morbidity cannot be 
overestimated.  
 The alarmingly high incidence of allergic sensitivities in the developed world – a 
conservative estimate being 30% of the population [99-101] – signifies that well-
coordinated policy proposals that motivate political action and social change will 
determine what medical treatment strategies are available to the growing number of 
allergy sufferers. While indispensable, the provision of affective treatments is not the 
sole moral imperative. Rather, greater ingenuity must also be directed towards public 
health prevention efforts in order to quell this growing epidemic and address the root 
determinants that cause allergic sensitivities in the first place. The sudden rise of atopic 
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disorders cannot be explained by genetic changes in the population, but rather are linked 
to environmental factors and life-style habits of Western society [102, 103]. Addressing 
these determinants falls within the jurisdiction of public health, thus indicating that 
many achievements in allergology will likely come from effective public health efforts 
[104].  The moral values held by the allergology community can and should guide 
future treatment and prevention efforts, due in part to the growing recognition of the 
responsibility for investigators and clinicians “to be accountable to the public and to 
answer questions about the implications of their work for health care, society, and 
policy” [89, p.1].  
 Given the identified paucity of ethical analysis in allergology, there is a need for 
more ethical discourse in order to define the moral values that will guide health policy 
and public health interventions.  
 
Principles of ethics as tools to define values in public health and policy 
for allergy 
“[W]e are scientists. How are we supposed to know what society wants from us? That is 
something for others to debate and formulate; we are perfectly willing to listen and 
respond.” 
! Daniel Cohen, in [63, p. 50] 
 
 The statement by Cohen is likely a familiar sentiment shared by many specialists 
in health science and clinical practice, where researchers and clinicians feel somewhat 
removed from the process of health policy development and designing public health 
campaigns; that task is typically reserved for another group of specialists, namely public 
health professionals. Further, Cohen describes a ‘top-down’ approach to policy, where 
the values held by investigators are not necessarily essential components that guide 
policy debates and determine what evidence will serve as justification for health 
interventions. This situation is arguably less-than-ideal. For one, this one-step-removed 
position from matters of public policy runs counter to growing calls for health 
researchers to bear a social responsibility to ensuring that the knowledge gained in their 
roles as scientists is used to achieve societal betterment [106]. An arguably better policy 
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development strategy would be to embrace the specialized knowledge and experience of 
allergologists at the start, where their values concerning optimal treatment and 
preventative efforts can guide health policy and public health initiatives, not the other 
way around. But how might the allergology community best define these values? 
 
Defining values: The utility of ethical principles 
 Defining goals and values, in health policy or otherwise, requires ethical 
reflection and debate, which in turn can be guided by core principles in ethics. One of 
the best and most concise explanations of the utility of employing principles of ethics as 
guides in health policy can be found in the recent work by Churchill [4]. Churchill notes 
how ethical reflection allows individuals (or groups) to identify, clarify, and define the 
aims and goals of health policy. Once goals are defined, a broader and more stable basis 
for health policy initiatives can be developed through ethical debate. These debates can 
enable consensus building which in turn provides a stable foundation of support for 
policy initiatives. Determining which policy goals constitute as “ethical” depends on 
whether policies support principles of ethics that are valued by decision-makers and the 
population that will be affected by such policy interventions. The application of 
principles of ethics in health policy is best demonstrated through pertinent examples.  
 First, consider the ethical implications of vast national disparities in the number 
of allergy specialists. Though most developed nations have a similar incidence of 
allergy, clinicians specializing in the treatment of this disease vary substantially across 
regions, ranging from 1:16,000 allergist per capita of the population in Germany, 
1:65,546 in the United States, 1:135,000 in Denmark, to 1:1,083,333 in the United 
Kingdom [107]. An even more unbalanced situation pertains to paediatric specialists in 
allergy. For example, in 2003 the Royal College of Physicians reported that the United 
Kingdom had fewer than 10 paediatric allergy specialists, compared to 96 in Sweden, 
and approximately 2000 in Japan [108]. Broad disparities and significant deficiencies in 
paediatric specialists exist despite the fact that allergic disease disproportionately afflicts 
children, and treatment of paediatric populations requires specific expertise. At the most 
basic level of ethical analysis, such vast inequalities raise questions as to whether 
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clinical allergists in many regions of the world can fulfil core values of providing 
adequate and essential care to the allergic population. 
 Despite all efforts and good intentions by clinicians, clinical allergists will not be 
able to provide optimal care under political conditions that lead to a chronic deficiency 
of certain specialists in medicine, but enable a more adequate provision of others. While 
these inequalities and shortages alone identify a need for change, clinical allergists need 
to define what would constitute a more ideal distribution of allergy practitioners. 
Utilizing principles of equity with respect to health outcomes would be a reasonable 
guide in recommending reforms in public policies that currently permit such vast 
inequalities in clinical expertise. Moreover, the allergology community will need to 
define which subspecialisations in clinical allergy policy reforms should be prioritized 
in order to best uphold values of optimal care. Being cognizant of the needs of children 
and why their health should be given priority [93], ethical principles that uphold and 
prioritize the protection of vulnerable populations would have utility in determining 
what constitutes a more appropriate proportion of paediatric specialists in clinical 
allergy. 
 As a second example, consider the link between technological innovation, the 
commercialization of novel therapies, and access to essential drugs. For many people 
with allergies and related atopic disorders, uninhibited access to therapeutic 
interventions is indispensable to achieving an appreciable quality of life. It is therefore 
disquieting that numerous social, legal, and political factors limit access to essential 
therapies. Consider recent innovations that enabled the transition to chlorofluorocarbon 
(CFC)-free asthma inhalers. Ozone depleting CFCs were banned in manufacturing 
except for the production of essential products, such as metered dose inhalers of drugs 
used in the treatment of chronic lung disease [109, 110]. The purpose for this exception, 
however, was to allow time for research to uncover suitable replacements. Indeed, the 
discovery of novel, non-aerosol administration techniques and the propellant 
hydofluoroalkane (HFA) enabled a gradual phase-out of CFCs in asthma medications 
[111-113]. But these cumulative innovations have not been exclusively beneficial.  The 
patenting of these novel drug administration methods has resulted in pharmaceutical 
companies regaining monopoly rights in the production of once common, and 
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inexpensive, generic asthma drugs [114]. Such monopoly privileges restrict access and 
impose cost-barriers [115, 116] to medications that many impoverished people require 
to live free of severe disability (elevated costs of treatment are a major factor in patient 
non-compliance to therapy [117]).              
 Surely these turn of events were not the intended goals of the academic 
researchers that contributed towards developing these CFC-free drug varieties. 
Moreover, inadvertent restrictions in access to essential drugs runs counter to core 
values that the application of research knowledge should serve to benefit society while 
avoiding the potential for harm whenever possible. Now cognizant of these 
contradictions in values, researchers must ask whether there are more ethical strategies 
to transfer research knowledge into clinical application. Such strategies would likely 
uphold and be guided by principles of benefit maximization, harm reduction, and justice 
in the provision of treatment; indeed, the choices made by senior investigators and 
directors of research institutions can help determine the success of these laudable 
strategies. For one, investigators and directors of research institutes could re-evaluate 
conditions that define patents on innovations developed through their efforts or at their 
institutions. Recent policies concerning the patenting of innovations discovered at the 
University of British Columbia (Canada) is a notable example [118]. Known as the 
Global Access Initiative, some university polices mandate that patent rights are 
transferred to corporations under the condition that products commercialized from 
patented technology will be available to populations of the developing world. To enable 
such access, corporations must provide discount pricing of products destined for 
developing world markets. Allergy researchers should consider adopting similar policies 
concerning patenting and whether these models will uphold their core values of 
maximizing access to, and the benefits of, medical innovations made at their institutes. 
 
Building knowledge in ethics in allergology will require interdisciplinary 
collaborations 
 Merging the terms ‘ethics’ and ‘allergology’ is a straightforward indication that 
advancing scholarship in this hybrid domain will necessitate interdisciplinary research, 
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and thus collaborative initiatives are likely inevitable (e.g., the combination of 
neuroscience and ethics to form the field of neuroethics [119]). Undeniably, it would be 
an overly demanding claim that specialists in allergy become equally specialized in 
another, unrelated domain of scholarship, that is applied ethics. The need for expertise 
beyond a level of general awareness and interest concerning ethical issues, however, is 
not essential. This expertise is already available through specialists in fields such as 
business ethics, bioethics or environmental ethics. Having raised arguments for greater 
awareness and interest in ethical analysis in the previous sections, this section will now 
discuss issues pertaining to establishing capacities to promote cross-disciplinary 
investigations in allergology.  
 With the realization of the complex aetiologies of most pathologies that 
challenge public health, experts agree that effective policy strategies for these diseases 
will require knowledge sharing between multiple disciplines in health research [120, 
121]. A growing call for training in health sciences to become more interdisciplinary 
and inclusive of academic disciplines outside of science are also voiced as strategies to 
improve academic training of new scientists and clinicians [122-124]. Overall, 
encouraging interdisciplinary research that integrates ethics and allergology would be 
consonant with this more general movement. Indeed, establishing greater ties between 
the biomedical and applied ethics communities sounds simple enough, though it does 
require a sustained initiative to bridge divides and build capacities that enable real 
collaboration. In practice, establishing the groundwork for interdisciplinary research is 
not simple and many experts voice the need for greater support to foster communication 
and interactions across disciplines [89, 120, 122, 125]. In particular, numerous 
administrative, cultural, funding allocation, and geographical factors favour research 
specialising in one discipline. However, there exist means to break down barriers to 
interdisciplinary research [120]; as noted by Robillard and colleagues [89], the 
establishment of dedicated ethical, legal and social implications (ELSI) programs, such 
as those fully integrated into genetics and regenerative medicine, provide models for 
reforms in other domains in the biomedical sciences. The take-home message here is 
that individual clinicians and researchers do not have the sole responsibility to establish 
contacts and build capacities in interdisciplinary research. Rather, research institutes and 
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departments in allergology have an equally important responsibility to establish 
programmes and administrative infrastructure that will favour fruitful collaborations 
with other domains, including applied ethics. 
 Despite administrative, cultural, and geographical barriers to interdisciplinary 
research, members of the allergology community do not need to wait for broad 
administrative changes in the structure of their organisations and research institutes 
before initiating interactions with specialists in applied ethics. For one, most allergy 
specialists will likely have had some association and familiarity with ethicists in their 
place of work through evaluations of research protocols by institutional review boards, 
or ethics consultations in the clinical context. This established professional network 
should not be underestimated, but rather seen as an opportunity. Merely engaging in 
conversations with these colleagues – outside contexts of evaluating research proposals 
or participating in ethical consults for particular dilemmas – would be a simple means to 
exchange ideas, and initiate future collaborations and shared learning opportunities. 
 
Conclusion 
 The paucity of ethical scrutiny in allergology described in this article does not 
aim to denote solely a weakness in this particular field of biomedical science. Rather, 
this analysis aims to advance the argument that fostering the development of applied 
ethics in allergology would enable many strengths and opportunities in allergy research 
and in the optimal design of treatment and prevention efforts. However, the fact that this 
preliminary literature search retrieved fewer than 35 articles on ethics and allergy 
signifies that much work remains to be done. The rapid development of bioethics 
scholarship over the past decade in relation to diseases like obesity should serve as 
inspiration of the potential that lies ahead for the allergology community. 
 The growing awareness [2, 4, 53, 126] that initiatives in public health and 
decisions in health policy are laden with ethical dilemmas and political tensions 
signifies that decision-makers in health would benefit from enhanced skills in applied 
ethics. A greater awareness and sensitivity towards the broader ethical, social, and 
political factors in health research would also be of benefit for clinicians and 
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investigators, including those specialising in allergy. At the very least, having the ability 
to identify and verbalize ethical issues in allergy would prove beneficial when members 
of the allergology community are called forth to provide their expert opinion concerning 
policy initiatives and public health interventions. In the absence of ethical reflection, 
one must question whether decision-makers in health are employing all the tools 
necessary to design optimal treatment and prevention strategies. Furthermore, a lack of 
academic publications that outline ethical issues that are specific to allergy raise 
questions as to whether policy makers are cognizant of important ethical tensions that 
affect clinical practice and abilities to transfer research knowledge into effective health 
interventions. Thus, the current paucity of academic work in ethics in allergology 
signifies that future imperatives in allergology should include greater collaborative 
efforts with members of the applied ethics community in order to advance knowledge in 
this largely overlooked domain of inquiry. 
 On a positive note, the seeming divide between ethics and allergy research and 
clinical practice appears to be on the cusp of change. In 2001, The European Academy 
of Allergy and Clinical Immunology (EAACI) called attention to major areas in clinical 
and research ethics that merited future intervention [127], and recommended the 
establishment of a European Committee on Ethics in Allergology (ECEA). The 
Canadian research network, AllerGen, which provides support for interdisciplinary 
training and research in allergy, states that one its three specific research goals is to 
advance knowledge in the domain of “Public Health, Ethics, Policy and Society” [128]. 
It is unfortunate that these capacity building efforts in ethics and allergology appear to 
have not yet reached their full potential; this author did not find evidence (e.g., a 
webpage) that the ECEA has been established, and the exhaustive literature search 
retrieved only one article where the authors were affiliated with AllerGen [7]. 
Regardless, the positive position concerning ethics scholarship put forth by these 
prominent organizations indicates, at the very least, a nascent recognition of the need for 
greater knowledge in this largely overlooked area of allergology. 
 One can hope that the preliminary efforts towards capacity building in 
interdisciplinary research made by these prominent allergy organizations will provide 
impetus for others to follow suit. This article aims to contribute to this process by 
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encouraging greater awareness of the untapped ethical resources that await their 
application towards addressing key dilemmas in allergology. Once awareness grows, it 
is only a matter of time before current islands separated by vast oceans will grow into 
mountains of knowledge and expertise. This is not a question of if, but when; the future 
success in developing effective policies and public health interventions for the epidemic 
of allergic disease depend on it. 
 
Annex to Chapter 1 
Table 3: Manuscripts other than articles excluded from primary analysis 
Year of 
publication 
 
Author(s) 
Bioethics  
sub-discipline 
Of 
interest 
 
Reference 
Murphy, Sandel Health policy, Public health X [93] 2011 
Kling Clinical X [129] 
Kling Clinical, Research X [130] 
Wolf et al. Clinical  [131] 
Bleecker et al. Research  [132] 
Martinez, Fabbri Research  [133] 
2010 
Naspitz, Warner Research X [134] 
Payne Research  [135] 2007 
Hourihane, Beirne Research X [136] 
2006 Coffey, Ross Research  [137] 
2004 Kling, Pead Clinical X [127] 
Carter Research  [138] 
Bisgaard et al. Research  [139] 2002 
Savulescu, Spriggs Research  [140] 
Bonetta Research  [141] 
Bush Research  [142] 2001 
Warmer Research  [143] 
1999 Ferdman, Church Research  [144] 
1998 Kelso Research  [145] 
Mansmann Clinical  [146] 
Eaton, Downing Clinical, Health policy X [147] 1995 
Reisman Research  [148] 
1994 Smith, Burton Clinical  [149] 
Reisman Clinical  [150] 
Schmidt Research  [151] 1993 
Frew Clinical, Research  [152] 
1987 Sly Research  [153] 
1980 Rubenstein Clinical  [154] 
2007 Revuz Clinical  [155] 
Bold font indicates a manuscript written in French.  
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Prelude to Chapter 2 
 Having identified the paucity of ethical analysis concerning allergy, the 
remaining chapters of this thesis will aim to support one of the main arguments put forth 
in Chapter 1. That is, Chapters 2 to 4 will defend the argument that merging knowledge 
between the disciplines of ethics and allergology can help clinician-scientists and policy 
makers in better structuring health policies for this chronic disease. Moreover, using 
principles of ethics as a guide in health policy development could serve as a means to 
ameliorate the decision-making capacities of officials involved in designing health 
interventions for allergy. The following chapter will begin a focused application of 
ethics within allergy policy developments by centring attention on justice in the 
distribution of health achievements amongst the population of allergy sufferers. 
 The Introduction of this thesis made note of the significant body of recent 
epidemiologic evidence that demonstrates the existence of large gaps in health 
achievements, particularly with regards to differences in average life expectancy 
between population subgroups, such as members of different socioeconomic classes [1]. 
The observation that social determinants, such as social class hierarchies, correlate with 
vast inequalities in health raise questions as to whether this inequality is fair or just. 
Indeed, in Justice is Good for our Health [2], Daniels, Kennedy, and Kawachi argue 
convincingly that such health inequalities do represent a profound injustice. These 
authors then propose tentative policies that are derived from philosophical theories of 
social justice to help attenuate health inequalities. For example, if health inequalities 
correlate with differences in socioeconomic classes, Daniels and colleagues suggest that 
policies that promote the more-equitable distribution of resources between classes, such 
as income, could improve the health of citizens in the lower and middle-classes. 
 While analysing health inequalities within a framework of social justice has 
utility in defining such inequalities as unfair and thus meriting targeted health 
intervention, the use of theories of social justice to guide ‘real-world’ public health 
interventions is not free of criticism. Due to a current lack of evidence that supports 
income redistribution as a valid health intervention, Barbara Starfield [3, p.67-70] 
questions whether such ‘pro-justice’ policies will be effective, feasible, and practical. 
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This lack of evidence also signifies that policies that aim to promote social justice as a 
health intervention are too abstract and hard to justify politically.  
 Despite these criticisms, employing principles of social justice in health policy is 
intriguing; perhaps the application of these theories within a different context could 
address some of the above criticisms and still have utility in guiding real-world policy 
developments. The following chapter will demonstrate one such possibility, that is, an 
application of the theories of social justice employed by Daniels and colleagues. The 
goal is not to propose specific policies – that task is left up to public health officials – 
but instead to show that principles of social justice can be used to develop a framework 
to assess: 1) the ethical acceptability of tentative public health interventions for allergy 
and asthma, and 2) help prioritize their implementation. This assessment framework 
calls attention to the need for public health interventions to provide equal benefit to all 
members of the allergic population. In situations where interventions aim to improve the 
health of a specific group of allergy sufferers, the population targeted in the public 
health intervention should be exceptionally vulnerable to allergy morbidity. Such an 
assessment framework, structured on principles of social justice, is arguably far less 
controversial than other approaches. Surely it would not be hard to justify politically the 
enactment of public health policies that aim to provide fair and equal benefit to all 
members suffering from disease? Rather, would it not be politically contentious for 
health policies to favour the needs of some while neglecting the needs of others? If a 
public health intervention must target a specific population, a reasonable argument is 
that this intervention ought to aim to improve the health of a population that is 
particularly deprived and disadvantaged in securing good health.  
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Abstract 
The growing epidemic of allergy and allergy-induced asthma poses a significant 
challenge to population health. This article, written for a target audience of policy-
makers in public health, aims to contribute to the development of policies to counter 
allergy morbidities by demonstrating how principles of social justice can guide public 
health initiatives in reducing allergy and asthma triggers. Following a discussion of why 
theories of social justice have utility in analyzing allergy, a step-wise policy assessment 
protocol formulated on Rawlsian principles of social justice is presented. This protocol 
can serve as a tool to aid in prioritizing public health initiatives and identifying ethically 
problematic policies that necessitate reform. Criteria for policy assessment include: 1) 
whether a tentative public health intervention would provide equal health benefit to a 
range of allergy and asthma sufferers, 2) whether targeting initiatives towards particular 
societal groups is merited based on the notion of ‘worst-off status’ of certain population 
segments, and 3) whether targeted policies have the potential for stigmatization. The 
article concludes by analyzing three examples of policies used in reducing allergy and 
asthma triggers in order to convey the general thought process underlying the use of the 
assessment protocol, which public health officials could replicate as a guide in actual, 
region-specific policy development. 
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Résumé 
L’épidémie en croissance d’allergie et d’asthme pose un défi important en matière de 
santé des populations. Cet article a pour but de contribuer au développement de 
politiques pour contrer la mortalité due à ces maladies en démontrant comment les 
principes de justice sociale peuvent guider les initiatives en santé publique par la 
réduction des causes d’allergies et de l’asthme. À partir des principes rawlsiens de 
justice sociale, il devient possible d’élaborer un protocole d’évaluation de ces politiques 
à l’attention des décideurs en santé publique. Ce protocole peut être utilisé comme un 
outil dans l’évaluation des priorités d’initiatives en santé publique et dans 
l’identification de problèmes éthiques des politiques mises en place. Les critères 
d’évaluation de ces politiques comprennent les points suivants : 1) une intervention 
spécifique en santé publique doit procurer un bénéfice en santé également réparti dans 
une population de patients atteints d’allergie ou d’asthme ; 2) si les initiatives ciblent un 
groupe particulier, ce groupe doit comporter principalement des populations 
défavorisées, et 3) les politiques ciblées ne doivent pas avoir un effet stigmatisant. 
L’analyse de trois politiques différentes en charge de lutter contre les déclencheurs des 
allergies et de l’asthme sera présentée dans le but de tester l’efficacité du protocole 
présenté dans cette étude. 
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Introduction 
Throughout the 20th century, the developed world has achieved vast 
improvements in population health, most notable in the dramatic increase in average life 
expectancy and decrease in infant mortality. The beginning of the 21st century, however, 
is seeing mounting evidence of stagnation—and sometimes regression—in previous 
population health achievements [1, p.2], which stem from the increasing prevalence of 
chronic diseases. The chronic disease of allergy is exemplary; the incidence of allergic 
sensitivities towards common substances within our environment is now of epidemic 
proportions and continues to rise [2, 3].  
Endemic allergic sensitivities do not imply a mere increase in the number of 
people with itchy eyes and runny noses. Rather, this chronic illness produces a 
multitude of morbidities ranging from irritable disorders such as dermatitis, to disabling 
conditions that have a high risk for mortality, such as asthma and anaphylaxis (sudden 
cardiac and respiratory arrest). These morbidities pose a significant challenge to public 
health. For one, they dramatically lower a person’s quality of life [4, 5]; they also result 
in huge costs for national health care systems in terms of pharmaceutical expenses and 
hospitalizations due to asthma and anaphylaxis [6-8]. Of further significance, allergies 
are a main cause of disability; for example, asthma is the leading source of disability 
amongst American children [9]. Indeed, there is pressing need for coordinated efforts to 
counter this escalating source of pathology. 
This article aims to contribute to efforts aimed at countering allergy morbidity 
by demonstrating the utility of incorporating ethical analysis within the development of 
public health policy. The discussion will centre on adapting Rawlsian principles of 
‘justice as fairness’ – with the aid of work by Daniels, Kennedy, and Kawachi [10] – as 
a means to identify the strengths and weaknesses inherent in policies aimed at reducing 
allergy and asthma triggers within the environment. Specifically, I use these principles 
of social justice as criteria for policy assessment, to help policy makers decide whether a 
tentative public health intervention would provide equal health benefit to a range of 
allergy and asthma sufferers, and whether targeting initiatives towards particular societal 
groups is merited based on the notion of ‘worst-off status’ of certain population 
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segments. In relation to the latter assessment, a concomitant criterion for evaluation will 
include analysis of whether a policy may have the negative consequence of stigmatizing 
the population targeted for the public health intervention.  
These principles of social justice will serve as a framework for the design of a 
step-wise assessment protocol that can aid public health officials in prioritizing policy 
initiatives. Furthermore, this protocol will also provide a means to identify ethical 
challenges inherent in some policies, thus signalling the need for specific reforms such 
as including measures to avoid possible stigmatization. After outlining the assessment 
protocol, three policies for the reduction of allergy and asthma triggers will serve as 
examples for assessment. These include policies of reducing air pollution, reducing 
allergens in automobiles, and reforming food labels to better indicate the presence of 
food allergens. The aim of this assessment is not to determine which are the ideal 
policies for reducing allergy morbidity. Rather, this analysis seeks to demonstrate the 
utility of the general thought process underlying the proposed assessment protocol – that 
is, one based on principles of social justice – which public health officials could 
replicate as a guide in actual policy development at the regional level.  
Before presenting the policy assessment protocol, an overview of the aetiology, 
treatment, and social determinants of allergy is necessary in order to demonstrate why 
Rawlsian principles of social justice are relevant within the context of this chronic 
disease. Furthermore, this overview provides information necessary for the final 
analysis of example policies for the reduction of allergy and asthma triggers. 
 
Aetiology of allergy and asthma 
Physiological and biomedical factors of allergy and asthma 
Allergy is a chronic disease of the immune system where the body overreacts to 
common, typically non-pathogenic, substances in the environment, such as pollen, 
mould, and certain food proteins. Simply stated, immune responses normally target 
pathogens (i.e. bacteria), where the binding of antibodies induce its elimination and the 
localized release of histamine. Histamine produces inflammation that prevents further 
infiltration of the pathogen into the body by causing a reduction in blood flow and 
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swelling. In allergy, the mistaken targeting of benign substances by the immune system 
results in a surge of histamine release where the resultant inflammation produces 
pathological conditions varying from skin rash, respiratory impairment (i.e. asthma), 
and in some cases, sudden death (i.e. anaphylactic shock). Allergy-induced asthma is a 
particularly noteworthy pathology in terms of prevalence and physical impairment. Up 
to 80% of certain allergic populations develop asthma [11], a burdensome disorder that 
is one of the leading causes of worker disability [12], and a major contributor to total 
population disability levels [9] in industrialized nations.  
Many chronic diseases, such as diabetes and arthritis, predominate in middle-
aged and elderly populations. Allergy is unusual since it is prevalent across a broad 
spectrum of the population (i.e. all age groups, both sexes, all socioeconomic classes, 
and all ethnicities), while young children in particular have the highest incidence of 
allergic sensitivities. For example, in the United Kingdom – a nation with a particularly 
high incidence of allergy – 39% of children and 30% of adults have been diagnosed with 
one or more allergic conditions [6]. The reason why some individuals develop tolerance 
to allergens with age is likely associated with the maturation of the immune and 
digestive systems [13].  
There are three main categories of treatment strategies for allergic sensitivities. 
The first and most common is pharmacotherapy, which involves the administration of 
drugs such as antihistamines that attenuate allergy symptoms. Immunotherapy is another 
strategy, and involves the injection of gradually larger doses of extracts of the 
problematic allergen, to physiologically induce tolerance in a sensitized patient. 
Immunotherapy is only available for treating sensitivities where medical extracts for that 
given allergen exists, and is largely unavailable for the treatment of food allergies due to 
elevated risks of adverse reactions to food allergen extracts [14]. A final strategy aims to 
prevent allergic reactions by reducing or eliminating altogether a person’s exposure to 
allergens. An example of an avoidance effort is the removal of carpets from living 
environments as a means to reduce exposure to dust. Allergen elimination is an extreme 
form of avoidance commonly employed in situations where no other medical options are 
available, as is the case with severe food allergies that necessitate the elimination of 
food allergens from a person’s diet [15]. 
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While certain genetic factors associated with immune function can elevate the 
risk of developing and severity of allergy and asthma [16], there is clear evidence that 
the incidence of allergic sensitivities correlates strongly with social and environmental 
determinants. 
 
Social determinants of allergy and asthma 
 There are several hypotheses as to why the developed world, and increasingly 
the developing world [17, 18], is witnessing an epidemic of allergy and concomitant 
asthma. It appears that increased urbanization is associated with a greater incidence of 
allergic sensitivities [19]. Exactly how urbanism in industrialized societies promotes 
allergic sensitivities, however, remains poorly understood. Yet evidence suggests that 
our current ‘artificial living habitats’ [20] – artificial in the sense that many individuals 
distance themselves from nature by spending large amounts of time indoors – may 
encourage the immune system to overreact towards substances common in nature, such 
as pollen. Further, living within buildings and employing transport vehicles also permits 
exposure to abnormally high levels of allergenic substances, such as dust mites, a known 
risk factor for the development of allergy towards dust [21]. Another purported cause of 
allergy has been termed the ‘hygiene hypothesis’ [22], where the reduced exposure to 
infectious agents in our society – due to improved urban sanitation, vaccination, and the 
use of antibiotics – may interfere with the development of the immune system and 
promote allergic hypersensitivities. 
 The incidence of allergy has additional associations with the structuring and 
organisation of society. For instance, Isolauri and colleagues [2] assessed the incidence 
of allergy within populations of different birth cohorts born between the years of 1923 
to 1990. They observed that while physiological attributes of the immune system 
remained roughly constant, the incidence of food allergy rose linearly in later cohorts, 
with one exception. Those people born during and immediately after World War II 
(WWII) had a significantly lower incidence of allergic sensitivities. The authors 
conclude that the mass disruption of society from WWII caused an unusual protective 
effect from allergic disease.  
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 Another factor in allergy concerns the societal constructs of socioeconomic 
classes and ethnic minority groups. While allergic sensitivities exist within all 
ethnicities and social classes, the distribution of pathology is uneven. To expand, 
morbidity from allergic disease follows a steep socioeconomic gradient [23], 
exemplified by the fact that hospitalizations for asthma predominate amongst low and 
middle socioeconomic classes [24], and that asthma morbidity rates are higher amongst 
ethnic minorities [9, 25]. It is interesting to note that the socioeconomic gradient in 
asthma morbidity remains even in nations such as Canada [24] that provide universal 
access to comprehensive health care services, thus indicating that unequal access to 
health services is unlikely to be the cause of these elevated morbidity levels. 
Additionally, allergic sensitivities are distinct amongst socioeconomic classes, where 
lower classes often display allergies to environmental allergens associated with factors 
of socioeconomic deprivation. For example, impoverished inner-city children 
commonly have sensitivities to cockroaches, rodents, mould, and dust, the root cause of 
which is living in substandard housing [26-28].  
 The social determinants of allergy and allergy-induced asthma demonstrate an 
important fact concerning these chronic illnesses. For one, allergy sufferers are a diverse 
population of various ages and ethnicities. Of greater significance is the fact that certain 
populations, such as children, ethnic minorities, and members of lower socioeconomic 
classes are particular vulnerable to allergy and asthma morbidity. 
 
The pertinence of social justice in assessing allergy and asthma 
morbidity 
Social justice and population health 
Justice centres on determining what is ‘fair’, focussing on philosophical notions 
of what ought to constitute a rightful distribution of resources, outcomes of 
deliberations, and the provision of just-deserts (rewards), amongst others. The focal 
point of deliberations concerning social justice concerns philosophical notions of the 
ideal, just society. There are numerous theories of social justice with varying focal 
points in assessing what constitutes the fair distribution of societal factors [29]. As a 
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general example (which relates to the subsequent discussion on Rawlsian social justice 
theory), certain social justice theories aim to define ideals such as the roles social 
institutions ought to have in ensuring an equitable distribution, amongst societal 
members, of protections, liberties, resources, and opportunities in achieving one’s 
ambitions in life. 
Theories of social justice are relevant in the context of population health, 
especially since health (defined here as normal functioning and the absence of 
pathology) is essential in providing individuals with the freedom and opportunity to 
achieve their chosen ambitions or goals in life [30, p.29-31]. Theories of social justice 
can provide useful tools for defining morally problematic, unequal distributions of 
health achievements, and arguments for the associated moral responsibility of 
governments to rectify these inequalities through social reforms. For example, 
malnutrition may predominate within a defined societal group, thus inhibiting some 
members of society from achieving their full potential. But is this unjust? If malnutrition 
is the result of the unequal distribution of resources that is beyond the control of 
deprived societal members, this situation would arguably be an unjust social 
arrangement. Furthermore, certain theories of social justice would affirm that social 
institutions, or societal reform, ought to provide additional protections and resources for 
this deprived population segment. To conclude, the application of theories of social 
justice in evaluating population health is a growing field of inquiry [31], and assessing 
health inequalities within ethical frameworks of justice provides additional means for 
identifying morally problematic deficiencies in population health that necessitate policy 
intervention.  
 
Social justice, allergy, and asthma 
 The previous discussion of the social determinants of allergy and asthma is a 
helpful case study with which to explain why public policy reforms based on theories of 
social justice are relevant within the context of these diseases. The observation that 
these illnesses predominate in industrialized nations suggest that social structures and 
the state of living environments are significant determinants of allergic disease. The fact 
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that allergy and asthma have emerged as a recent burden to population health, and 
continue to increase in prevalence, also confirms that these illnesses are due mainly to 
socio-environmental factors and not genetic factors that are beyond the remit of social 
reforms. The observation that sudden disruptions of society, by events such as war, can 
influence the incidence of allergic disease is of additional interest. For one, it suggests 
that social reforms, orchestrated by positive means such as public health initiatives, hold 
promise in significantly countering allergy morbidity. 
 While allergy and asthma are associated with attributes of a society, can their 
presence in a population constitute an injustice, where theories of social justice would 
have utility in guiding public health policy development? Current levels of morbidity 
are arguably an injustice in certain groups of allergy and asthma sufferers. It is unjust 
that factors beyond the control of an individual, such as being a member of an ethnic 
minority, place some members of society at an increased risk of allergy and asthma 
morbidity. The same rationale applies to impoverished children – who obviously have 
little control over their living environments – develop allergic sensitivities because of 
substandard living conditions.  
As a final note, the observation that allergy and asthma morbidity levels follow a 
socioeconomic gradient, where morbidity increases as one moves down the 
socioeconomic ladder, suggests that differentials in health correlate with the current 
means by which society allocates resources across the population. Differentials in 
wealth and divisions amongst social classes are arguably social constructs, constructs 
that can be changed through policy developments. As an example, policies that 
encourage a more even distribution of resources between socioeconomic classes could 
improve the health prospects of many impoverished population segments suffering from 
allergy and asthma. Overall, morbidity levels amongst lower socioeconomic classes are 
elevated, unnecessary, avoidable, and thus unjust. Therefore, orienting public health 
policy towards enacting social reforms is a possible strategy to alleviate a significant 
proportion of allergy and asthma morbidity.  
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A policy assessment protocol based on Rawlsian principles of social 
justice 
Why Rawlsian principles of social justice? 
 To quote Amartya Sen [32, p.75], “[b]y far the most influential theory of justice 
to be presented in this century has been John Rawls’s ‘justice as fairness’”. Indeed, 
Rawlsian principles of social justice continue to have significant influence in numerous 
academic fields, including health policy [30]. The policy discussion presented in this 
article will be yet another example of the continuing applicability of Rawls’ 
philosophical contributions. However, before describing some of the key principles of 
‘justice as fairness’ presented in A Theory of Justice [33], a short explanation is required 
as to why these particular principles have been chosen.  
 Rawlsian social justice theory was determined as a relevant framework to 
analyze allergic disease from observations of its utility in analyzing macro-level 
population health inequalities. For example, in their chapter in the edited collection Is 
Inequality Bad For Our Health? [10], Daniels, Kennedy, and Kawachi analyze 
differentials in population health measures in terms of life expectancy, both globally and 
within particular nations. They note the existence in many societies of a socio-economic 
gradient in life expectancy, where lower classes consistently fair worse in health 
achievements than higher classes. Subsequently, the authors analyze these inequalities 
from a social justice perspective where they argue that because such health inequalities 
are elevated, unnecessary, and avoidable, they constitute an injustice. Daniels and 
colleagues conclude their paper by formulating tentative policy initiatives, based on 
Rawlsian principles of social justice, which may be used to counter these health 
inequalities. They argue for the use of Rawlsian principles as an appropriate framework 
for the assessment of health inequalities on the basis the attention that Rawls’ theory 
gives to guaranteeing fair equality of opportunity for all individuals. Opportunities in 
this context refer to the abilities that individuals have in fulfilling their chosen life 
course and achievements. Since securing good health would significantly protect the 
range of opportunities available to individuals, employing principles that aim to provide 
equality of opportunity are an appropriate guide for health policy development to 
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counter health inequalities. The policy proposals put forward by Daniels and colleagues 
are grounded on the notion that a more just or even distribution of resources between 
socio-economic classes would raise the life expectancy of lower income groups. 
Additionally, they suggest that policies which would provide greater opportunities for 
members of lower income brackets to improve their socioeconomic status, such as 
enabling greater access to higher education, could uncouple the social determinants that 
produce lower life expectancies in these population segments.  
 The thesis presented by Daniels, Kennedy, and Kawachi has many similarities 
with the assessment of allergic disease presented in this article. For one, as is the case 
with life expectancy, a significant degree of allergy morbidity is arguably an injustice 
since it follows a socio-economic gradient. This suggests that the elevated allergic 
morbidities in low and middle social classes are unnecessary and likely avoidable if 
these groups had equivalent opportunities to those of higher social classes. The 
observation that allergy morbidity is significantly higher amongst visible minorities and 
the poor indicate that their opportunities are limited by allergic disease. Thus, public 
health initiatives that aim to provide equality in the opportunity to avoid allergy 
morbidity between all groups of allergy sufferers is an appropriate framework to guide 
policy development in minimizing allergic disease. This article, however, will not re-
iterate the broader health policy reforms put forth by Daniels and colleagues. Rather, the 
discussion will focus exclusively on policy proposals implemented at the regional level 
in order to reduce environmental allergy and asthma triggers. Therefore, the context 
here is brought down a notch, so that the application of Rawlsian principles of social 
justice is implemented as a guide within regional public health policy development for a 
specific chronic ailment. 
  
Overview of Rawlsian principles of social justice used to formulate a 
policy assessment protocol 
Rawls’ theory of social justice centres on the premise of equality of opportunity. 
According to Rawls, an ideal society is one that is organized to be fair and free where all 
people possess equal basic liberties and equal potential to achieve their defined 
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prospects in life. Discrimination in any form is counterproductive to promoting 
opportunity, and so social institutions ought to safeguard human rights such that 
everyone is guaranteed equivalent protections. Two main principles here are of 
significance to policy development. The first concerns the notion of equality of 
opportunity. This principle signifies the importance for social institutions to enact 
policies and social reforms that will provide equal opportunity for benefit to all diverse 
members of society. In relation to public health, this implies that policies directed 
towards a disease ought to be formulated upon the goal of ameliorating the health of all 
individuals afflicted by that given ailment. Recall that allergy sufferers form a diverse 
group of various ages, ethnicities, and allergic sensitivities. Thus, from a Rawlsian 
perspective, ethical public health policies would be those that aim to reduce allergy 
morbidity amongst the broad spectrum of allergy sufferers. Furthermore, promoting 
equality of opportunity implies that the health needs of certain groups of allergy suffers 
ought not to be ignored due to influences such as lobbying for health resources by 
another segment of allergy sufferers.  
 The second principle concerns protections against discrimination. The ethical 
imperative for social institutions to protect against discrimination is relevant to public 
health policy in terms of stigmatization. The incidence of illness within a defined 
population segment can inadvertently promote the misconceived idea that all individuals 
within this group have the negative attribute of being ‘diseased’. Therefore, public 
health officials need to be sensitive to stigmatization and so have a responsibility to 
employ methods that minimize this possibility. But public health initiatives themselves 
may play a role in promoting stigmatization. For example, targeted policies could aim to 
reduce allergy morbidity amongst impoverished children through educational campaigns 
in low-income areas that encourage people to remove dust and mould from their homes. 
This targeted policy carries a risk of stigmatizing those of lower socio-economic status 
by conveying the idea that they live in ‘dirty’ conditions. Public health officials thus 
have a responsibility to enact measures to protect these people from inadvertently 
acquiring the misconceived label of ‘being unclean’.  
Now we face a contradiction. How can we justify targeting public health 
initiatives to a particular group of people (as in the example above concerning 
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impoverished children) when the principle of equality of opportunity requires that 
policy initiatives ought to provide equal health benefit to all? Rawlsian social justice 
theory can provide guidance in this situation according to the difference principle. As a 
further requirement of equality of opportunity, Rawls argued that social institutions 
ought to mitigate the effects of socio-economic inequalities that prevent less fortunate 
members of society from having equal opportunities in life. This entails implementing 
policies for directing resources towards those that are ‘worst-off’. Overall, Rawls claims 
that priority ought to be directed towards promoting betterment within particularly 
deprived, vulnerable populations in order to raise their level of opportunity to a level 
that is achieved by more privileged population members. In other words, social 
institutions are justified in favouring the distribution of resources towards ‘worst-off’ 
population groups in order to decrease differences in opportunities between societal 
members. 
The difference principle thus provides guidance in determining whether targeted 
public health policies are justified. It would be justifiable to place priority in directing 
public health initiatives, and thus health benefit, towards a specific population if this 
group meets criteria of being particularly vulnerable and deprived. The previous 
example concerning impoverished children would meet such criteria. These children are 
vulnerable in the sense that they have little control over their health, and their low socio-
economic status suggests that they are deprived.  
 
A step-wise assessment protocol for public health policies 
 I will now present a policy assessment protocol formulated on the previous 
discussed principles of equality of opportunity, ensuring protections against 
discrimination, and the difference principle of favouring the redistribution of resources 
towards the ‘worst-off’ members in a population. A summary of the protocol appears in 
Figure 2. 
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Figure 2: Schematic overview of a policy assessment protocol formulated upon 
Rawlsian principles of social justice 
 
Numerous factors influence regional population health, including culture, 
climate, distribution of wealth, and access to health care. These multiple influences on 
health signify that regional as well as individual variations in morbidity and mortality 
are to be expected. Thus, in the context of public health, the beginning of policy 
development starts with identifying morbidity within regions and population groups. 
Upon identifying morbidity, preliminary public health policies aimed at countering the 
root determinants of disease then follow. Of those policies deemed feasible in reducing 
disease, subsequent evaluations centre on prioritizing policies and determining whether 
particular policies pose ethical challenges that require specific reforms or protections.  
  The first step in policy assessment (step 1) centres on determining whether a 
tentative policy is blatantly unjust and defies the principle of equality of opportunity. 
These would include policies that carry a high risk for stigmatization, where the efficacy 
of the policy requires that certain groups be associated with a negative label. Another 
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category of unjust policies is those that provide betterment to some to the adversity of 
others, which completely counters the notion of equality of opportunity. A final example 
of unjust policies includes those that are pushed forward due to unjustified lobbying and 
pragmatism. All policies meeting such criteria of assessment are ethically unsound and 
ought to be rejected. 
 If the tentative policy passes the initial ethical assessment, the subsequent steps 
aid in determining what general level of priority the policy should have relative to other 
policies. This is particularly important in situations of resource constraints that permit 
the limited implementation of public health initiatives. The first priority assessment 
(step 2) asks whether the proposed policy aims to provide equal health benefit to all 
members that compose the population requiring the public health intervention. Policies 
that meet this criterion support the principle of equality of opportunity and should thus 
receive priority in implementation.  
If the policy aims to focus health benefit to a defined sub-group of a population 
experiencing morbidity, subsequent priority assessments (step 3) ask whether the 
targeting of resources towards this group is justified. If the targeted population does not 
possess characteristics of being particularly vulnerable, deprived, and thus ‘worst-off’, 
the policy is not justified for it does not support the difference principle. These policies 
ought to be rejected. 
Subsequent assessments (step 4) must focus on reassessing whether if by 
targeting policy initiatives towards a specific, vulnerable group, the policy initiative 
may inadvertently stigmatize that population. If there is minimal risk for stigmatization, 
this policy proposal should receive high priority since it will likely bring health benefits 
to a ‘worst-off’ population that is in greatest need of aid. However, if there is a risk for 
stigmatization, the final assessment (step 5) should determine whether it is feasible to 
incorporate within the policy additional protections to minimize or circumvent this 
problem. There are various methods to minimize harms from stigmatization in public 
health; which Thompson et al. [34] argue centre on: 1) the need to protect privacy, and 
2) the provision of public education to correct misconceptions about disease incidence 
and to offset misattribution of blame to particular communities (a full detailed 
description of such mechanisms is beyond the scope of this article). If harm reduction 
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strategies such as these cannot be incorporated within the targeted public health policy, 
then the policy ought to be rejected. 
 
Applying the protocol: assessing policies in the reduction of allergy and 
asthma triggers 
To recapitulate, avoidance and elimination treatment strategies are common 
strategies for reducing exposure to environmental allergens and asthma triggers. These 
treatment strategies require regional reforms in social and environmental factors, and 
thus fall largely within the jurisdiction of public health policy. Therefore, these 
strategies will be the focus of the current policy analysis rather than the biomedical-
focussed treatment strategies of pharmacotherapy and immunotherapy, which fall more 
within the jurisdiction of the acute care health system. Analysis of three policies will 
serve as examples to demonstrate the step-by-step thought process underlying the use of 
the assessment protocol presented above, which public health officials could replicate as 
a guide in regional policy development. 
 
Reducing air pollution 
 Outdoor pollutants – smog, ozone, and sulphur dioxide – negatively affects 
everyone, yet places a particularly heavy burden on those inflicted with respiratory 
illnesses like asthma [26]. Of additional consideration is the fact that residential areas 
located proximal to regions of high air pollution, such as busy highways, are often low 
cost housing inhabited by low-income earners. Recall that factors of substandard 
housing and low socio-economic status correlate with elevated asthma morbidity. 
Overall, health policies aimed at reducing air pollution are potential strategies to reduce 
asthma triggers. Therefore, feasible policies could centre on decreasing automotive 
emissions through encouraging public transit and redirecting heavy traffic away from 
residential areas. How might these policy initiatives fare in terms of assessment by the 
above protocol? 
 Reducing air pollution via public transit or the redirection of traffic does not 
carry an overt risk for stigmatizing a particular group of people. Since the policy focuses 
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on pollution due to traffic congestion, it does not convey a negative label towards 
asthma sufferers. Furthermore, policies aimed at reducing air pollution do not appear to 
contradict principles of equality of opportunity. The health benefits that would be 
achieved by this policy do not depend on denying certain opportunities to other 
population groups. 
Advancing from step 1, the next assessment concerns the distribution of health 
benefits. This policy appears sound in terms of providing equal health benefit to all 
asthma sufferers. Yet, it could be argued that this public health intervention would have 
added benefit to asthma sufferers residing in low-income neighbourhoods since they are 
often living in regions containing elevated levels of pollution. This is not problematic 
since providing added benefit to this socio-economically deprived population is 
justifiable in terms of the difference principle. Overall, this policy should receive 
priority in implementation.  
 Normally the assessment process would end here, however this example contains 
a hidden complication. Asthma is but one of many morbidities that arise from allergic 
sensitivities. Thus, policies for reducing air pollution will be primarily of benefit to 
those with allergy-induced asthma and less so for those experiencing other allergy 
morbidities. Is this justified? Such a policy does nonetheless appear to be justified in 
light of an aforementioned fact concerning asthma, that is, that asthma is a leading cause 
of disability, especially amongst children. Therefore, asthma sufferers fit criteria of 
being a particularly disadvantaged, ‘worst-off’, segment of allergy sufferers. Upon 
further analysis, it appears that policies for reducing air pollution should receive high 
priority in implementation. 
 
Reducing allergens in automobiles 
 Efforts to minimize exposure to allergens typically focus on living 
environments. With a general upward trend in commute times, a significant segment of 
the population is spending an increasing amount of time in their cars, thus making the 
car somewhat of a ‘living environment’. Indeed, one study indicates that car interiors 
can develop high concentrations of allergens [35]. Therefore, public health initiatives 
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that reduce the build-up of allergens within automobiles may be an effective means to 
lower allergy and asthma morbidity. 
 A tentative public health intervention aimed at reducing allergens within 
automobiles could involve lobbying car manufacturers to change the structure of 
automobiles so that they are less likely collect allergens. For example, upholstered car 
seats, which are excellent at trapping a variety of allergens such as pet hair, could be 
redesigned so that they are easier to clean or are impermeable to common allergens. 
Now we turn to the assessment. 
 Early steps within the assessment protocol indicate inherent weaknesses in these 
policy proposals. While there is a small risk of stigmatizing certain allergy sufferers as 
having poor cleaning habits, this problem could be avoided by incorporating public 
education campaigns within the policy. For example, the public could be informed that 
allergen accumulation in cars is primarily due to the ability for car seats to trap allergens 
rather than poor cleaning habits. The main problems arise at step 2.  
Such policies would primarily benefit allergy sufferers that are also vehicle 
owners. Being a policy that targets a specific sub-population, further analysis should 
determine whether this is justified. There does not appear to be evidence indicating that 
this population group is particularly vulnerable or is heavily disadvantaged by elevated 
levels of morbidity. Furthermore, their ability to own and operate a vehicle suggests that 
they are less likely to be socio-economically deprived, or at least not amongst the most 
disadvantaged. Therefore, the reduction of allergens within automobiles should not have 
priority relative to other initiatives, such as the aforementioned example of reducing air 
pollution.  
This does not mean that this policy is not of any value; the policy assessment 
simply indicates that public health officials should not be aggressive in implementing 
this policy, especially if it would direct resources away from policies deemed as more 
ethically sound by the assessment protocol. In situations such as this, public health 
officials should then assess whether it is possible to implement the policy in a more 
‘hands-off’ manner that would require few resources. For example, merely informing 
car manufacturers that current car interiors trap allergens may be sufficient in initiating 
reforms to car interiors. 
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Reforming food labels to better indicate the presence of food allergens 
 There are several important issues related to food allergy. First, people with 
allergic sensitivities to food allergens compose a large segment of the population of 
allergy sufferers. Second, food sensitivities are more common amongst children than in 
adults. Of those with food allergy, many experience life-threatening reactions upon 
exposure to a given food allergen and this is a source for psychological stress and 
heightened caution surrounding the daily activity of eating [36]. Of particular 
importance, and as previously noted, there are virtually no biomedical interventions to 
prevent severe reactions to food allergens, so food allergic individuals must employ 
strict measures to eliminate the problematic allergen from their diet and environment.  
People with food sensitivities therefore rely on ingredient listings on food labels 
to indicate the presence of allergens. Current regulations concerning food labels, 
however, are less than ideal. For example, ingredient listings such as ‘natural flavours’ 
may not indicate the fact that a food product contains milk products, milk being a 
common allergen [37]. Therefore, current regulations concerning food labels allow 
certain common allergens not to be clearly listed on food labels, and this can place food 
sensitive individuals at unnecessary risk. Thus, a tentative public health initiative could 
focus on reforming food labels to better indicate the presence of common allergens. 
Upon analysis, this tentative policy does not appear to carry risks for 
stigmatization. A clearer listing of food ingredients (e.g., from ‘natural flavours’ to 
‘natural flavours, including milk’) would not imply any negative connotations towards 
food allergic individuals. Nor does this policy appear to counter principles of equal 
opportunity since reformed food labels would not disadvantage any particular group of 
the population.  
Legislating reforms to food labels is an example of a targeted policy intervention 
since it will be of exclusive health benefit to food allergic individuals. Therefore, the 
assessment of this policy advances from step 2 to step 3. Is targeting health benefits to 
this particular group justified? Such initiatives are justified since food allergic 
individuals fit criteria of being a particularly disadvantaged group of allergy sufferers. 
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For one, many food allergic individuals experience elevated morbidity since food 
allergies commonly induce severe reactions, and food allergies predominate amongst 
children, a particularly vulnerable population group. Furthermore, unlike other allergic 
sensitivities, there are virtually no other treatment strategies, such as pharmacotherapy 
or immunotherapy, for severe food allergies. Therefore, many food allergic individuals 
could be classified as being particularly restrained, and thus disadvantaged, in their 
ability to minimize morbidity from their allergic sensitivity. Overall, the following 
analysis indicates that policies for reforming food labels should receive high priority in 
implementation.  
 
Summary 
 The analysis above of initiatives in reducing allergy and asthma triggers aims to 
highlight a key issue concerning public health policy. For one, it aims to show how 
ethical analysis can serve as a general guide in determining preliminary strengths and 
weaknesses inherent in particular health policies. Within the context of allergy and 
asthma, Rawlsian principles of social justice focus attention on determining if public 
health interventions are ethically sound in terms of the provision of equal benefit to all 
allergy sufferers. Rawlsian principles also focus scrutiny on the provision of protections 
from stigmatization. In addition, these principles provide rational to justify the targeting 
of health benefits towards particularly disadvantaged groups of allergy sufferers. 
Overall, the protocol for ethical analysis of policies presented here outlines a systematic 
thought process useful in priority setting. Relative to the above three examples, ethical 
analysis indicates that public health officials should place preference towards policies 
aimed at reforming food labels and reducing air pollution, while reducing allergens in 
automobiles should receive lower priority. This systematic thought process can be 
replicated as guide within regional development of various strategies in reducing allergy 
and asthma triggers, and thus allergy morbidity.  
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Conclusion 
 The increasing incidence of chronic diseases is raising a fundamental challenge 
for policy makers seeking to secure population health. This article focuses on the 
particular health burden caused by allergy and concomitant asthma and proposes tools 
for public health policy development that will hopefully contribute to countering current 
morbidity levels originating from these ailments.  
 This article demonstrates how Rawlsian principles of social justice have utility 
in formulating an assessment protocol for policies of reducing morbidities associated 
with environmental allergens. The Rawlsian principles of equality of opportunity, 
ensuring protections against discrimination, and priority in the redistribution of 
resources towards the ‘worst-off’ members in a population have particular relevance in 
policy analysis. These principles translate into criteria that are directly pertinent for 
policy assessment. In practice, this means testing public health initiatives to see if they 
would provide equal benefit to the range of allergy suffers, and whether the targeting of 
health benefits to a particular group of allergy sufferers is justified. Additionally, 
analyzing these policies from a social justice perspective provides means to identify 
early on whether a policy is ethically unsound and requires rejection or reforms, such as 
including provisions to minimize the harms of stigmatization. Overall, this article 
demonstrates the utility of applying Rawlsian principles of social justice in regional-
level public health policy development. 
While the proposed policy assessment protocol was designed specifically within 
the context of allergic disease, it is possible that it may have utility in guiding policy 
development for several other pathologies. Namely, this protocol may have utility in 
guiding public health strategies in countering other chronic illnesses that exist within a 
wide spectrum of the population that includes segments of particularly vulnerable and 
deprived peoples. 
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Prelude to Chapter 3 
 In 1946, the World Health Organization (WHO) proposed a new and broader 
definition for ‘health’, as “a state of complete physical, mental, and social well-being 
and not merely the absence of disease or infirmity” [1]. This definition has notable 
strengths, namely that it recognises that health is not just determined by the inner 
workings of the body. Rather, many additional determinants in an individual’s 
environment and social network play an equally important role. In turn, this more 
expansive vision of health signifies that all members of society can have an important 
role in securing the health and well-being of others, whether or not they play a direct or 
active role in the healthcare system. Moreover, policies unrelated to the provision of 
medical interventions, or ones that do not target directly a particular morbidity, may still 
be of great significance in contributing to the health and well-being of a population. 
 As was the case with the previous chapter, the following chapter will reflect on 
approaches to policy development that are conducive to the above expansive vision of 
health by presenting a framework to structure food allergy policies for childcare 
institutions. While some of the policy proposals in this chapter will focus upon medical 
intervention (e.g., availability of epinephrine for anaphylaxis), others will not. These 
will include policies based on ideals of empowerment, confidentiality, and the emotional 
bond between parents and children. Though not directly ‘medical’ in nature, these 
factors will be shown to be relevant to the health and well-being of allergy sufferers.  
 An additional recurrent theme will be the need for recognition of distinct 
populations that are vulnerable to allergy morbidity; however, unlike the previous 
chapter that centred attention towards large segments of society (such as lower 
socioeconomic classes), this analysis focuses on the specific population of children 
within the school environment. This chapter will once again demonstrate how factors 
related to stigmatization are important issues necessitating consideration in health policy 
for allergy. Yet another familiar theme in this chapter will be attention to the need to 
distribute health benefits equally amongst the school population of food allergic 
children. However, unlike the target audience in the previous chapter, i.e., being public 
health officials, this chapter aims to help improve the decision-making capacities of 
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officials that indirectly play significant roles in protecting the health of allergy sufferers, 
that is, school administrators and school nurses.  
 
 
  
164
 
References 
1. WHO: WHO definition for health. Preamble to the Constitution of the World 
Health Organization as adopted by the International Health Conference 1946; 
New York 
  
165 
CHAPTER 3: ETHICAL PRINCIPLES AS A GUIDE IN 
IMPLEMENTING POLICIES FOR THE MANAGEMENT OF 
FOOD ALLERGIES IN SCHOOLS 
 
Jason Behrmann, 2010. Journal of School Nursing 26(3): 183-193. 
 
Abstract 
Food allergy in children is a growing public health problem that carries a significant risk of 
anaphylaxis such that schools and child care facilities have enacted emergency 
preparedness policies for anaphylaxis and methods to prevent the inadvertent consumption 
of allergens. However, studies indicate that many facilities are poorly prepared to handle 
the advent of anaphylaxis and policies for the prevention of allergen exposure are missing 
essential components. Furthermore, certain policies are inappropriate because they are 
blatantly discriminatory. This article aims to provide further guidance for school health 
officials involved in creating food allergy policies. By structuring policies around ethical 
principles of confidentiality and anonymity, fairness, avoiding stigmatization, and 
empowerment, policy makers gain another method to support better policy making. The 
main ethical principles discussed are adapted from key values in the bioethics and public 
health ethics literatures and will be framed within the specific context of food allergy 
policies for schools. 
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Introduction  
 The industrialized world is witnessing a growing incidence of allergy [2-4]. Allergy 
is a chronic disease wherein the immune system becomes hyper-responsive (also described 
as hypersensitive) to common substances in the environment, such as allergenic 
components in pollen, dust, and animal dander. Typical allergic reactions produce watery 
eyes, nasal congestion and skin irritations such as hives. However, certain allergic 
individuals experience severe allergic reactions that carry a significant risk for mortality. Of 
particular concern are allergic responses that induce asthma or anaphylactic reactions. 
Anaphylaxis is a systemic allergic reaction resulting in extreme cardiac and respiratory 
impairment and is typically fatal if medical attention is not sought immediately. 
 One major category of allergic disease is food allergy. Food allergies are prevalent 
in the industrialized world and it is estimated that eight percent of children under the age of 
three have a food allergy [5], with approximately 1.5 percent of the population being 
allergic to peanuts [6]. Studies also indicate that the incidence of food allergic disease is 
increasing dramatically [7, 8]. The most common allergenic foods include peanuts, nuts, 
egg, milk, soy, and fish; yet hypersensitivities are also observed for a variety of other food 
products, including many fruits, vegetables, food colouring agents, and spices [9]. 
 Food allergies have certain particularities relative to other forms of allergic disease. 
Therapeutic interventions of pharmacotherapy and immunotherapy provide treatment for 
most forms of allergy. These therapeutic options are typically not applicable with food 
allergy, where the primary means to avoid a food reaction is to eliminate the allergenic 
substance from one’s diet [10]. Furthermore, the risk of experiencing a severe reaction or 
anaphylaxis is generally higher with allergic reactions to food [11]. Another characteristic 
of food allergy is that it is particularly prevalent in children and adolescents [10].  
The widespread incidence of food allergy in children, and thus risk for anaphylaxis, 
poses a significant challenge to those individuals (i.e., parents, educational and health 
professionals) that oversee their wellbeing. A large amount of responsibility in the 
management of severe food allergic reactions has fallen on administrators and health 
professionals of childcare settings, such as schools and daycares, locations where reactions 
to food commonly occur. Eighty-four percent of food-allergic children will experience an 
allergic reaction while at school [12], and one quarter of initial allergic reactions to food 
arise in the school environment [13]. The presence of at least one food allergic student 
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within a childcare setting or school appears to be nearly inevitable, with one American 
study finding that 55 percent of elementary schools surveyed reported having 10 or more 
affected students [14]. The high number of food allergic students has resulted in numerous 
schools implementing policies that aim to prevent allergic reactions and reduce the risk of 
mortality should an anaphylactic reaction occur. 
To aid schools and childcare settings in developing appropriate policy responses, 
several allergy medical organizations and experts have published guidelines on 
preventative strategies for food allergen exposure and anaphylaxis [10, 15-20]11 (hereon 
cited as simply, “Guidelines”). These guidelines typically describe factors such as 
emergency action plans for anaphylactic reactions, provide templates of medical 
information files for allergic students, and propose guidelines on how to minimize the risk 
of accidental ingestion of problematic foods. While such recommendations have been 
available for many years, studies demonstrate various (often limited) degrees of 
compliance, much heterogeneity in the application of policies, and a highly variable ability 
of many school officials to respond appropriately to severe food reactions [12, 14, 21]. 
Furthermore, certain policies employed in schools are arguably unethical and place undue 
psychosocial stress on food allergic students. For example, some policies inadvertently 
cause food allergic students to be separated from “normal” students, thus encouraging 
stigmatization and even discrimination [22]. These are significant problems. If schools and 
childcare settings are to fully address the needs of food allergic students, they must employ 
a more thorough application of guidelines, have better emergency preparedness, and avoid 
stigmatizing policies. 
 This article provides further guidance for school nurses and administrators to take a 
lead in the oversight and protection of food allergic children. Many school nurses likely 
face difficulties when determining which strategies will best address the needs of students. 
Indeed, depending on factors such as student population, age, variety of food allergy, and 
availability of food services, food allergy policies will have to be adapted to meet the 
specific contexts of educational facilities. How can this be done and how is one to 
determine if the resulting policies are most appropriate? Certain ethical principles can aid 
school nurses in this process. By basing policy decisions on sound ethics, school nurses and 
                                                
11  Several of these guidelines and mission statements date from the 1990’s and represent 
foundational policy documents on food allergy in relation to childcare settings. Though they may 
appear dated, these documents remain relevant within current food allergy policy developments. 
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administrators gain a valuable tool that can help them in determining which policies are 
best for their institution. This article will present the ethical principles of confidentiality 
and anonymity, the fair distribution of benefits and burdens, and empowerment. Key 
principles in the public health ethics literature will also be presented. These principles are 
placed within context of common food allergy policies where through ethical reasoning, 
good policies can be made better and the appropriateness of policies can be identified 
relative to alternatives12. For example, paying attention to the principle of anonymity can 
help prevent the enactment of stigmatizing policies, while attention to the fair distribution 
of benefits can guide decision-making in determining whether to ban certain food 
ingredients from a cafeteria menu. Before commencing the discussion of how to integrate 
ethical principles into food allergy policies, it will be helpful to have an overview of 
common recommendations and policies, and the key problems observed with the 
implementation of such policies.  
 
Common guidelines and policies for the management of food allergies in 
childcare settings 
Several guidelines and recommendations have been proposed by various experts 
and committees, including paediatricians specializing in food allergy as well as the 
American Academy of Allergy, Asthma, and Immunology (as previously cited: 
Guidelines). Most guidelines provide information on two main issues for food allergic 
students. One topic pertains to emergency preparedness, which refers to how facilities 
ready themselves before a severe food reaction occurs in a child and what childcare 
administrators are to do immediately following the onset of an anaphylactic reaction 
(Emergency Action Plans for food allergy are available online; see Young et al. [23] for a 
recent example). The other main issue is one of prevention, where strategies are provided 
                                                
12 Within the United States, several national and regional laws and regulations mandate certain 
practice parameters and policies concerning food allergic children within the school environment 
(e.g., national regulations include statutes within section 504 of the Rehabilitation Act, Americans 
with Disabilities Act [ADA], and the Family Educational Rights Privacy Act [FERPA]). This article 
will not focus discussion towards such legislation, which will likely be already familiar to school 
nurses and administrators. Rather, this discussion aims to advance knowledge on food allergy 
policy developments and thus focuses on ethical frameworks, exclusively – ethics being a subject 
that is currently absent within the academic literature concerning food allergy. 
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on how childcare facilities can minimize the risk of accidental consumption and exposure 
to food allergens.  
The first step recommended for emergency preparedness is for facilities to maintain 
medical information files on allergic students that are readily accessible to school heath 
professionals. The American-based Food Allergy and Anaphylaxis Network provided a 
template medical file that is endorsed by several experts [10, 12, 24]. The template – which 
is to be completed in conjunction with the child’s primary care provider – contains sections 
that allow for listing of the child’s allergic triggers and the medication to be administered 
depending on the degree of allergic reaction. Also present are emergency contacts for the 
child and diagrams on how to administer epinephrine (adrenaline) if an anaphylactic 
reaction should occur. To clarify, the administration of epinephrine is the first line of 
defence in countering anaphylaxis prior to seeking medical attention at a healthcare facility. 
The general function of health records is to give health professionals at educational 
facilities the opportunity to assess periodically the particular needs of food allergic 
students. These documents also provide a resource that school nurses and administrators 
can turn to in the advent of an allergic reaction. The availability of epinephrine in childcare 
facilities and educational settings is essential in strategies aimed at reducing the risk of 
fatalities from severe allergic reactions. Recommendations of multiple professional 
organizations (as previously cited: Guidelines) state that epinephrine should be easily 
accessible and stored in a known location. Staff members that commonly work with food 
allergic students should be trained in identifying an allergic reaction and know how to 
administer epinephrine when necessary. Therefore, emergency preparedness for severe 
food reactions can be viewed as a three component initiative: 1) accessible medical 
information files on allergic children, 2) availability of epinephrine in the advent of an 
anaphylactic reaction, and 3) training of staff in the appropriate administration of 
epinephrine.  
 The underlying cause of severe food reactions is the inadvertent consumption by 
individuals of food not known to contain a problematic allergen. Policies that have as their 
goals the prevention of food allergy reactions focus on preventing children from consuming 
food that is unfamiliar to them. One common method is to enforce strict “no food sharing” 
policies that prohibit the sharing (or trading) among students of food, utensils, and food 
containers [20, 25]. When food services, namely cafeterias, are available at a school, efforts 
are to be made to ensure the safety of the food provided and that allergen-free alternatives 
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are available. To this end, it is recommended that food service staff be educated in methods 
to avoid the cross-contamination of prepared meals through the proper washing of surfaces 
and utensils [20]. Food service staff should also be educated in the reading of food labels in 
order to identify the presence of allergens [14]. Other common strategies in preventing the 
inadvertent consumption of allergen-containing food are for facilities to restrict the 
consumption of certain foods to specific areas, or to ban the presence of some foods 
altogether. Such methods can include having a designated “allergen-free” table in the 
cafeteria where products that contain common allergens, like peanuts, are not to be 
consumed. It should be noted that “allergen-free” does not imply a dining area that is only 
of use for food allergic children. Rather, the area should be available to all children that 
choose not to consume common allergens within that space. Many experts note that 
administrators of schools and childcare facilities must be vigilant to ensure that the 
presence of a food allergy does not result in the segregation of the food allergic child from 
other children (as previously cited: Guidelines). While children with food allergy have a 
serious medical condition, their allergy should not result in their exclusion from events, 
such as field trips, or in their isolation during meal times. 
 With regards to food bans, most experts do not endorse such policies [20, 26]. 
Many argue that broad food bans are largely ineffective, provide a false sense of security, 
and are burdensome on families that do not have food allergic children [10]. Some studies 
have demonstrated that peanut bans in schools do decrease substantially the presence of 
peanuts in school lunches [27]. The complete elimination of peanuts, however, appears to 
be next to impossible. Despite criticisms, policies for the banning of certain foods from 
schools are relatively widespread [28]. In settings with particularly young children that are 
incapable of objectively selecting the food they eat, such as preschools, food bans are 
recommended for major allergens [20]. The general principle in preventing severe food 
reactions is to prevent the inadvertent consumption of the allergen.  
 It should also be noted that additional policies not related to eating habits have been 
developed to prevent severe food reactions. Anaphylactic reactions have been induced in 
children due to arts and crafts activities and science projects [13]. In these situations, 
allergenic components were part of the project (e.g., the use of peanut butter in the making 
of birdfeeders). It is recommended that schools and childcare facilities avoid the use of 
common allergenic compounds during such learning activities.  
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 A curious fact concerning food allergic children is that their medical condition can 
make them the target of bullying and harassment. There have been documented incidents of 
fellow students, perhaps not understanding the seriousness of food allergies, forcing 
allergic students to consume allergen containing food, with dire consequences [24]. 
Because of this threat, some experts recommend the promotion of anti-bullying policies as 
an essential component in the prevention of accidental allergen exposure [20, 28]. 
Furthermore, most relevant guidelines strongly endorse the need for the education of staff 
and all students on the issue of food allergy [20]. Only once administrators, teachers and 
students fully understand the severity of food allergy, and the best methods for the 
prevention of severe reactions, can precautionary policies be enforced, appreciated and thus 
effective.  
 To summarise, efforts to prevent severe food reactions must go beyond discussions 
about eating habits to also include broad education initiatives concerning food allergy, the 
promotion of respect for food allergic children (e.g., by preventing bullying and 
harassment), and the avoidance of allergenic compounds in school activities.  
 
Weaknesses observed in policies for the management of food allergies in 
childcare settings 
 While the availability of guidelines for managing food allergy have provided 
valuable resources for administrators and school nurses, many challenges are observed 
when food allergy policies are executed in real-world settings. Studies conducted in the US 
have shown that many schools are inconsistent in their application of guidelines and that 
policies vary widely among facilities [12, 14, 28]. Heterogeneity in policy application is not 
problematic per se – depending on the specificity of a given educational facility (e.g., size, 
variety of food allergies, the availability of food services), some policies will not apply or 
will need to be adapted to fit the particular needs of a given facility.  
 This heterogeneity becomes problematic, however, when the inconsistent 
application of guideline recommendations compromises an educational facility’s ability to 
manage appropriately the risks of childhood food allergy. For example, Rhim and 
McMorris [14] observed that some schools do not keep medical information files on food 
allergic students, thus compromising the ability of school health professionals to address 
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the health and safety needs of these students. Furthermore, the authors noted that some 
schools did not keep emergency epinephrine (two percent of schools surveyed), while a 
significant proportion (10 percent of schools surveyed) did not have staff trained in the 
administration of this life saving drug. These observations demonstrate important gaps in 
emergency preparedness strategies within certain educational facilities. Similar 
observations have been made by Powers, Bergren, and Finnegan [12], who found that 
numerous schools did not have written food allergy emergency plans, and many school 
personnel felt unsure with regard to how and when to administer epinephrine.  
 The presence of gaps is also observed in policies aimed at preventing the 
inadvertent consumption of food allergens. Rhim and McMorris [14] found that while 
many schools offered food substitution and meal replacements in cafeterias, most did not 
educate food service staff on the reading of food labels in order to identify the presence of 
hidden allergens. Another problem that has been voiced by children concerning policies for 
the management of food allergy is that certain measures are blatantly discriminatory. In 
some facilities, food allergic students are required to leave the general queue in order to 
collect their meal from another location, thus branding them as distinct and different from 
other students [22]. Furthermore, students have complained about the poor quality of meal 
replacements and allergen-free alternatives provided in school [22]. The poor quality of 
these meals was attributed to a lack of knowledge and interest on the part of cafeteria 
personnel in preparing tasty allergen-free meals. 
 The above observations indicate that many educational facilities need to review the 
current strengths and weaknesses within their policies for the management of food allergy. 
Particular vigilance is needed to eliminate gaps in emergency preparedness and allergen 
avoidance policies. It also appears that a degree of poor judgement can be present during 
the formulation of certain policies, such as those that inadvertently promote discrimination. 
Ethical principles can be used to both help school nurses in their role to support 
administrators in decision-making, and provide guidance on how to make acceptable 
policies better by having them meet minimum ethical standards. 
 
Ethical principles as a guide in developing food allergy policies  
 Preventing severe food reactions in children is a matter of public health, and 
numerous resources are available that can aid officials in implementing effective public 
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health initiatives. One resource is the 2002 publication of a code of ethics for public health 
[29]. The first clause of this code of ethics is particularly pertinent to beginning an ethical 
dialogue on food allergy policies: “Public health should address principally the 
fundamental causes of disease and requirements for health, aiming to prevent adverse 
health outcomes” [29, p.1058]. This clause is important, because in the context of 
schooling and childcare, it means that facilities cannot permit the partial enactment of 
guidelines or allow for gaps in efforts to prevent anaphylaxis. If school nurses are to 
prevent the adverse health outcomes of food-induced anaphylaxis, they must ensure the 
policies are sound, robust, and follow the standards set forth by experts, even if these 
recommendations are not enforced through legislation. For example, school nurses must 
ensure that their emergency preparedness plans are complete: having epinephrine available 
is not sufficient if staff are not trained on how this potentially life saving medication is to 
be administered; having medical information files readily available is not sufficient unless 
all students with food allergy are included in this registry. This first principle of public 
health ethics affirms that the goal of proper management of food allergy is the prevention 
of anaphylaxis, and thus, the complete enactment of emergency preparedness plans and 
avoidance policies is essential.  
 Another general principle that can aid school nurses and administrators in policy 
decisions is to pay attention to their professional and fiduciary responsibilities, that is, the 
trust or care relationship they have with food allergic children requiring assistance. To 
expand, many feminist scholars argue that our relationships with others are not impartial 
since they are linked to responsibilities of care for others that play a role in our daily lives 
[30]. Decision makers in public health – including school health – should thus imagine 
themselves as “caring parents” for members of society under their responsibility, and they 
should ask themselves the following question: “what resources and level of protection 
would you expect if it were your food-allergic child?”. The answer to this question can 
prove valuable in informing choices about which policies to enact within a given school or 
childcare facility.  
 
Confidentiality and anonymity 
 Respect for confidentiality and protection of privacy are core ethical principles in 
health care, as well as prominent core values upheld in many social democratic societies, 
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especially in North America and Europe. Individuals afflicted with a given ailment – 
something that may have a significant impact on their personal lives – have the right to 
keep this fact private if they so choose. The right for individuals to choose to keep their 
medical needs confidential stems from both a respect for their autonomy as individuals, and 
recognition of the very real risks that the inappropriate disclosure of health information 
may entail. These risks may include, among others, unjust discrimination in employment, 
the loss of health or life insurance coverage, and stigmatization on the basis of a particular 
medical condition [31]. Thus, it is important that sensitive health or medical information be 
dealt with carefully, treated as confidential, and be disclosed only to those professionals 
that need such personal information in order to protect the health of the individual. Any 
documentation, such as personal medical files, that are formulated during interactions with 
medical professionals should be secured to ensure these documents remain confidential.  
 The principle of confidentiality is particularly relevant for food allergic children. 
Interviews with children with food allergies confirm that occasionally, their food allergy 
results in discrimination and stigmatization by other students, and this produces significant 
psychosocial stress [22]. Furthermore, being labelled as “food allergic” carries an increased 
risk to a child’s wellbeing since this can make them the target of bullying and harassment, 
and has already been mentioned, resulted in instances of children being force-fed food to 
which they were allergic [24]. Therefore, when school nurses and administrators are 
formulating policies for food allergy, they must be vigilant that policies do not cause food 
allergic children to become identified as different from other children. For example, having 
allergic children line up in a different line in order to collect their meal alternatives is 
unacceptable. Similarly, guidelines that recommend the provision of an “allergen-free” 
eating area, such as peanut and milk-free cafeteria table, can be problematic. This policy 
would only be appropriate if food allergic students do not exclusively occupy this table. To 
prevent exclusion and assure anonymity of the allergic condition, policies ought to include 
efforts that encourage friends of the allergic student to also bring in allergen-free lunches, 
thus allowing for inclusion of all students. Of course, it is recommended that use of 
allergen-free areas not be mandatory for food allergic children [24].  
 The principle of confidentiality is pertinent to food allergy policies in relation to 
emergency preparedness. An essential component of emergency preparedness is the ready 
availability of medical information files so that school health professionals have easily at 
hand the information necessary to help a child should they experience an allergic reaction. 
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However, this policy ought to be employed alongside efforts that ensure these files remain 
confidential. Any additional staff members (e.g., secretarial or computer maintenance staff) 
that might view such files must also be informed that these files contain medical 
information and thus must be treated as confidential. After viewing a child’s file, school 
health professionals must inform staff members that they are not to provide information 
found in that file to anyone else.  
 At times, keeping an absolute stance on anonymity may prove impractical. For 
example, if school administrators choose to impose a food ban, they need to inform parents 
of the food to be banned and the reasons for the policy. A dilemma surfaces in determining 
how much specific information should be divulged when informing others (parents), while 
maintaining confidentiality and anonymity of the affected children. Thompson and 
colleagues address this issue with an ethical value concerning privacy: “Disclose only 
private information that is relevant to achieve legitimate and necessary public health 
goals” [32, p. 6]. By applying this principle, school nurses can help administrators inform 
others of food allergy and their efforts in preventing anaphylaxis without violating the 
privacy of food allergic children. For example, it is appropriate to inform others that an 
educational facility has several students with severe food allergies that carry a significant 
risk for anaphylaxis. Additional information, like identifying characteristics and the 
medical requirements of food allergic students are irrelevant and ought not to be divulged.  
 Additional challenges may arise when communicating the health needs of allergic 
students to other children. Imagine the situation where a child unknowingly sits at an 
“allergen-free” table with a meal that may possibly contain allergens. Rather than inform 
the child that that they are not permitted at the table because of the needs of a specific, 
identified student, the school nurse should inform school officials to explain that the 
student’s nutritious meal might be harmful to other students and staff (emphasis added) at 
that given table. School health professionals should then communicate to the parents or 
guardian of that child to consider preparing allergen-free meals as a means to ensure their 
child’s safe inclusion at any table within the school setting.  
 
Fair distribution of benefits and burdens 
 Another core ethical principle is justice or fairness; that is, that all individuals have 
equal access to resources that ensure their happiness and wellbeing. From a public health 
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perspective, this implies that policy initiatives will be of broad health benefit to all 
applicable members of society. Fairness also implies that if policies require a certain degree 
of restrictions on behaviour or liberties, these burdens ought not to be discriminatory and 
ought to be applied evenly throughout society. 
 The value of fairness is applicable to food allergy policies on several levels. For 
one, when formulating policies, administrators ought to ensure that policies will be of 
benefit to all, and not for only certain food allergic students. For example, administrators 
should ensure that policies do not focus on a given allergen, to the exclusion of others. 
Peanuts are commonly scrutinized during discussions on food allergy as peanut allergy is 
notoriously associated with anaphylaxis [13]. Therefore, it is common for policies to focus 
on peanuts, and implement peanut food bans or peanut free classrooms. However, other 
allergens, like milk, are also common inducers of anaphylaxis [33]. Therefore, for policies 
to be of equal benefit for all food allergic students, policies such as “no food sharing” ought 
to be favoured over specific bans of one particular allergen. Furthermore, it is generally 
agreed that food allergy policies should be age appropriate, so that as children mature, they 
can and should acquire a greater responsibility in managing their allergy [20]. However, 
this does not imply that food allergy policies should focus exclusively on the needs of 
young children while leaving those of adolescents unaddressed. Indeed, it is known that the 
majority of severe food reactions occur in children over the age of 5 and are especially 
prevalent in food allergic adolescents [22, 24]. So in applying the principle of fairness, 
policies ought not to benefit only young children or assume that the needs of more mature 
students can be met by their own efforts. For example, school health officials should not 
assume that more mature, adolescent students would consistently carry emergency 
epinephrine and thus only provide emergency epinephrine in settings for the care of young 
children that are understandably less capable of upholding such a responsibility.  
 Additionally, when formulating food allergy policies, school nurses ought to ensure 
that food allergic students have access to the same opportunities and resources as other 
students. For example, it is recommended that common allergens not be included in science 
or art projects, therefore permitting the participation of all students. However, this policy 
ought to be extended so that food products are not used as rewards for academic 
performance or during classroom celebrations [24]. Rather, to allow all students to 
participate, these items ought to be replaced with non-edible items like sports cards or 
colourful school materials (pens, pencils) [24]. Another example pertains to allergen-
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elimination meals provided at school cafeterias. Food allergic students note that these 
meals can be of lower quality and less palatable than regular meals. Food preparation staff 
should be supported to ensure they are knowledgeable in preparing allergen elimination-
diet meals that are of the same quality as regular meals served at the educational facility. 
Additionally, the meals ought not to be provided at extra costs to the allergic child [15]. To 
avoid possibilities for stigmatization, the meals could be demarcated subtly with a small 
sticker or pen mark placed on the cellophane wrapping or at the edge of a serving plate.  
 Another issue of fairness pertains to the fair distribution of burdens that may arise 
from certain food allergy policies. In general, school nurses and administrators must ensure 
that policies do not unduly burden the eating habits of certain children. For example, food 
bans ought to be avoided for they can significantly compromise the daily eating habits of 
many children not affected by food allergy. Take the example of a broad food ban on soy, a 
common allergen. Such a ban will unduly burden the eating habits of children that are 
vegetarian or members of certain ethnic communities, where soy is a common protein 
replacement or staple food. However, under certain circumstances, policies may be justified 
in restricting the eating habits of certain children. For example, specific food bans can be 
deemed appropriate in facilities with very young children that are incapable of objectively 
deciding which food they can consume [20]. Determining whether restricting specific 
eating habits is appropriate can be resolved by applying Thompson and colleague’s ethical 
values on restricting liberties. They state that restricting liberties is appropriate if “the 
restriction is proportional to the risk of public harm and is necessary and relevant to 
protecting the public good” [32, p. 6]. Thus, by applying this principle, it would be 
appropriate that school nurses inform administrators to apply food bans in the preschool 
setting where the risk for the accidental consumption of allergens is high. However, such 
bans might not be appropriate in a cafeteria where policies such as allergen-free dining 
tables and the provision of allergen-free meal alternatives are appropriate measures that do 
not involve restricting a child’s liberties. 
 
Empowerment 
There are two ways to orient initiatives for securing the health and wellbeing of a 
community. One method, which may be overly or unreasonably paternalistic, involves the 
imposition of policies and regulatory efforts on others without providing alternatives or 
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explanations as to why such rules are important. The other, arguably more ethical approach 
(i.e., less coercive), involves empowering people in the control of their health and 
wellbeing. Examples of empowerment include educating the public on sound health 
choices and the provision of resources so that people are more able to protect their 
wellbeing. The notion of empowerment is integral to the code of ethics for public health 
proposed by Thomas and colleagues; the fourth clause states that: “Public health should 
advocate for, or work for the empowerment of, disenfranchised community members, 
ensuring that the basic resources and conditions necessary for health are accessible to all 
people in the community” [29, p. 1058]. But how do notions of empowerment apply to food 
allergy?  
 Munoz-Furlong states that empowerment of food allergic children is essential since 
“[e]mpowering a child to participate in food allergy management strategies will yield a 
confident child who is less likely to make mistakes or take unnecessary risks and who can 
rebound after an allergic reaction” [24 p. 1654]. Thus, when school health professionals are 
formulating policies for food allergy, an essential component should be the empowerment 
of all students and staff. Primary methods to achieve empowerment include the broad 
education of all students and faculty on food allergy, anaphylaxis, and methods to avoid 
food reactions [15, 20, 27]. Other means to empower food allergic children include 
encouraging them to carry, and be knowledgeable in the administration of, emergency 
epinephrine. Of course, this will only be appropriate with older children and it does not 
absolve educational facilities of the responsibility for keeping their own supplies of 
epinephrine available. Additionally, administrators should take threats to the safety and 
wellbeing of food allergic children seriously, as would be the case with bullying and 
harassment. Overall, school nurses and administrators should strive to ensure that their 
efforts in the management of food allergy include elements of empowerment by providing 
children and staff with resources that will enable them to gain better control of the 
children’s health and wellbeing.  
 
Conclusion 
 The industrialized world is witnessing a growing incidence of allergic disease and 
food allergy in children and this poses a significant challenge to public health. The main 
concern with food allergy is the possibility for the inducement of life-threatening 
  
179 
anaphylactic reactions due to the inadvertent consumption of a food allergen. To address 
this concern, most schools have enacted policies to prepare for the sudden onset of 
anaphylaxis in food allergic children. Such efforts include the provision of emergency 
epinephrine and the training of staff in its administration. Additionally, schools and 
childcare facilities commonly employ policies that aim to prevent food allergic children 
from mistakenly consuming allergen containing foods. Such efforts include employing “no 
food sharing” policies or the provision of “allergen-free” tables in dining areas.  
 Despite these efforts, numerous studies have demonstrated that many schools are ill 
prepared to effectively prevent severe food-induced allergic reactions. This is due to 
incomplete emergency preparedness plans and gaps in methods for the avoidance of food 
allergens. Furthermore, some policies require reform because they allow (or even 
encourage) the discrimination and stigmatization of food allergic children. Thus, many 
educational facilities need to review and reformulate their policies concerning food allergy. 
When doing so, school health officials and administrators should follow some basic ethical 
principles to guide decision-making and policy development. The ethical principles of 
confidentiality and anonymity, the fair distribution of benefits and burdens, and 
empowerment can guide policy decisions for food allergy (summarized in Table 4).  
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Table 4: Key ethical principles to aid in implementing policies for food allergic 
children 
Ethical 
principles Policy response or areas of particular vigilance Examples 
Underlying 
principles 
• Policies should address the fundamental causes of 
disease and requirements for health, aiming to 
prevent adverse health outcomes. 
• Imagine if the food allergic child was your own. 
What level of protection would you expect for your 
child? 
 
• Enact appropriate, and 
complete, emergency 
preparedness and allergen 
avoidance policies. 
Confidentiality 
and Anonymity 
• Do policies cause a food allergic child to become 
distinct from others? 
• Are medical files confidential and does staff respect 
confidentiality? 
• Only disclose private information that is necessary 
for protecting health. 
• Do not make allergic 
children form a separate 
queue when collecting their 
meals. 
• Do not disclose identifying 
characteristics of allergic 
children or their specific 
medical needs. 
Equal benefits 
and burdens 
• Avoid unduly burdening the eating habits of certain 
children. 
• Enact policies that will be of benefit to all food 
allergic students. 
• Ensure food allergic students have access to the 
same opportunities and resources as others.  
• Provide allergen-free meals 
that are of the same quality 
as regular meals. 
• Focus policies on all 
allergens (no food sharing), 
not one allergen (e.g., 
peanuts). 
Empowerment 
• Ensure the education of staff and students on 
allergic reactions to food.  
• Provide resources so that food allergic children can 
gain further control over their health 
• Take threats of bullying 
seriously. 
• Encourage allergic children 
to carry epinephrine. 
 
By employing these principles, school nurses can aid administrators in policy 
making and gain another means to ensure that food safety policies are complete and ethical, 
while avoiding problems seen with discriminatory polices that place undue psychosocial 
stress on food allergic children. With a greater concerted effort and the endorsement of 
effective and ethical policies, the threat of fatalities from severe food reactions in childcare 
settings can be made virtually non-existent. 
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Prelude to chapter 4 
 
As to diseases, make a habit of two things –to help, or at least, to do no harm.  
! Hippocrates 
 
 In the previous two chapters we observed how factors related to ethnicity, lower 
socioeconomic status, bullying, and the unequal distribution of health burdens and 
benefits could cause individuals to become exceptionally vulnerable to disease. 
Conversely, these two chapters also demonstrated how policies that counter individual 
vulnerability, such as by promoting ethical imperatives of empowerment and protection 
from harm, can have significant utility in securing health for the population. Without 
question, vulnerability and susceptibility to harm are typically defined as something 
‘negative’ and ‘unwanted’, and those in power to enact necessary protections from harm 
likely have a duty to do so. This is especially true in cases where an individual’s 
vulnerability to harm is imposed and beyond their control.  
 However, is it possible that in certain situations the underlying reasons that 
cause an individual to become vulnerable to harm could enable greater benefits to 
society as a whole? And if such a situation exists, do we still have a moral duty to 
minimize this specific vulnerability and risk of harm? What if an individual voluntarily 
consents to being placed at risk because they know that their sacrifice will help 
minimize risks to others? Does this situation merit reform? Indeed, as the final chapter 
of this thesis will demonstrate, the above circumstances and related ethical questions do 
exist in a heretofore ignored context: the production of allergen-immunotherapeutic 
drugs, also termed allergenic extracts. 
 The following chapter focuses attention on the use of human subjects to assess 
the potency of immunotherapeutic drugs, which in turn enables patients to benefit from 
the production of higher quality allergenic extracts. However, potency testing is not a 
risk-free procedure. Despite the fact that human subjects voluntarily engage in this 
testing and that this procedure enables benefits in the treatment of allergy, this chapter 
will argue that there is an ethical imperative for future drug legislation to eliminate 
human subject testing for potency. This is in spite of the fact that testing procedures 
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implementing human subjects are currently the best method currently available to 
regulate the production of these drugs. Biomedical innovation will likely provide 
alternatives to this testing in the near future. Thus, ought drug regulations for allergenic 
extracts strive to phase-out human subject testing as soon as possible? Several 
arguments concerning how to best structure future regulations will once again centre on 
issues related to the fair distribution of health benefits and burdens. 
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CHAPTER 4: HAVE TECHNOLOGICAL INNOVATIONS MADE 
UNETHICAL THE USE OF HUMAN SUBJECTS FOR POTENCY 
ASSESSMENTS OF ALLERGENIC EXTRACTS? 
 
Jason Behrmann, 2011. Journal of Asthma & Allergy Educators 2(6); 272-281. 
 
Abstract 
Since the 1990’s, production batch consistency and the standardization of potency units 
of allergenic extracts used in allergen-immunotherapy has been the focus of drug 
regulatory reforms and much academic debate. This article seeks to expand the current 
debate by identifying ethical arguments in support of regulatory reforms to eliminate the 
use of human subjects for potency assessments of these therapeutics. While human 
subject testing is the best method to assess biological potency, it also exposes subjects to 
significant risks, risks that ought to be avoided as much as possible. Innovation in in-
vitro immunoassays will soon provide feasible alternatives to biological assessments. 
This article will argue that the allergology community must now consider eliminating 
human subjects in standardization and potency assessment methods as an ethical 
imperative in regulatory reforms. Moreover, the allergology community will soon need 
to reach consensus regarding when in-vitro tests are ‘good-enough’ in replicating 
biological potency assessments, so that human subject testing could be avoided without 
compromising the safety and efficacy of allergen-immunotherapy. Overall, this 
discussion will provide an overview on how to structure global standardization 
regulations for allergenic extracts based on the principle of minimizing human subject 
testing, a topic which, to date, has been largely overlooked in relation to extract 
standardization policies. 
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Introduction 
Allergen-immunotherapy will soon mark an important milestone: the 100th 
anniversary of its use in recorded clinical practice. Much has changed since 
immunotherapy was first described by Dr. Leonard Noon in 1911 (London, U.K.) [1], 
where administration of pollen extracts was observed to minimize hay fever symptoms. 
For one, the incidence of allergic disease is exploding into pandemic proportions and 
will afflict roughly one quarter of the population of several nations (e.g., Canada, United 
Kingdom, United States) [2]. In addition to the growing clinical importance of allergen-
immunotherapy in securing public health, biotechnology-derived allergens may soon be 
added to complement the current therapeutic arsenal [3], thereby expanding a 
therapeutic base that is currently comprised of allergenic extracts (AKA allergen 
vaccines) that are obtained through the extraction of biological source materials. Though 
primarily administered via subcutaneous or intra-dermal injection, sublingually 
administered forms of allergenic extracts are another recent revolution in allergen-
immunotherapy [4]. Of arguably greatest importance are the growing standardization 
efforts for allergenic extracts that are significantly improving the quality and safety of 
immunotherapy by ensuring a more consistent potency and composition of therapeutics 
around the globe [5].  
This article focuses attention on future regulatory developments that aim to 
encourage a more global standardization of allergenic extracts. Current regulatory 
reforms by the American Food and Drug Administration (FDA) [6, 7] and the European 
Union European Medicines Agency (EMEA) [8-11] have made improvements in the 
quality and safety of certain varieties of these drugs. However, despite these regulations, 
several important weaknesses remain, the most notable being that the FDA and EMEA 
each recommend different standardization procedures. The result is that standardized 
products of the same allergen from either continent often have large discrepancies in 
their potency and composition.  
This situation has motivated the allergology community to call for improved 
regulatory measures, and most importantly, the development of a universal 
standardization procedure for all allergenic extracts [12]. Exactly how to develop such a 
universal standardization protocol remains a matter of debate, one that has largely 
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centered on the general technological feasibility of various proposed strategies [13, 14]. 
An important and closely related issue, but one that has been largely overlooked in this 
debate, is whether there is still a need for human subjects to be used in biological 
potency assessments of this class of therapeutics. The use of human subjects in routine 
biological potency assessments is currently an important component of standardization 
policies. However, routine biological potency assessments expose human subjects to 
significant risks, such as severe allergic reactions, risks that should be avoided as much 
as possible. Thus, the allergology community will soon face an ethically contentious 
issue. Encouraging standardization efforts will increase risks to human subjects around 
the globe if additional nations choose to apply regulations that employ human subject 
testing as a “gold-standard” in biological potency assessments. Must this be so, or is 
innovation in in-vitro immunological testing providing acceptable alternatives to 
biological tests? Moreover, if alternatives become available, this availability does not 
affirm why regulators should choose novel in-vitro methods if human subject testing is 
the most accurate and reliable method to measure biological potency.  
 This article aims to expand current, rather ‘techno-centric’, debates on regulatory 
reforms for allergenic extracts by analyzing the legitimacy of employing human subject 
testing in standardization efforts. Following a brief overview of current potency 
assessment and standardization methods, this article will describe proposed regulatory 
reforms and recent technological innovations in in-vitro potency assessments that may 
one day eliminate the need for human in-vivo testing. This overview will support the 
main arguments that: 1) eliminating human subjects in standardization and potency 
assessment methods should be an ethical imperative in regulatory reforms; and, 2) that 
the allergology community should reach consensus regarding when in-vitro tests are 
‘good-enough’ in replicating biological potency assessments, so that in-vivo tests could 
be avoided without compromising the safety and efficacy of allergen-immunotherapy. 
By analyzing the ethics of human subject potency assessments, this article aims to 
encourage the development of regulatory policy developments by value-based 
judgments that are not overly or exclusively focused on issues of technological 
feasibility. Indeed, an equally important issue in this debate is whether it is unethical to 
encourage human subject testing in standardization efforts throughout the globe. 
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A unique class of drugs: extracted allergens and their challenging 
standardization 
Allergenic extracts 
To describe allergenic extracts as a particularly distinct class of drug would be 
an understatement. While the vast majority of pharmaceuticals contain one well-defined, 
synthetic active moiety that is easily manufactured as a final product of consistent 
potency, allergenic extracts are known best for their complexity and irregularities in 
their composition. This complexity and irregularity is due to the fact that the active 
ingredients for these drugs are not synthetic, but of biologic origin. 
As their name implies, allergenic extracts are composed of allergens extracted 
from a given biological compound. While this may appear as a relatively simple 
process, the vast biological diversity that exists amongst members of the same species 
means that, depending on the biological source materials used in the extraction process, 
there will be radical differences in the composition and potency of allergenic extracts 
between production batches and manufacturers [15]. Numerous environmental 
conditions can also influence the allergen content of a biological source [15, 16]; for 
example, a particularly rainy growing season can reduce the allergen content of pollens. 
Further, the allergenicity of a substance is often due to multiple components, each 
representing distinct allergens with unique physiochemical properties; and these 
physiochemical differences can result in variations in the amount of allergens extracted 
during the manufacturing process [15, 16]. Therefore, manufacturers employing distinct 
production procedures will invariably produce allergen vaccines that are non-equivalent 
in terms of concentration of active ingredients. To conclude, unlike most pharmaceutical 
products, the composition of active moieties in allergenic extract preparations can be 
radically different.  
 The complexities of allergenic extracts extend beyond issues of pharmaceutical 
composition. Most classes of pharmaceuticals employ a common measurement to 
denote potency (e.g., mg/tablet), making the potency of a given drug easy to compare 
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between different manufacturers. The same situation does not exist for most allergenic 
extracts. Rather, manufacturers can present the potency of their products using one of a 
variety of units that cannot be inter-converted (e.g., BAU, AU, LU, JAU, PNU, Noon, 
etc.) [12]. Certain units are archaic, dating back to the clinical beginnings of 
immunotherapy (e.g., Noon, PNU), yet are still in current use despite the fact that they 
do not accurately reflect the potency of the therapeutic [15]. For example, Noon units 
represent a given mass of allergenic material extracted with a volume of extraction fluid 
(mg/ml). Due to the aforementioned variations in allergen source materials, extracts of 
the same allergen source labelled as containing equivalent Noon units of potency can in 
fact vary substantially in their actual therapeutic potencies.  
 
Allergen-immunotherapy 
   Indeed, allergenic extracts are a pharmaceutical oddity. The unique attributes of 
these therapeutics are made all the more significant when employed in allergen-
immunotherapy. A typical immunotherapy regimen involves the subcutaneous injection 
of the offending allergen in a series of increasing potencies over the course of months, 
sometimes years. The controlled exposure to the allergen induces tolerance by 
physiologically altering the patient’s immune system [17]. Since the therapy 
necessitates the administration of a substance known to illicit a hypersensitivity 
response, it is imperative that the allergenic extract not be over-administered in order to 
avoid severe systemic and life-threatening reactions, such as anaphylaxis [18]. 
Conversely, the under-administration of the therapeutic compound will compromise 
treatment efficacy.  
 Discrepancies in the potency of administered allergenic extracts are thus a 
critical factor in the safe and effective use of immunotherapy. Confusion stemming from 
multiple units of measure and unforeseeable fluctuations in allergen content between 
production batches and manufacturers are significant sources of clinician error and 
adverse reactions to immunotherapy [19]. Fortunately, death from allergen-
immunotherapy is exceedingly rare. Nonetheless, even the low incidence of anaphylaxis 
– recently estimated to occur at 6 events per 1000 injections [20] – is still significant. 
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Current standardization protocols 
 A logical solution to improve the safety and efficacy of immunotherapy is to 
enact regulations that ensure the production of allergy vaccines of a consistent or 
‘standard’ composition and potency. Two government regulatory agencies, the FDA 
Center for Biologics Evaluation and Research and the EMEA, have pioneered 
standardization efforts for allergen-immunotherapy [21]. The FDA base their regulatory 
strategy on the development and distribution of well-characterized allergen reference 
standards [22]. These reference standards are essentially a mock vaccine made by the 
extraction of allergens through a consistent production process and from restricted 
sources that are controlled for biological variability. Each reference standard is assessed 
for their composition of major allergens and biological potency, measured in terms of 
Bioequivalent Allergen Units (BAU). The potency of final standards is set at a specific 
BAU per millilitre concentration for each category of allergen. Manufacturers must then 
perform a comparative analysis between production batches of their allergenic extracts 
and the FDA standard in order to demonstrate that the potency of the two are equivalent. 
This standardization procedure has notable strengths. The FDA determines a constant 
potency with a universal unit for an entire allergen category, thereby eliminating 
potency variations between drug brands and production batches. The main weakness 
with the FDA standardization strategy, however, is that only 19 reference standards 
have been developed for a few select allergen sources (e.g., cat, dog, stinging insect 
venom) [23]. Since there are numerous additional allergens employed in 
immunotherapy, a significant amount of allergenic extracts remains exempt from FDA 
standardization efforts.  
 The EMEA employs a separate standardization strategy that focuses on the 
production processes of individual manufacturers. EMEA regulations recommend that 
each manufacturer produce their own extensively characterized in-house reference 
(IHR) vaccine [11] (for the sake of simplicity, the term ‘reference standard’ is used in 
this article to denote both FDA and EMEA standard extracts). For some manufacturers 
the reference standard is assessed in terms of biological potency, but unlike the FDA 
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standards, potency is typically recorded in Biological Units (BU). Manufacturers 
employ their reference standard in final quality assessments of allergenic extract batches 
much like the FDA standards, where the final composition of major allergens and 
potency must be equivalent to that of their standard. The main benefit of the EMEA 
strategy is that, technically, all extracts can be standardized for batch-to-batch 
consistency. However, most allergenic extract products were commercialized before the 
establishment of the European Union and are therefore exempt from EMEA regulations 
[21]. And even the minority of EMEA standardized products are not without significant 
problems. As each manufacturer determines the final potency and unit of measure for 
their products, it is very difficult to compare extracts between manufacturers; different 
products of the same allergen are typically not interchangeable and a multitude of 
confusing units are still used to denote allergenic potency. 
 
Biological potency assessments: the need for human subjects 
Despite the weaknesses inherent in both strategies, these standardization efforts 
have resulted in safer and higher quality allergen-immunotherapeutic drugs [5], as well 
as the development of methods to accurately measure the biological potency (i.e., 
‘allergenicity’) of this class of therapeutics. Recall that allergenic extracts are complex 
mixtures of biological material that contain several allergenic compounds that are both 
known and well characterized and others that remain to be defined. All allergenic 
compounds in an extract constitute therapeutically relevant active moieties, and together 
they determine the allergic response induced when administered to a patient, better 
known as its biological potency.  
The multitude of known and unknown allergens makes potency assessments of 
extracts challenging, such that most in-vitro analytical tests provide only rough 
estimates of true allergenicity. For example, certain in-vitro immunological tests using 
synthetic antibodies measure specific known allergens by quantifying their association 
with antibodies. Potency quantifications by this method are by default an estimate of 
true allergenicity since unknown allergens are not measured with this test; the binding 
of antibodies is not equivalent to quantifying an allergic reaction. The inherent 
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deficiencies in in-vitro assessments can be circumvented by quantifying the actual 
allergic immune response induced in human subjects. Unsurprisingly, the complex 
human immune system is superior to in-vitro assessments since it will recognize all 
allergenic compounds in an extract, regardless of how complex the mixture may be.  
In general, the methods used in Europe and the United States to test immune 
response are relatively straightforward, comparable to skin prick tests commonly 
employed in the diagnosis of an allergic sensitivity. In America13 a population of 15-20 
highly allergic adults is administered intradermally serial dilutions of the extract, while 
in Europe14, 20 or more allergic adults can comprise the test subject population. In both 
situations, the visible allergic reaction observed on the skin’s surface (in the form of an 
inflamed welt) is proportional to the biological and therapeutic potency of the extract 
[24].  
 
The consequence of using human subjects in standardization efforts 
The above overview of allergenic extract standardization and human subject 
potency assessments identifies several issues of particular significance. First, the best 
assessment of an allergenic extract’s potency involves inducing an allergic reaction, 
which is best determined by in-vivo methods. Allergenic extracts assessed for biological 
potency are in turn more predictive in the severity of reaction induced when 
administered to the average allergic patient. Thus, biological units of potency can help 
reduce clinician error due to the inadvertent over-administration of the extract during 
immunotherapy. Overall, these benefits demonstrate that the use of human subjects is 
the ‘gold-standard’ in potency assessments of reference standards and therefore is 
inextricably linked with extract standardization efforts by the FDA and EMEA. It is 
important to note that reference standard extracts are made of labile biological materials 
                                                
13 Also known as the ID50EAL method [24], subjects are administered intradermally with 3-fold dilutions 
of the allergenic extract. This in turn produces a visible allergic reaction on the skin’s surface, known as 
an ‘erythema response’ (i.e., an inflamed circular welt or ‘wheal’). The diameter of the resultant welt is a 
function of the concentration of the extract, which is assigned a biological potency in terms of BAU. 
14 Also known as the Nordic method, subjects are also administered serial dilutions of a given extract, 
however, the resultant allergic response is compared to the welt produced from the percutaneous 
administration of a known amount of histamine (histamine constitutes as a control that mimics an allergic 
response). Comparisons between welt diameters of the extract and the histamine control determine 
biological potency in terms of BU. 
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that have a limited shelf-life, thus each renewal of a reference standard will require yet 
another round of human subject potency assessments. As current regulatory strategies 
strive to standardize a growing number of products, an increasing number of allergic 
individuals will likely be implicated in the production of immunotherapeutic drugs. 
This need for human subjects could very well become common worldwide. 
Recall that allergic disease is a growing global pandemic, and as such, allergen-
immunotherapy is conducted in many countries around the world, in addition to Europe 
and the United States [2]. Furthermore, due to ecological and geographical factors, 
many allergenic plant and animal species are region-specific, thus immunotherapeutic 
drugs need to be produced at a regional level in order to cater to the health needs of 
local populations. As a result, individual nations will likely in the near future develop 
their own regulations for extract standardization, undoubtedly using the FDA and 
EMEA strategies as models, or simply adopt one of these standards in their entirety 
(e.g., Australia has adopted the EMEA regulations [25, 26]).  
 While a more concerted effort to standardize allergenic extracts worldwide is 
laudable – and endorsed by the World Health Organization [12] – the need to involve an 
increasing number of human subjects in this process raises significant practical and 
ethical concerns. From the perspective of efficient drug development, the growing need 
for human subjects for routine potency assessments of reference standards could counter 
standardization efforts due to shortages in research participants willing to undergo such 
testing, thus making the whole process impractical. Indeed, similar shortages in research 
participants have slowed the completion of numerous clinical drug trials [27]. It is 
important to note, however, that biological potency assessments of allergenic extracts 
are not benign procedures or free from risk; they can be painful and even induce severe 
systemic allergic reactions. These and additional examples will form the basis of the 
argument that future regulatory efforts around the globe ought to avoid implicating 
human subjects in this process as much as possible. Effective means to eliminate the use 
of human subjects should be sought-out despite the fact that this in-vivo testing strategy 
is currently the most accurate and reliable method to measure biological potency. 
However, this argument carries little weight so long as there are no technologically 
feasible alternatives to human testing. The following section will provide an overview 
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of technological innovations in in-vitro potency tests that may provide the analytical 
tools necessary to replace human testing without compromising the safety of allergen-
immunotherapy.  
 
Future directions in allergen extract standardization: examples of 
recent innovations 
Quantification of one major allergen is reliable for some extracts  
 No matter how revolutionary scientific innovation may be it is unlikely, at least 
in the near future, that technology will be able to reproduce all the complex details of 
the human immune system. But that does not signify that science has not made 
considerable improvements in measuring the allergen content of complex mixtures and 
in replicating allergic responses in-vitro. For example, the radial immunodiffusion 
(RID) technique has been adapted to measure the allergen content of allergenic extracts 
[13]. This assay quantifies the binding of synthetic antibodies to the major allergen in 
the extract mixture. Recall that for most allergenic extracts this quantification typically 
provides an estimate of actual biological potency; however, studies have demonstrated 
that certain extracts are exceptions. RID quantifications of the major allergen content of 
short ragweed pollen [28], ryegrass pollen [29], and cat [29, 30] extracts were 
determined to correlate significantly with their biological potency. Such observations 
suggest that future regulatory reforms might replace human potency assessments with 
RID methods for the standardization of these particular allergenic extracts [13]. While 
potency measures by RID may not provide accurate assessments of the biological 
potency for all extracts, being able to do so for some suggests that future research will 
uncover additional extracts for which this correlation applies [31].  
 
Complex extracts require quantification of several allergens 
The main weakness with the RID technique is that this analysis focuses on 
quantifying one major allergen by one antibody in an extract that typically contains 
several allergenic components that are all therapeutically relevant. Expanding the 
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number of synthetic antibodies employed in a given immunoassay would correct for this 
deficiency since each additional antibody included in an analysis would detect an 
additional allergenic component. The FDA Center for Biologics Evaluation and 
Research is in the process of developing such a multi-antibody testing strategy 
specifically for the purpose of extract standardization [32]. Known as the multiplex 
microbead antibody method, preliminary findings demonstrate that this in-vitro testing 
strategy can measure potency with an appreciable level of accuracy to that of biological 
assessments for cat and ragweed extracts [33, 34]. Being in the preliminary stages of 
development, it is unknown how applicable this immunoassay will be for the 
standardization of all allergenic extracts. However, the fact that it is being developed by 
a leading drug regulator specifically for standardization efforts suggests that this in-vitro 
test may soon be employed in routine potency assessments, thus providing a feasible 
alternative to human subject testing of FDA reference standards. 
 
Developing biotechnology-derived allergens as ‘ideal’ reference 
standards 
In addition to FDA innovations, a European network of public sector drug 
regulators, academic researchers, and private pharmaceutical companies have made 
significant progress in the global standardization of allergenic extracts. This network, 
known as the CREATE Project [35, 36] (acronym for the Development of Certified 
Reference Materials for Allergenic Products and Validation of Methods for their 
Quantification), initiated the development of reference standards and a common set of 
in-vitro analytical tests to assess the potency of extracts. The availability of these 
reference standards and consistent testing methods would address many of the 
aforementioned weaknesses in current EMEA standardization protocols [35]; however, 
the CREATE Project also aspires to develop a common set of reference standards that 
could be implemented by manufacturers around the world. 
 Revolutionary in terms of its aspiration for global drug regulatory reform, the 
CREATE standardization strategy has additional attributes of interest. For one, their 
efforts have focused on the development of reference standards composed of 
  
198
biotechnology-derived allergens. Unlike extracts from biological sources, biotech-
allergens can be purified to near homogeneity and produced in a consistent form with 
relative ease, thus providing an ideal, unchanging reference standard. The predictable 
and homogeneous consistency of CREATE Project standards also signifies that common 
in-vitro immunoassays could provide potency quantifications of these purified allergens 
with appreciable accuracy. Indeed, in-vitro quantification of a collection of pollen and 
dust mite standards using the in-vitro radioallergosorbent test (RAST) was recently 
observed to correlate with biological potency assessments of these common allergens 
[14]. 
 
Replicating human immune responses in-vitro 
 The final example of an emerging revolution in in-vitro immunological testing 
merits particular attention. As mentioned previously, the human allergic response is a 
complex physiological reaction involving numerous metabolic processes. The majority 
of in-vitro immunological assays do not reflect this complexity since they focus on only 
one aspect of an allergic reaction, i.e., the association of an antibody with an allergen. 
Therefore, a logical strategy for improving current immunoassays is to develop a system 
that mimics human allergic reactions in-vitro. Vogel and colleagues [37] have made 
promising developments in replicating this complex physiological process. Their 
strategy involves ‘humanizing’ a rat basophilic leukemia cell line by transferring genes 
for human cell membrane receptors that associate with IgE antibodies. Upon mixing an 
allergenic extract with IgE antibodies obtained from the sera of allergic patients 
(obtained from a blood sample), these humanized cells will then associate with the 
antibody-allergen complexes in the solution. This final association induces metabolic 
changes within the cells which are quantifiable, and in turn, more representative of 
immune processes that initiate an allergic response. Though still in early development, 
as well as a highly simplified representation of a human allergic reaction, this in-vitro 
assay represents an innovative step forward in producing a ‘test-tube immune response’ 
that could eliminate the need for human subject potency assessments of allergenic 
extracts. 
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Innovation does not guarantee future standardization efforts free of 
human subject testing  
This brief overview of technological innovation in in-vitro immunological 
testing demonstrates that feasible alternatives to the ‘gold-standard’ of human subject 
potency assessment are emerging. Further, current immunoassays are sure to become 
increasingly more sophisticated and representative of human allergic reactions [38]. 
Thus, the possibility of government regulators reforming current standardization 
guidelines so that human subject potency assessments are gradually phased-out and 
replaced with suitable in-vitro methods appears foreseeable. Indeed, the above examples 
indicate that both American and European drug regulators are making efforts to execute 
such a transition. Moreover, as the allergology community encourages standardization 
efforts around the globe, government regulators will have the option to enact 
standardization guidelines that minimize or avoid altogether the use of human subjects 
in their future regulatory process. However, the key word in these tentative 
standardization policies is option, meaning that eliminating human subjects from 
standardization efforts is a value-based decision and by no means definitive.  
Government regulators around the world could choose to continue employing 
human subject potency assessments based on justifiable rationales. For instance, in-vivo 
potency assessments have a proven track record of efficacy and are considered to be the 
most accurate method to quantify the biological potency of allergenic extracts. So why 
adopt a new strategy when current testing methods already work extremely well? 
Correspondingly, replacing human subject assessments with any in-vitro test will 
inevitably involve a compromise, where any decreases in the accuracy of the recorded 
biological potency by an in-vitro test may raise the risk for adverse reactions to 
immunotherapy amongst the general patient population. Opting for regulatory protocols 
that may raise the risk of adverse drug reactions seems counterintuitive. There are also 
practical issues with employing innovative in-vitro tests, which include the possibility 
that novel testing methods may not be considered as cost-effective in certain regions, 
most notably in developing countries. The following section will respond to these 
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critiques by arguing that avoiding human subjects in standardization efforts ought to be 
an ethical imperative despite the aforementioned justifications.  
 
Why not use human subjects for potency assessments of allergenic 
extracts? 
 Ethical arguments that explain why the use of human subjects in this particular 
context ought to be eliminated when possible will centre on two main issues: the 
practicality of such tests and the ability to avoid harm to persons.  
 
Testing practicality 
To begin, it is important to note the many similarities between routine biological 
potency assessments and clinical drug trials. Clinical trials of experimental therapies 
typically progress through four phases of assessment in terms of their toxicity and 
efficacy. Phase one clinical trials centre on the controlled administration of an 
experimental drug to small populations of volunteer (usually healthy) subjects in order 
to determine possible adverse reactions, and correspondingly, determine a rough dosing 
profile for the drug in terms of toxicity. Though biological potency assessments of 
allergenic extracts are conducted on commercialized therapies and reference standards 
that have passed experimental clinical assessment, the procedure still relies on exposing 
a select number of volunteers to a therapeutic compound in order to assess its dosing 
profile, which is directly related to its toxicity/risk of inducing an adverse reaction. 
While distinct, the similarities shared by human subject potency assessments and phase 
I clinical trials help contextualize the broader methodological complexity of such 
potency assessments.  
For instance, conducting clinical trials requires independent oversight to ensure 
such testing and volunteer recruitment procedures meet international standards for ethics 
in research (e.g., the Declaration of Helsinki [39]). While these ethical standards are 
essential tools in protecting human subjects from harm and coercion, such standards 
have made finding suitable volunteers for clinical trials an arduous procedure that 
commonly results in delays in conducting analyses [27]. In terms of standardizing 
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allergenic extracts, potency assessments involving human subjects also need to follow 
international ethical standards and require independent oversight to ensure such routine 
testing is safe and conducted in an appropriate setting. Thus, similar challenges seen 
with the execution of clinical trials may arise as a growing number of governments 
attempt to standardize allergen-immunotherapeutic drugs. This is not a purely 
hypothetical possibility since experts in allergen standardization have previously 
described the recruitment of human subjects for potency assessments as “laborious and 
time-consuming” [40, p.66]. A shortage of suitable volunteers is also a real possibility. 
Recall that biological potency assessments often require patients that are highly 
sensitive to the allergen source being tested. Therefore, despite the high incidence of 
allergic disease, only a subgroup of the allergic population is appropriate for testing, and 
identifying and recruiting highly sensitive individuals is known to be very difficult [24]. 
Drug regulatory schemes that are inextricably linked with human subject 
potency assessments may encounter significant tensions as regulators aim to standardize 
a growing number of allergenic extracts both nationally and internationally. Within a 
given nation, the possible shortage in volunteers willing to undergo such testing could 
delay the availability of essential reference standards for an entire industry. At an 
international level, the necessary government and corporate oversight needed to ensure 
that such testing meets accepted standards of safety and ethical conduct may dissuade 
governments from initiating standardization efforts in the first place. This is especially 
true for resource-poor nations with limited government infrastructure. Either situation 
will be ethically problematic; an inefficient standardization strategy will delay access to 
needed therapeutics, and the abandonment of such efforts will prevent the production of 
high quality therapeutics for an entire patient population. 
 
Risks associated with biological potency assessments 
The aforementioned practical difficulties with human subject potency 
assessments are not insurmountable; indeed, European and American regulators are able 
to sustain standardization efforts despite these challenges. Regardless, standardization 
efforts face additional considerations in terms of exposing human subjects to foreseeable 
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risks of harm that must be considered when developing drug regulations for allergenic 
extracts. Without over-inflating the risks associated with human subject potency 
assessments, it is important to recognize that the risks are not negligible and thus ought 
to be avoided as much as possible.  
Problems associated with human subject potency assessments arise even before 
executing the actual test. Given that the test aims to measure an allergic reaction, 
research subjects must forego treatment for their allergies prior to the potency 
assessment [41-43]. This makes sense since administration of common allergy 
medications such as antihistamines will attenuate an allergic response. Though good for 
test results, withdrawal of treatment is not ideal for the allergic individual who must 
endure higher levels of allergy morbidity in order to participate in potency assessments. 
In terms of the actual test, recall that biological potency assessments require the 
administration of the allergenic extract into the skin in order to produce inflamed welts 
that are readily measurable. At the very least, the induced allergic response can be 
painful and itchy, with the associated natural tendency to scratch the irritated skin 
thereby raising the possibility of infection. At the very worst, the allergic response can 
become systemic and induce a life threatening anaphylactic reaction.  
The possibility of allergenic extracts inducing severe systemic reactions is well 
known. Correspondingly, the allergology communities of several nations [17, 19, 44, 
45] stipulate in best practice guidelines that immunotherapy should be conducted with 
appropriate medical supervision in a facility that is equipped to treat severe allergic 
reactions. High levels of compliance with such best practice guidelines has meant that 
anaphylaxis in the clinical setting is increasingly rare, but still significant (6 events per 
1000 injections). Death from anaphylaxis is exceedingly rare; nonetheless, deaths from 
the administration of allergenic extracts have been documented despite being conducted 
by competent clinicians in medically supervised environments [46, 47]. Even in 
situations where swift medical intervention prevents a fatality, experiencing an 
anaphylactic reaction can produce long-term psychological distress [48] (anaphylaxis is 
commonly described as a near death experience where its onset induces “feelings of 
impending doom” [49, p. 703]). Taken as a whole, the risk associated with the 
administration of allergenic extracts is significant since the degree of harm from such a 
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reaction (death or psychological scarring) is very high, even though the incidence of 
severe adverse reactions may be quite low. Note that this risk assessment pertains to the 
administration of allergenic extracts within the clinical setting, which is distinct from 
biological potency assessments within the regulatory and drug manufacturing settings. 
How, then, do the risk profiles compare between each venue? 
On initial reflection, it may appear reasonable to assume that the risks are 
roughly equivalent. It is highly unlikely that biological potency assessments, which 
require stringent technical and statistical protocols [13], would ever be conducted by 
individuals other than skilled medical researchers in appropriate testing facilities. 
Critical distinctions in risk of harm do arise, however, in relation to the human test 
subjects and the administered allergenic extract. Unlike the average patient undergoing 
immunotherapy, potency assessments are typically conducted on highly allergic 
individuals, a population known to be at much higher risk for anaphylaxis and death 
[46]. Moreover, unlike a commercialized extract used in immunotherapy that is labeled 
with a given potency, biological potency assessments aim to assess the unknown 
concentration of a reference standard extract. Thus by default, it is unknown how much 
of an allergic response these reference standards will induce in highly allergic subjects; 
as such, there is a risk of administering an amount of allergenic material capable of 
inducing a severe systemic reaction. To conclude, drug regulators should not assume 
that routine human subject potency assessments will be spared of any adverse events. 
The probability of adverse outcomes from biological potency assessments will only 
increase if additional standardization efforts around the globe remain inextricably linked 
with the need for human subject testing. A better situation would be to develop 
standardization protocols that minimize human subject testing as much as possible.  
 
Eliminating human subjects is a question of ethics 
At this point it should be clear that the foreseeable risks associated with 
allergenic extract standardization efforts are not a result of negligence but rather an 
ethically debatable issue. The use of human subject potency assessments is, without 
question, necessary since these assessments enable the production of quality 
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therapeutics, which in turn lower the risk of severe adverse reactions to allergen-
immunotherapy amongst the general patient population. From a risk-benefit perspective, 
biological potency assessments focus ‘reasonable’ and ‘unavoidable’ risks on a small 
group of human subjects for the greater benefit of society. This risk-benefit profile is the 
basic justification for exposing volunteers to potentially significant risks in phase I 
clinical trials, and correspondingly is a premise supported by prominent research ethics 
guidelines (for example, see section 21 of the Declaration of Helsinki [50]). However, 
innovation in in-vitro immunological tests is providing feasible alternatives to biological 
testing methods and this fact must raise questions about whether the risk to human 
subjects from potency assessments remain reasonable and unavoidable. Since the main 
guiding principle in research ethics involving human subjects is to minimize risks and 
harms as much as possible [51], it is apparent that global standardization efforts of 
allergenic extracts that maintain the status quo of human subjects for routine potency 
assessments will eventually become an unethical practice in pharmaceutical regulation.  
As the use of allergen-immunotherapy approaches its 100th anniversary in 
clinical practice, the allergology and drug regulatory communities will need to engage 
in a more intricate debate concerning how to encourage a greater standardization of 
allergenic extracts around the world. Rather than debating the strengths and weaknesses 
of the current FDA and EMEA standardization strategies, which could be adopted in 
some form or another in various nations, regulators ought to consider a novel regulatory 
structure that breaks away from a dependence on human subject testing as a gold-
standard in potency assessments. But how ought such a novel standardization strategy 
be structured, and based on what justifications? The concluding section of this article 
will now aim to answer this question by providing an overview of preliminary value-
based judgments to support the development of ethically sound standardization 
protocols. 
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Framing the debate concerning standardization reforms relative to 
human subject testing and innovative in-vitro assays 
 Regulatory reforms that centre on the issue of biological potency assessments 
will require extensive debate on two interrelated, yet distinct, issues concerning 
technological innovation and risk of harm to persons. The first issue must address the 
main critique of what degree of compromise – if any – is acceptable in terms of 
avoiding the risks and impracticalities of human subject testing and possible increases in 
the risk of adverse drug reactions amongst the general patient population. From this 
initial debate, the second issue will need to assess what in-vitro-replacement testing 
strategy will meet an acceptable risk profile for individual categories of allergenic 
extracts with the aim of avoiding human subject testing as much as possible.  
 To begin the discussion concerning any possible compromise in risk distribution, 
it is necessary to define the main principle that ought to guide value-based decisions 
(Figure 3). The ability to avoid risks from human subject testing is essential; however, 
this laudable goal is unacceptable if it is achieved by placing greater risks on the general 
patient population due to less accurate potency assessments of reference standards. In 
other words, ideal regulatory reforms ought to diminish risks towards human subjects 
while maintaining an equivalent quality and safety profile for standardized allergenic 
extracts.  
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Figure 3: Main guiding principle in regulatory reforms  
Reforms that reduce risks to human subjects, yet shift greater risks towards the general patient population 
(e.g., potency assessments that require fewer human subjects but are less accurate), are unacceptable. 
Reforms must aim to reduce the need of human subjects (e.g., employ in-vitro testing) while maintaining 
an equivalent level of safety of immunotherapeutics for the patient population. HS: human subjects; PP: 
patient population; In-vitro: In-vitro immunoassays. 
 
 This situation is achievable if in-vitro assays alone can provide reliable measures 
of biological potency, or if less reliable in-vitro measures can be cross-checked for 
accuracy by employing fewer human subjects in the process (e.g., 5 human subjects 
rather than the norm of 20). From this main guiding principle, debate on possible 
regulatory reforms will then need to define when, or to what acceptable degree, this 
ideal situation can be achieved in actual (i.e., ‘real world’) standardization efforts 
(Figure 4). 
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Figure 4: Defining an acceptable threshold for in-vitro testing  
Human subject testing provides the most accurate assessment of biological potency, yet is ethically 
contentious. Minimizing human testing with in-vitro assays ought to be encouraged. Not all in-vitro tests 
can provide accurate potency assessments. Drug regulators will need to reach consensus concerning what 
constitutes as an acceptable threshold in the accuracy of novel testing strategies that minimize the use of 
human subjects, yet provide appropriate measures of potency relative to biological potency assessments. 
 
  At this point, it is important to recapitulate specific regulatory challenges in real 
world standardization efforts. First, the majority of the global supplies of allergen-
immunotherapeutic drugs are not standardized; as such, these drugs can have 
considerable fluctuations in their composition and are labelled with potency units that 
are not necessarily representative of their ability to induce an allergic response when 
administered to the average patient. The main priority is thus to encourage standardized 
production of these drugs with concomitant labelling of their biological potency. While 
innovative in-vitro immunoassays can measure potency with a high degree of precision, 
human subject testing remains the most accurate means of defining the potency of 
immunotherapeutics in terms of biological allergenicity. Therefore, the allergology and 
drug regulatory communities will need to reach consensus on what constitutes a 
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reasonable threshold for when novel potency assessment protocols are ‘good enough’ 
relative to the human subject gold standard.  
 For instance, an exclusive application of the in-vitro test ‘A’ could provide 
potency measures that are on average 80% representative of biological potency relative 
to conventional testing involving 20 subjects. This discrepancy may be considered too 
high in terms of potentially increasing adverse drug reactions amongst the general 
patient population. However, coupling test ‘A’ with fewer human subjects (say, 10) 
could be 90% representative. This situation could constitute a fair middle ground since 
the 10% discrepancy would minimize the number of human subjects yet result in a 
negligible increase in risk for patients. Furthermore, the fewer human subjects needed in 
this standardization strategy would help reduce the aforementioned impracticalities with 
human subject testing (e.g., shortage of volunteers), and thus could increase the 
efficiency of standardization efforts (a benefit that should be considered when 
determining what constitutes as an appropriate threshold in potency assessments). Of 
course, an even better situation would be identifying an in-vitro test that when applied in 
exclusivity would have a negligible discrepancy in potency assessments. 
 Upon deciding what constitutes an appropriate threshold for assessing biological 
potency, it is important to recognize that regulatory experts will then need to evaluate 
what in-vitro-replacement testing strategy will be applicable to particular categories of 
allergenic extracts (Figure 5). Recall that all categories of allergenic extracts have 
distinct physiochemical properties; for example, allergic sensitivities to many biological 
materials (e.g., dog) is often due to multiple allergens (i.e., ‘major’ and ‘minor’ dog 
allergens), some of which are well-known and others that remain to be defined. Human 
subject testing can account for the intrinsic complexity of analyzing the content of 
allergenic extracts since the human immune system will recognize all allergenic 
compounds, regardless of the complexity of the extract. Correspondingly, individual in-
vitro immunoassays will vary in the degree to which their potency quantifications are 
representative of actual biological potency, and thus particular testing methods or 
combinations of methods will likely be better suited for certain allergen categories and 
not others. 
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Figure 5: Regulatory reforms should foresee the need for multiple testing strategies 
 
While human subject testing is applicable to all classes of allergenic extracts, physiochemical differences 
between allergens signify that appropriate in-vitro testing alternatives may be unique to each allergen 
category. 
 
 To expand, recall that for a minority of allergen categories, such as ragweed, 
quantification of the major allergen from this biological source correlates with the 
biological potency of extracts. In the minority of situations where this correlation 
applies, quantification of the major allergen content by, for example, the RID 
immunoassay, could meet the minimum threshold in potency assessment required by 
regulatory experts. For allergenic extracts of greater complexity, it likely will be 
necessary to conduct a RID analysis in tandem with an additional assay (e.g., “In-vitro 
humanized immune system” in development by Vogel et al. [37]), which could also 
include a smaller number of human subjects as a means to ensure that potency 
assessments are accurate. In conclusion, while human subject testing is applicable to all 
categories of allergenic extracts, it unlikely that drug regulators will be able to rely on 
only one in-vitro testing strategy in future standardization efforts. Rather, the ethical 
imperative to transition to standardization strategies that minimize the use of human 
subjects will require extensive debate and empirical research in order to determine 
which ‘shoe’ (allergen category) will fit the right ‘foot’ (testing method).  
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Conclusion 
 From a pharmacological perspective, allergenic extracts are surprisingly 
complex therapeutics, and routine drug analyses, such as potency assessments, remain 
difficult despite a century of use in clinical practice. Coupled with the fact that the 
incidence of allergic sensitivities are rising at alarming rates and there is thus increasing 
demand for allergen-immunotherapy, it is now all the more important to establish 
comprehensive international regulatory guidelines to ensure that allergenic extracts are 
produced at the highest level of quality and safety.  
However, a continued application and expansion of current regulations that aim 
to standardize this category of therapeutics will face growing critique if regulations 
remain inextricably associated with the “gold-standard” of human subject potency 
assessments. This should come as no surprise since all forms of pharmaceutical research 
involving human subjects involve risks of harm in various forms. As described in this 
article, it is apparent that the risks associated with routine human subject potency 
assessments are significant, ranging from the possibility of compromising the overall 
efficiency of standardization efforts to causing severe morbidities, which includes the 
very low risk of mortality, among test subjects. These risks are morally defensible as 
long as there are no feasible alternatives that will provide equal benefit to the general 
patient population when applied in drug regulatory strategies. Indeed, while human 
subject testing has long been the best method for assessing the allergen content of 
complex mixtures, rapid innovation in in-vitro immunoassays means that feasible 
alternatives to current standardization guidelines may soon become a reality.  
 This article has provided a focused discussion on the legitimacy of current 
standardization strategies in terms of ethically contentious attributes of potency 
assessments. While very specific, it is curious that this topic has been largely 
overlooked in the academic literature pertaining to allergen-immunotherapy. Thus, in 
addition to being the underlying motivation for this manuscript, the analysis herein will 
hopefully encourage further debate on this pertinent topic within the allergology and 
drug regulatory communities. Furthermore, the framework and overview of value-based 
judgments can hopefully provide guidance in future debates concerning how best to 
reform drug regulation policies for allergenic extracts. On a final note, we have much to 
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look forward to as we celebrate the 100th anniversary of allergen-immunotherapy in 
clinical practice. Much pride is due to the innumerable technological innovations that 
have dramatically improved the safety, efficacy, and availability of this therapeutic 
regimen. With confidence, it appears that we too will soon celebrate another revolution, 
being the ability to provide high-quality allergenic extracts to patients without placing 
risks on volunteers that, in the past, have graciously enabled the production of these 
therapeutics. 
 
Acknowledgements 
 The author would like to express deep gratitude to Dr. Bryn Williams-Jones 
(PhD) and Catherine Olivier (MSc) of the Université de Montréal for many helpful 
comments and discussions concerning preliminary drafts of this article. This research 
was graciously supported by fellowships from Université de Montréal, Les Fonds de 
Recherche en Santé du Québec (FRSQ), Group d’Étude sur les Politiques Publiques et 
la Santé (GÉPPS, École Nationale d’Administration Publique), and the Social Sciences 
and Humanities Research Council of Canada (SSHRC). A travel fellowship from the 
Institut de Recherche en Santé Publique de l’Université de Montréal (IRSPUM) 
provided funding that enabled the author to first present this work at the Second 
International Conference on Science in Society, Madrid, Spain (November 2010). 
 
Conflicts of Interest 
The author declares no conflicts of interest. 
  
212
References 
1. Noon L: Prophylactic inoculation against hay fever. Lancet 1911, 1:1572-
1573. 
2. Warner JO, Kaliner MA, Crisci CD, Del Giacco S, Frew AJ, Gh L, Maspero J, 
Moon H-B, Nakagawa T, Potter PC, et al: Allergy Practice Worldwide: A 
Report by the World Allergy Organization Specialty and Training Council. 
Allergy Clin Immunol Int – J World Allergy Org 2006, 18:4-10. 
3. Behrmann J: Looking ahead at the potential benefits of biotechnology-
derived allergen therapeutics. Clin Mol Allergy 2007, 5:3. 
4. Pajno GB: Sublingual immunotherapy: The optimism and the issues. Journal 
of Allergy and Clinical Immunology 2007, 119:796-801. 
5. Becker WM, Vogel L, Vieths S: Standardization of allergen extracts for 
immunotherapy: where do we stand? Curr Opin Allergy Clin Immunol 2006, 
6:470-475. 
6. FDA. Allergenics. 2009 [cited 2010 May]; Available from: 
 www.fda.gov/BiologicsBloodVaccines/Allergenics/default.htm 
7. FDA. Allergenic Guidances. 2010 [cited May 2010]; Available from: 
www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInforma
tion/Guidances/Allergenics/default.htm 
8. EMEA. European Medicines Agency Evaluation of Medicines Guideline on 
Allergen Products: Production and Quality Issues. 2008 [cited January 2010]; 
Available from: [www.emea.europa.eu] 
9. EMEA. European Medicines Agency Evaluation of Medicines Guideline on 
the Clinical Development of Products for Specific Immunotherapy for the 
Treatment of Allergic Diseases. 2008 [cited January 2010]; Available from: 
[www.emea.europa.eu]  
10. EMEA. European Medicines Agency Evaluation of Medicines Guideline on 
Allergen Products: Production and Quality Issues. 2008 [cited January 2010]; 
Available from: [www.emea.europa.eu] 
  
213 
11. EMEA. Note for guidance on allergen products. CPMPBWP/243/96. 
European Agency for the Evaluation of Medicinal Products; 1996. 
12. Bousquet J, Lockey RF, Malling H-J: Allergen immunotherapy - therapeutic 
vaccines for allergic diseases. Allergy 1998, 53:4-42. 
13. Esch RE: Evaluation of Allergen Vaccine Potency. Current Allergy and 
Asthma Reports 2006, 6:402-406. 
14. van Ree R, Chapman MD, Ferreira F, Vieths S, Bryan D, Cromwell O, Villalba 
M, Durham SR, Becker WM, Aalbers M, et al: The CREATE Project: 
development of certified reference materials for allergenic products and 
validation of methods for their quantification. Allergy 2008, 63:310-326. 
15. Esch RE: Allergen source materials and quality control of allergenic 
extracts. Methods 1997, 13:2-13. 
16. Esch RE: Manufacturing and standardizing fungal allergen products. J 
Allergy Clin Immunol 2004, 113:210-215. 
17. Leith E, Bowen T, Butchey J, Fischer D, Kim H, Moote B, Small P, Stark D, 
Waserman S: Consensus guidelines on practical issues of immunotherapy-- 
Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy, 
Asthma, and Clinical Immunology 2006, 2:47-61. 
18. Rezvani M, Bernstein D: Anaphylactic reactions during immunotherapy. 
Immunology and Allergy Clinics of North America 2007, 27:295-307. 
19. Malling HJ: Minimising the risks of allergen-specific injection 
immunotherapy. Drug Saf 2000, 23:323-332. 
20. Ronit C-C, Arnon G: Allergen immunotherapy-induced biphasic systemic 
reactions: incidence, characteristics, and outcome: a prospective study. 
Annals of allergy, asthma & immunology 2010, 104:73-78. 
21. Cox L, Jacobsen L: Comparison of allergen immunotherapy practice 
patterns in the United States and Europe. Ann Allergy Asthma Immunol 2009, 
103:451-460. 
22. Morrow KS, Slater JE: Regulatory aspects of allergen vaccines in the US. Clin 
Rev Allergy Immunology 2001, 21:141-152. 
  
214
23. Slater JE: Standardized allergen extracts in the United States. Clin Allergy 
Immunol 2004, 18:421-432. 
24. Dreborg S: Skin Testing in Allergen Standardization and Research. 
Immunology and Allergy Clinics of North America 2001, 21:329-354. 
25.  EMEA. Guideline on the Clinical Development of Products for Specific 
Immunotherapy for the Treatment of Allergic Diseases. 2008, Australian 
Governement; Available at: 
http://www.tga.gov.au/docs/pdf/euguide/ewp/1850406en.pdf 
26. EMEA. Guideline on allergen products: production and quality issues. 2008, 
Australian Government; Available at: 
http://www.tga.gov.au/docs/pdf/euguide/bwp/30483107en.pdf 
27. Sung NS, Crowley WF, Jr, Genel M, Salber P, Sandy L, Sherwood LM, Johnson 
SB, Catanese V, Tilson H, Getz K, et al: Central Challenges Facing the 
National Clinical Research Enterprise. JAMA 2003, 289:1278-1287. 
28. Baer H, Godfrey H, Maloney CJ, Norman PS, Lichtenstein LM: The potency 
and antigen E content of commercially prepared ragweed extracts. J Allergy 
1970, 45:347-354. 
29. Baer H, Maloney CJ, Norman PS, Marsh DG: The potency and Group I 
antigen content of six commercially prepared grass pollen extracts. J Allergy 
Clin Immunol 1974, 54:157-164. 
30. Ohman JLj, Lowell FC, Bloch KJ, Kendall S: Allergens of mammalian origin, 
V: properties of extracts derived from the domestic cat. Clin Allergy 1976, 6. 
31. Dreborg S, Einarsson R: The major allergen content of allergenic 
preparations reflects their biological activity. Allergy 1992:418-423. 
32. Slater JE: Standardized allergen vaccines in the United States. Clin Allergy 
Immunol 2008, 21:273-281. 
33. deVore N, Slater JE: An Antibody-Based Multiplex Bead Assay to Determine 
the Potency and Composition of Allergen Extracts. Journal of Allergy and 
Clinical Immunology 2008, 121:S57-S57. 
  
215 
34. deVore NC, Slater JE: Development of a Microarray Assay to Determine the 
Potency of Allergenic Extracts Using Recombinant Antibodies. Journal of 
Allergy and Clinical Immunology 2007, 119:S267-S267. 
35. van Ree R: The CREATE project: EU support for the improvement of 
allergen standardization in Europe. Allergy 2004, 59:571-574. 
36. van Ree R, Dorpema JW, Vieths S: Allergy vaccines: a need for 
standardisation in mass units of major allergen. Pharmeuropa Bio 2005, 
1:27-30. 
37. Vogel L, Luttkopf D, Hatahet L, Haustein D, Vieths S: Development of a 
functional in vitro assay as a novel tool for the standardization of allergen 
extracts in the human system. Allergy 2005, 60:1021-1028. 
38. Wild D (Ed.). The Immunoassay Handbook, Third edition. San Diego CA: 
Elsevier Ltd.; 2005. 
39. Carlson RV, Boyd KM, Webb DJ: The revision of the Declaration of Helsinki: 
past, present and future. British Journal of Clinical Pharmacology 2004, 
57:695-713. 
40. Dreborg S: Standardization of allergenic preparations by in vitro and in vivo 
methods. Allergy 1993, 48:63-70. 
41. Turkeltaub PC: Biological standardization. Arb Paul Ehrlich Institut 1997, 
91:145-156. 
42. Turkeltaub PC, Rastogi SC, Baer H, Anderson MC, Norman PS: A 
standardized quantitative skin-test assay of allergen potency and stability: 
studies on the allergen dose-response curve and effect of wheal, erythema, 
and patient selection on assay results. Journal of Allergy and Clinical 
Immunology 1982, 70:343-352. 
43. Malling H-J: Skin prick testing in biological standardization of allergenic 
products. Arb Paul Ehrlich Institut 1997, 91:157-163. 
44. Position paper: Immunotherapy. (EAACI) The European Academy of 
Allergology and Clinical Immunology. Allergy 1993, 48:7-35. 
45. Position statement on the administration of immunotherapy outside of the 
prescribing allergist facility. Drugs and Anaphylaxis Committee of the 
  
216
American College of Allergy, Asthma and Immunology. Ann Allergy Asthma 
Immunol 1998, 81:101-102. 
46. Greineder DK: Risk management in allergen immunotherapy. Journal of 
Allergy and Clinical Immunology 1996, 98:S330-S334. 
47. Koshak EA: Could a routine skin test to penicillin lead to fatal anaphylaxis? 
Eastern Mediterranean Health Journal 2000, 6:526-531. 
48. Brown SG, Mullins RJ, Gold MS: Anaphylaxis: diagnosis and management. 
MJA 2006, 185:283-289. 
49. Sicherer SH: Food allergy. Lancet 2002, 360:701-710. 
50. WMA: World Medical Association (WMA) Declaration of Helsinki - Ethical 
Principles for Medical Research Involving Human Subjects. 59th WMA 
General Assembly; 2008. 
51. Emanuel EJ, Wendler D, Grady C: What Makes Clinical Research Ethical? 
JAMA: The Journal of the American Medical Association 2000, 283:2701-2711. 
 
  
217 
DISCUSSION—A PRACTICAL APPLICATION OF ETHICAL 
THEORIES TO AID DECISION-MAKERS IN ALLERGY  
 
Real knowledge is to know the extent of one's ignorance. 
! Confucius 
  
 Despite the phenomenal surge in the incidence of allergic sensitivities these recent 
years, those fortunate not to have an allergy may underestimate15 the significance and 
severity of this chronic disease [1-3]. Common misconceptions include that allergy 
symptoms are psychosomatic, or are representative of an overly frail individual, or are 
claimed as an excuse to avoid participating in specific activities such as culinary events. 
These negative preconceptions of individuals with allergic sensitivities are simply not true, 
but rather suggest that many members of the public who claim such disregard towards the 
actual social and medical ramifications of this chronic immune disorder possess a 
significant degree of ignorance concerning allergy.  
 Now at the concluding segment of this doctoral thesis, I feel the need to confess my 
own profound ignorance that influenced my former preconceptions of allergy. Prior to 
immersing myself into the study of this disease, I would often roll my eyes when hearing 
people speak about their allergies. Thoughts of, "Oh, get over it already", or "What's wrong 
with you? It's just a cat", would often cross my mind. I can also recall attending a stand-up 
comedy performance where a comedian jokingly ridiculed food allergic children as being 
weak, where death from consuming a single peanut was purported as Nature's way of 
ensuring that only 'strong' children live to reproduce. I found the performance to be quite 
humorous—at the time.  
                                                
15 It is interesting to note that the growing notoriety of allergy also has the opposite effect. Population surveys 
[4] note that a proportion of the public mistakenly associate or assume a variety of common disease 
symptoms, such as digestive disturbances, are due to allergic sensitivities. This self-diagnosis of allergy is 
often due to a completely unrelated medical condition, such as food intolerance (e.g., intolerance to the milk 
sugar, lactose, stems from a deficiency of the digestive enzyme, lactase, a condition which is unrelated to 
milk allergy).  
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 Now armed with a robust understanding of allergy, these false preconceptions have 
evolved into convictions of concern and respect for allergic afflictions. Furthermore, 
recognition of the real suffering experienced by many allergic patients has instilled 
personal motivations that this doctoral research project should not only serve as a means for 
academic training, but also contribute towards a social responsibility to enact change. 
Below is a summary of the efforts presented herein that aim to contribute towards 
minimizing the health burden of allergy.  
 
Synopsis: breaking new ground in allergology while providing new tools 
for decision-makers  
 The overarching goal of this research project aims to encourage—and in many 
cases, initiate—further research attention towards a domain in allergology that remains 
underdeveloped. But first, initial investigations sought to answer one fundamental question: 
What is the extent of analysis devoted towards assessing the ethical implications of allergy 
morbidity and treatment provision? The results from an exhaustive literature review 
identified fewer than 35 academic articles address ethical issues in detail concerning 
allergy, three of which are articles originating from this doctoral project. This paucity of 
ethical analysis exists despite the fact that numerous ethical issues surface from the toll this 
chronic disease imposes on population health. The observed deficiency of employing 
principles of ethics within allergology then served to advance the argument that this 
research domain represents a wealth of opportunity for future interdisciplinary 
investigations. 
 The subsequent goal of this thesis was then to contribute towards developing 
reflective tools and theoretical frameworks that could be used by decision-makers to guide 
health policy interventions for allergy and co-morbid conditions. The aim of this research 
initiative was to develop practical tools for a broad range of health professionals 
implicated in allergy. With that said, it is important to assert that the theoretical frameworks 
proposed herein aim to empower ‘meso-level’ health professionals in their daily practice. 
Thus, rather than target ‘macro-level’ health professionals, such as national ministers of 
health that are responsible in determining complex resource allocation strategies for 
national health care systems, this thesis centres analysis down one level towards health 
professionals employed within institutions and not the upper echelons of government. As 
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demonstrated throughout Chapters 2 to 4, such meso-level health professionals include 
public health officials tasked with developing regional health interventions (e.g., for cities 
or specific neighbourhoods), administrators of child care settings and nurses employed 
within educational institutions, and policy analysts working within specific jurisdictions of 
drug regulatory bodies. A common analytical theme that unites the theoretical frameworks 
proposed in this thesis include a focused attention towards issues concerning: 1) 
populations particularly vulnerable to allergy morbidity; 2) the duty for decision-makers to 
minimize risks of individuals experiencing an allergic reaction and how their disease might 
be source of stigma, and; 3) ensuring the fair distribution of health benefits and burdens 
arising from tentative policy interventions. By employing core principles of ethics in health 
policy, public health, and bioethics, policy recommendations from this thesis will aid 
decision-making capacities within three specific contexts.  
 First, Norman Daniels' application of Rawlsian theories of social justice in health 
inspired the use of these same theories as a guide in public health policy development for 
allergy and asthma. Rather than replicate Daniels' analysis—where Rawls' theory served as 
a framework to critique unjust distributions of health achievements—principles of social 
justice were used to define focal points for assessment in the development and prioritization 
of policies targeting environmental allergens and asthma triggers. The step-wise assessment 
protocol presented herein focuses evaluation on: 1) whether a tentative public health 
intervention would provide equal health benefit to a range of allergy and asthma sufferers, 
2) whether targeting initiatives towards particular societal groups is merited based on the 
notion of ‘worst-off status’ of certain population segments, and 3) whether targeted policies 
have the potential for stigmatization. 
  Investigations then centred on current weaknesses and deficiencies observed in the 
structuring of food allergy policies for school children. In this context, ethical principles 
that uphold the duty to protect confidentiality and anonymity, fairness, avoiding 
stigmatization, and empowerment, served as guides in the development of a theoretical 
framework to define the adequacy and legitimacy of food allergy prevention efforts. This 
policy assessment protocol, in turn, provides a reflective tool to aid administrators and 
school nurses in their decision-making capacities when structuring food allergy policies for 
childcare and educational institutions.  
 The final chapter placed scrutiny on regulations and global standardization efforts 
for allergenic extracts used in immunotherapy. Research centring on current regulatory 
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protocols identified questions regarding whether emerging technical capacities in 
immunology will obviate the use of allergic patients as human subjects for potency 
assessments of these drugs. Despite human subject potency assessments being a reasonable 
and accurate testing method, the fact that this testing is not free of risks advances the 
argument that such testing ought to be avoided when possible. Core principles of research 
ethics concerning harm prevention and the fair distribution of research benefits and burdens 
then served as a guide concerning how to reform standardization efforts in light of 
technological advances that may enable the primary application of in-vitro testing 
strategies.  
 The application of a select set of ethical principles within specific contexts proved 
useful in the formulation of frameworks to guide health policy development. However, the 
select focus of this project also signifies that the analysis herein is bound by inherent 
limitations. 
 
Limitations of this research project: A question of scope   
 The first limitation of this thesis project concerns issues of the reach (scope) and 
applicability of this research in allergic populations others than the allergic populations 
targeted herein. Namely, it is worth questioning whether the health policy frameworks 
presented in these latter chapters could be of equal utility in other regions of the globe. 
Note that this analysis focussed exclusively on the allergy epidemic within the developed 
world where allergy predominates. However, as a significant component of the developing 
world is now experiencing rapid economic growth and is becoming "Westernized", the 
allergy epidemic is expanding its reach into populations once 'immune' to this disease [5-7]. 
Thus, while the allergy policy proposals in this thesis were defined as ethical imperatives 
for Western countries, such policies might be over-demanding in areas of prolonged 
conflict, severe resource constraints, and a limited development of social institutions. In 
these locales, inability to meet, or disinterest in following, certain ethical principles in 
health policy might not be a morally reprehensible act.                         
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 Consider enacting school food allergy policies in a resource poor nation16 as an 
example. In Chapter 3, a main duty stated for school administrators was the need to have 
epinephrine available on hand should an anaphylactic reaction arise. Would this duty be 
reasonable at a school that barely has enough resources to provide books to its students, let 
alone the refrigerator needed to store the epinephrine? From this example it is apparent that, 
overall, the moral arguments that could guide pertinent allergy policies in the developing 
world would be different from many guiding principles presented in this thesis.       
 Another apparent limitation of this research project is that it does not demonstrate 
the vast breath and diversity of ethical principles and ethics scholarship that has emerged 
recently from the Philosophy and Bioethics communities (recent examples of prominent 
scholarship concerning ethics and health include: [9-14]). Without a doubt, these additional 
ethical principles and theories could have equal utility in health policy development, and if 
applied to relevant research questions, could serve as essential tools in guiding policy 
initiatives for allergy as well. A brief description of one prominent theory of social justice 
recently applied to analyse population health, yet not employed in this thesis, will 
exemplify this claim.  
 The theory refers to the recent work by Powers and Faden [15], where the authors 
develop a framework using six "core dimensions" [p.16] of well-being as means to 
prioritize public health interventions and assess key justice issues in the distribution of 
health achievements amongst population sub-groups. These six core dimensions, defined as 
being essential components for well-being, are categorized as the following: health, 
personal security, reasoning, respect, attachment, and self-determination. (For the sake of 
brevity, a detailed definition for each dimension will not be provided). Powers & Faden 
argue that "a life substantially lacking in any one of these [dimensions] is a life seriously 
deficient" [p. 29], where by identifying the degree by which morbidity negatively affects 
each dimension serves as a framework to determine which health inequalities constitute the 
most significant forms of social injustice, and thus, merit priority in public health 
intervention. Moreover, analysing how current health interventions directed towards ailing 
populations fail to ameliorate multiple dimensions of well-being could serve another 
function. Namely, it provides a means to define weaknesses inherent in health policies and 
                                                
16 Just prior to submitting this thesis, Hossny and colleagues [8] published the population incidence of food 
allergy to peanuts in a sample of Egyptian school children. 3% of children were confirmed to have peanut 
food allergy, an incidence that is roughly equivalent to that seen in the developed world.   
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thus why certain populations remain vulnerable to morbidity despite the availability of 
health interventions. Indeed, Powers & Faden's framework is appealing, especially 
considering how the topic of vulnerable populations is a central subject in this thesis.   
  
 Rather than negative, the limitations of this research project should be viewed in 
more positive light. For one, they indicate that many principles of ethics have yet to be 
employed as tools in policy developments for allergy. This in turn signifies that there are 
additional means to improve decision-making capacities in health interventions, each 
representing pertinent avenues to advance research.  
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CONCLUSION 
Building upon foundations: Future directions in research 
Never let the future disturb you. You will meet it, if you have to, with the same weapons of 
reason which today arm you against the present. 
! Marcus Aurelius Antoninus 
 
 The final segment of this thesis will now provide three examples of promising areas 
of future research. The following proposed research projects are a selection of pertinent 
topics that would build upon the knowledge foundations developed in the previous three 
published research articles that compose this academic work. We begin this discussion in 
relation to Chapter 2, where further attention centres on issues of social justice in the 
provision of allergy treatment to disenfranchised population segments. 
 
Alleviating allergy morbidity necessitates a greater focus on justice and the 
promotion of equal capabilities in health achievements  
 The need for greater equity in abilities to control allergy morbidity within 
disenfranchised populations cannot be overemphasized. It is particularly disquieting that, to 
this day, factors related to race and poverty continue to significantly hamper the health of 
populations in the developed world. This must change. 
 There are several issues related to allergy treatments and health inequalities that 
require ethical scrutiny. One problem with current treatment regimens is that they are 
notoriously expensive—in fact, prescription medications account for the largest direct 
medical expenditure in asthma treatment [1]. In addition, annual pharmaceutical expenses 
are typically over $1300 for patients with particularly aggressive forms of allergy and 
asthma, patients which tend to predominate in lower socioeconomic classes [2]. Because of 
these costs, many patients are unable to afford needed pharmaceuticals and thus non-adhere 
to treatment [3], which in turn produces elevated morbidity levels and frequent visits to 
emergency departments in order to receive care [4]. In addition to social factors related to 
socioeconomic deprivation, racial factors are known to compromise the efficacy of 
biomedical interventions for allergy and asthma. Even when controlling for factors related 
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to income, patients of African descent are less likely to receive prescriptions for 
medications recommended by best practice medical guidelines, and are less likely to 
receive training in how best to use inhalers commonly employed in the treatment of asthma 
[5]. 
 It is apparent that one integral component missing from current biomedical and 
public health interventions is to couple these treatment strategies with policies that promote 
social justice. If current interventions work well for middle, and even better for upper 
classes, as well as the racial majority, it seems logical that we need to raise the lowest strata 
upwards and promote the opportunities of minorities in order for these interventions to 
work well for all population segments. It is apparent that future commitments to reducing 
allergic disease cannot champion public health and biomedical interventions while 
excluding broader social reforms that would better position these interventions for success 
in all societal groups. The allergology community needs to be made more aware of this 
fact.  
 Having reaffirmed the importance of justice in allergy treatment strategies, we now 
return to policy dilemmas within the specific context of childcare settings and the 
population of food allergic children.  
 
Foreseeable challenges for administrators of childcare settings: balancing 
the rights of the disabled with the needs of parents, children, and childcare 
institutions 
 Where until recently only avoidance and elimination efforts were the best strategy 
to prevent food-induced anaphylaxis [6], treatments for childhood food allergy, primarily in 
the form of immunotherapy, are gradually becoming more accepted by allergists and 
available to the average patient [7]. While such therapeutic innovation is arguably long 
overdue and will be of significant benefit, the availability of this health intervention will 
likely raise several contentious issues that require extensive debate. Foreseeable tensions 
will centre on whether childcare settings should continue to be held responsible in 
protecting the health of food allergic children, or whether immunotherapy should be 
obligatory for this minority of children attending the institution. 
 Mandating that children undergo specific medical assessments or interventions as a 
contingency for admittance at a childcare institution is not uncommon; for example, many 
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districts in the United States mandate childhood vaccinations as a prerequisite for school 
enrolment [8]. It is therefore a possibility that officials could require immunotherapy for 
children with severe food allergies on the basis of several justifications. As described in 
Chapter 3, effective food allergen avoidance policies are complicated, burdensome, and 
require significant time and resource expenditures. Certain policies also require restricting 
the activities of parents and non-allergic children, and also impose specific duties on staff 
and faculty members. It is thus not irrational to want to avoid these challenges by directing 
greater responsibility in health protection towards food allergic children and their parents.  
 The benefits accrued to the majority in this situation, however, may be met with 
strong opposition by the minority targeted by these policy decisions. As is the current 
situation concerning mandatory vaccination programmes [9], many parents and members of 
the public fiercely oppose the imposition of medical treatments upon their children. This 
opposition can stem from unfounded fears (e.g., the thoroughly debunked, yet continuing 
fear, that vaccines cause autism [10]), as well as reasonable concerns of possible adverse 
reactions to therapy, and most importantly, philosophical convictions that such policies are 
an affront to one's civil liberties and autonomy in individual determinism.  
 It is highly likely that mandated immunotherapy for severely food allergic children 
would be met with similar philosophical convictions and concerns [11, 12]. School officials 
and policy-makers must be made aware of this possibility. However, unlike policies such as 
vaccination, which aim to prevent illness, immunotherapy aims to cure an ailment. This 
ailment can be viewed as a "contextual" disability, where food allergy is made problematic 
when childcare settings do not establish appropriate safeguards for these disabled children. 
We now see how ethical issues concerning the mandated treatment of food allergy will 
require an analysis of the rights of the disabled, as well as debate concerning the duties 
school officials and policy-makers have to protect and uphold these much valued rights. 
Without question, this debate must be initiated in the near future in order to avoid 
foreseeable conflicts between children, parents and administrative officials.   
 Indeed, allergen-immunotherapy for food sensitivities will raise several challenging 
policy-related questions concerning the broader benefits and risks of this medical 
intervention. Because of the undeniable importance allergen immunotherapy will have in 
contemporary medicine, future research developments concerning the production of quality 
immunotherapeutic drugs is a pertinent subject requiring further investigation. 
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Shot-in-the-arm: pharmaceutical companies have a duty to further 
standardize allergen-immunotherapeutic drugs  
 The final chapter of the thesis described in detail specific duties that government 
regulators have in terms of encouraging the standardization of allergen-immunotherapeutic 
drugs. This chapter, however, made little mention of another key stakeholder that 
undoubtedly plays a vital role in this process, being pharmaceutical manufacturers. Indeed, 
what role ought pharmaceutical companies have in global allergenic extract standardization 
efforts? Do the private corporations that manufacture these drugs have a duty of their 
own—also phrased as a corporate social responsibility [13]—to standardize their products, 
regardless of whether government legislation mandates such production methods? 
Moreover, is it morally acceptable that, despite having standardization protocols readily 
available, companies continue to produce substandard therapeutics that unnecessarily 
complicate allergy treatment regimens and thus raise risks of adverse reactions for patients?  
 Unequal application of drug regulations also raises important questions of whether 
corporations share duties amongst themselves. Namely, is it fair that certain companies—
but not others—are exempt from regulations, and thus the costs associated with 
standardizing their extracts, since their products were commercialized before the advent of 
drug regulations for allergenic extracts? These regulatory exemptions and resultant cost 
savings are arguably not fair and not favourable to the needs of patients. For one, emerging 
forms of immunotherapeutic drugs have novel benefits over age-old allergic extracts, which 
include improved safety and shortened treatment intervals [14]. However, the additional 
costs due to regulatory oversight of these novel drugs may provide a competitive advantage 
for substandard allergenic extracts and thus impede innovation.    
 Overall, a significant extension to the work presented in the final chapter of this 
thesis would be to define and analyse the ethical and policy implications of the above 
questions. The goal of this project should not be to point an overly accusatory finger at the 
private sector. A more receptive approach would be to argue that when all stakeholders 
(e.g., regulators, companies, patient representatives) are onside and aim for the same goal, 
initiatives achieve their desired goals with greater ease. And what could be a better goal 
than enabling the production of the best therapeutics on offer that can cure patients of a 
debilitating and sometimes life-threatening disease?    
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The unexpected benefits are often the best 
 The rewards of this doctoral training extend far beyond the acquired knowledge and 
analytical capabilities developed during this training experience. Instead, the greatest 
rewards from this doctoral training were made apparent through unexpected events that 
demonstrated how this research might have the capability to make a positive difference in 
the lives of allergy sufferers. This was made apparent after receiving emails from deeply 
concerned parents requesting copies of the article pertaining to food allergy policies for 
schools. Their correspondence conveyed emotional stories of having severely allergic 
children that they feared were at risk of a fatal reaction due to inaction on the part of school 
administrators. Other concerns voiced by these parents were that school allergy policies 
placed a heavy burden on food-allergic students, and this in turn compromised their 
learning experience. They hoped that my article could help guide them in their fight to 
make their school a safer learning environment for their children. I am honoured to have 
contributed to this fight.  
 There are many more worth fighting. 
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